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ABSTRACT

Quantitative Studies of Amyloidogenic Protein Residue Interaction Networks and
Abnormal Ammonia Metabolism in Neurotoxicity and Disease

by
Jeddidiah Wayne Duke Griffin

Investigating similarities among neurological diseases can provide insight into disease
processes. Two prominent commonalities of neurological diseases are the formation of
amyloid deposits and altered ammonia and glutamate metabolism. Computational
techniques were used to explore these processes in several neurological diseases. Residue
interaction networks (RINs) abstract protein structure into a series of nodes (representing
residues) and edges (representing connections between residues likely to interact).
Analyzing the RINs of non-amyloid forms of amyloidogenic proteins for common network
features revealed similarities not previously known. First, amyloidogenic variants of
lysozyme were used to demonstrate the usefulness of RINs to the study of amyloidogenic
proteins. Next, I compared RINs of amyloidogenic proteins with randomized control
networks and a group of real protein controls and found similarities in network structures
unique to amyloidogenic proteins. The use of 3D structure data and network structure data
of amyloid-beta (1-42) (Abeta42) in a hydrophobic, membrane-mimicking solvent led to
the identification of an interaction between Val24 and Ile31 as potentially involved in
preventing Abeta aggregation. Since Abeta causes oxidative damage, since the ammonia
2

metabolism enzyme glutamine synthetase is particularly susceptible to oxidative damage,
and since glutamate plays a central role in neuronal function, I expanded my research to
include the study of ammonia and glutamate metabolism in neurological diseases. A
computational model of the effects of the interactions between the amount of dietary
protein and the activities of ammonia metabolism enzymes on blood and brain ammonia
levels supports potentially important roles for these enzymes in the protection of neural
function. Next, I reviewed the role of amino acid catabolism in Alzheimer’s disease (AD).
Common tissue pathology and the ability of memantine, an NMDA receptor antagonist, to
relieve symptoms in patients and animal models of AD, major depressive disorder (MDD),
and type 2 diabetes (T2D) further support a role for ammonia and glutamate metabolism
in disease. Lastly, I found that single nucleotide polymorphisms (SNPs) in select ammonia
metabolism genes are associated with these three diseases. The results presented in this
dissertation demonstrate that investigating neurological diseases using computational
approaches can provide great insight into the common underlying pathologies.
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CHAPTER 1
INTRODUCTION

Many Neurological Diseases Have Common Etiologies and Phenotypes
Neurological diseases are a diverse group of disorders, so researchers often study
them using a reductionist approach. This view has successfully led to a large body of
knowledge and successful treatments for some diseases. However, a broader approach that
attempts to find similarities among some of the proposed causes of neurological disease
could lead to novel and more broad-spectrum treatments. Improper protein folding and
metabolic abnormalities are two of the proposed shared causes of neurological diseases
and their symptoms. Improper protein folding results in the formation of insoluble protein
deposits called amyloid plaques (Rambaran and Serpell 2008). Metabolic abnormalities are
understandably diverse in neurological diseases due to the central role of metabolism in
cellular function, but amino acid and ammonia metabolism stand out as having influential
roles in many diseases. The overall goal of this dissertation is to use computational
analyses to provide insight into potential molecular contributors to select neurological
diseases by investigating abnormal ammonia metabolism and the residue interaction
network structures of amyloidogenic proteins, two likely contributors to neurological
diseases. I propose two guiding hypotheses for this series of studies.
(A) Amyloidogenic proteins have similarities in their residue interaction network
structures that will provide insight into the formation of amyloid plaques.
(B) Altered ammonia metabolism and changes in the amount of dietary protein
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under certain conditions affect neurological function and play causative roles
in several neurological diseases.
These studies investigated possible contributing factors to neurological diseases
and report commonalities in improper protein folding and abnormal metabolism. Studies
of broad scope that attempt to find commonalities in the causes of neurological diseases
could provide novel insight into possible treatments or preventions. This series of studies
is organized into specific aims which address hypotheses (A) and (B).

Specific Aim 1
To determine if amyloidogenic proteins have commonalities in their residue
interaction networks and to determine how these network structures may affect amyloidbeta plaque formation when combined with 3D structural data. This aim addresses
hypothesis (A).

Amyloidogenic Proteins Are Involved in Many Neurological Diseases
Amyloidogenic proteins are polypeptides that can form amyloid plaques (Knowles
et al. 2014). Amyloid plaques are associated with a variety of diseases ranging from
neurological disorders (Glenner and Wong 1984; Hardy and Higgins 1992) to
gastrointestinal disease (Granel et al. 2002). The symptoms of the diseases depend on the
tissue in which the amyloids are deposited. There are dozens of different amyloid diseases
caused by dozens of different proteins (Knowles et al. 2014). The structure of amyloid
plaques of a variety of proteins consists of insoluble stacks of cross-beta sheets (Sunde et
al. 1997). There is little known similarity in native structure, sequence, or function of
25

amyloidogenic proteins in monomeric form (Knowles et al. 2014). Several amyloid diseases
(amyloidoses) are characterized by deposition of plaques in the central nervous system
(CNS), leading to a variety of different but related symptoms. Amyloidoses of the CNS
include amyloid-beta (Abeta) in Alzheimer’s disease (Glenner and Wong 1984), alphasynuclein (α-syn) in Parkinson’s disease (Spillantini et al. 1997), and human prion protein
(hPrP) in transmissible spongiform encephalopathies (TSEs) (Kretzschmar et al. 1986;
Nizhnikov et al. 2016).

Amyloid-Beta and Alzheimer’s Disease. The amyloid hypothesis for Alzheimer’s
disease was first proposed in 1992 by Hardy and Higgins (Hardy and Higgins 1992), but it
has its roots in the first studies of purified Abeta (Glenner and Wong 1984). The hypothesis
states that aggregates of the Abeta peptide are responsible for the cognitive decline and
cellular damage observed in Alzheimer’s disease. Since then, the amyloid hypothesis has
been thoroughly investigated with data both supporting and refuting it (Herrup 2015).
Abeta comes in two main forms that differ in length by only two amino acids: amyloid-beta
(1-40) (Abeta40) and amyloid-beta (1-42) (Abeta42). However, a recent study suggests
many other Abeta fragments are also prevalent in AD brain (Wildburger et al. 2017).
Studies suggest Abeta42 is more toxic than Abeta40 (Kuperstein et al. 2010). This may be
because it more readily forms amyloid fibrils (Ogawa et al. 2011). Fibrils are the most
prevalent form of Abeta found in those with AD, but oligomers appear to be the most toxic
form (Sakono and Zako 2010). Abeta42 has been shown to stimulate inflammation (White
et al. 2005) as well as form channels in cellular membranes that disrupt ion homeostasis in
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neurons (Furukawa et al. 1994; Weiss et al. 1994). The amyloid plaques are typically
extracellular and are thought to disrupt synaptic signaling (Ferreira et al. 2015).
Abeta appears to have intrinsically unstructured N- and C-termini with some
secondary structure in the middle regions of the protein. Studies have found that the
central hydrophobic cluster (CHC, residues 17-21) plays an important role in forming
amyloid plaques (Wurth et al. 2002). Residues 24-26 and 31-34 appear to be important for
fibrillization of Abeta40 (Williams et al. 2004). While it has been suggested that Abeta
monomers in solution do not have secondary structure, there are studies that suggest
Abeta does have secondary structure that is critical for amyloid formation (Chen and Glabe
2006). Although Abeta has been extensively studied, there is a lot of variability in
experimental results possibly due to differences in experimental conditions. Therefore,
examining amyloidogenic proteins for similarities using a novel computational approach
could provide insights into structural features that other methods could not address.

Other Amyloidoses of the CNS. The brains of Parkinson’s disease patients have
cytoplasmic inclusions known as Lewy bodies (LBs) (Braak et al. 2003). LBs are mainly
composed of α-syn (Tu et al. 1998), a 140 amino acid protein that forms alpha-helices
when in a hydrophobic, membrane-like environment (Ulmer et al. 2005). While α-syn can
form fibrils, it is thought that oligomers are the most toxic form of the protein (Conway et
al. 2000). The α-syn protein has been shown to inhibit synaptic transmission through a
variety of mechanisms (Stefanis 2012), including altering the distribution of SNARE
proteins (Garcia-Reitböck et al. 2010) and decreasing the release of neurotransmitters
(Nemani et al. 2010).
27

Human prion protein is an infectious protein that is the cause of TSEs. There are
several types of TSEs that involve the conversion of the cellular form of the prion protein
(PrPC) to the infectious form (PrPSC) (Colby and Prusiner 2011). The concept of infectious
proteins was proposed by Prusiner in 1982 (Prusiner 1982). While hPrP often forms
amyloids in vivo (Colby et al. 2007), amyloid formation is not required to cause disease
(Wille et al. 2000). Like α-syn and Abeta, there is evidence that oligomeric PrP species are
more toxic than fibrils for pathogenesis (Sokolowski et al. 2003). Because both α-syn and
hPrP can form amyloids, they are included in the group of amyloidogenic proteins studied
in Chapter 3.

Lysozyme Amyloidosis as a Model for General Amyloidosis. Lysozyme is a 14.7 kDa
antimicrobial protein discovered by Alexander Fleming (Fleming 1922) and found in
secretions such as tears (McDermott 2013) and saliva (van’t Hof et al. 2014). While wild
type (WT) lysozyme does not form amyloids in vivo, rare amyloidogenic mutants of
lysozyme exist and are known to cause human disease (Granel et al. 2006). Because
lysozyme is a well-studied protein and single amino acid substitutions can cause lysozyme
to form amyloids, it is a useful model for studying the general process of amyloidogenesis
(Merlini and Bellotti 2005). Several lysozyme point mutations are catalogued in the
database Online Mendelian Inheritance in Man (OMIM 153450). These include I56T (Pepys
et al. 1993), D67H (Pepys et al. 1993), W64R (Valleix et al. 2002), and F57I (Yazaki et al.
2003). It is generally thought that these mutations cause regions of instability between the
alpha and beta domains, leading to unfolding (Booth et al. 1997). As the lysozyme
molecules unfold, new intermolecular interactions can form between them, allowing
28

lysozyme to form amyloid plaques. While regions of instability have been clearly
demonstrated to be involved (Booth et al. 1997), there may be other factors involved in
amyloidogenesis. Applying residue interaction network analysis to lysozyme structures
available in the Protein Data Bank (PDB) may yield new insights into the primary
nucleation of lysozyme amyloids. Since lysozyme is a model for general amyloidogenesis,
understanding the residue interaction network changes that occur in amyloidogenic
variants of lysozyme could provide insight into the primary nucleation of other proteins as
well. A better understanding of the amyloidogenic process could lead to more effective
pharmacological interventions.

Residue Interaction Networks Provide a Novel Perspective into Protein Structure and
Function
Complex networks analysis is a growing field that applies network science to a
variety of systems (Estrada 2012). Proteins can be abstracted into a network of interacting
amino acid residues where a node is represented by an amino acid and an edge represents
a likely connection between amino acid residues (Di Paola et al. 2013; Yan et al. 2014).
Conceptualizing a protein’s structure as a network has proven to be a powerful technique
that has provided several insights into protein structure (Dokholyan et al. 2002; Amitai et
al. 2004; Brinda and Vishveshwara 2005; Liu and Hu 2011; Hu et al. 2014; Emerson and
Louis 2015; Di Paola and Giuliani 2015). There are a variety of metrics available to describe
a network (Junker and Schreiber 2008). These include global network measures such as
average clustering coefficient, average shortest pathlength, average degree, and number of
nodes and edges. There also exist local measures of a network such as clustering
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coefficient, degree of a node, betweenness, and stress. Both global and local metrics have
proven useful for protein network analysis. Network metrics applied to residue interaction
networks (RINs) have been associated with features of proteins such as folding dynamics
(Dokholyan et al. 2002) and active sites (Amitai et al. 2004). RINs are most useful for
analyzing protein structure when combined with traditional 3D structural data and
sequence data.
As described above, the 3D structures and sequences of monomeric and soluble
amyloidogenic proteins are generally very well studied, but there have been no strong
sequence or structural similarities found among them that suggest common features
involved in amyloidogenesis (Knowles et al. 2014). Adding RIN data could better identify
common features in amyloidogenic proteins. RINs provide a novel perspective of
amyloidogenic proteins that could lead to the generation of information useful in further
refining the current model of primary nucleation of amyloid fibrils.
As mentioned previously, Abeta plaques are a hallmark of AD. One of the hypotheses
for the toxic effects of Abeta focuses on the potential of Abeta to cause oxidative damage
(Smith et al. 1994; Smith et al. 1998; Rottkamp et al. 2001; Boyd-Kimball et al. 2005; BoydKimball et al. 2006). Oxidative damage is increased in those with AD (Castegna et al. 2003;
Perluigi et al. 2009) and in animal models of AD (Praticò et al. 2001). One of the enzymes
especially sensitive to oxidative inactivation is glutamine synthetase (GLUL) (Butterfield et
al. 1997), an enzyme that ligates ammonia and glutamate to produce glutamine. GLUL is
oxidized in vitro after Abeta42 treatment (Boyd-Kimball et al. 2005) and has been shown
to be oxidized in patients with mild cognitive impairment (MCI) (Butterfield et al. 2006)
and in a mouse model of AD (Shen et al. 2015). Because of the sensitivity of GLUL to
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oxidative inactivation and the potential effects on ammonia metabolism due to oxidative
damage, I expanded my research to examine the role of ammonia metabolism enzymes on
blood ammonia levels and the potential neurotoxicity when enzyme activity is altered in
disease conditions.

Specific Aim 2
To create a mathematical model to determine if the amount of dietary protein and
degree of liver function interact to affect blood ammonia levels and to determine if the
predicted changes could affect neuron health. This aim addresses hypothesis (B) and
investigates the potential role of ammonia metabolism in neural function using an
organismal and tissue level approach.

Urea Cycle, CPS1, GLS, and GLUL in Ammonia Metabolism
Ammonia is a toxic byproduct of amino acid catabolism (Auron and Brophy 2012)
that is processed in mammals into the relatively nontoxic molecule urea by enzymes of the
urea cycle. The urea cycle is composed of a series of enzymes located mainly in the liver,
but also in the kidneys and small intestine. The first committed step of the urea cycle is
catalyzed by the enzyme carbamoyl phosphate synthetase 1 (CPS1), a mitochondrial
protein that synthesizes carbamoyl phosphate from ammonia, carbonic acid, and ATP. CPS1
deficiency, a disease caused by mutations in the CPS1 gene that reduce the enzyme’s
activity, results in increased systemic ammonia levels (Klaus et al. 2009). Severe CPS1
deficiency typically leads to death at an early age due to the sensitivity of the brain to high
ammonia levels.
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Many other enzymes exist that are involved in ammonia metabolism but are not
part of the urea cycle. These include glutamine synthetase (GLUL), as mentioned earlier,
and glutaminase (GLS). Glutamine is relatively inert as a signaling molecule (Albrecht et al.
2010). However, glutamine can be broken down into ammonia and glutamate by the
enzyme glutaminase (Albrecht and Norenberg 2006). Glutamate is an important
neurotransmitter involved in synaptic function (Zhou and Danbolt 2014) and is discussed
in more detail below. GLUL has a very low Km (high affinity for substrate) (Listrom et al.
1997), so it efficiently processes free ammonia into glutamine when glutamate is present.
The interplay among these ammonia metabolism enzymes has important implications for a
variety of diseases.

Liver Physiology and Hepatic Encephalopathy
The liver carries out a variety of critical physiological functions. One of the most
important functions is the removal of ammonia from the blood to create urea for excretion.
This is carried out through a series of enzymes that are spatially separated in the acinus,
the functional unit of the liver. Briefly, the hepatic portal vein carries blood from the small
intestine to the liver. The blood then diffuses across about 22 hepatocyte cell layers in the
acinus and then collects in a branch of the central vein. The hepatocytes of the acinus are
divided into three zones which each express a set of enzymes to metabolically process the
compounds in the blood coming from the small intestine (Häussinger et al. 1992; Brosnan
and Brosnan 2009; Lautt 2009). Zone 1 is closest to the hepatic portal vein. These
hepatocytes express the enzymes CPS1 (Moorman et al. 1989) and GLS (Moorman et al.
1994). Zone 2 largely contains the same ammonia metabolism enzymes as zone 1 but with
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lower levels of GLS (Moorman et al. 1989; Moorman et al. 1994). Zone 3, however, is
closest to the central vein and contains GLUL instead of CPS1 and GLS (Gebhardt and
Mecke 1983). The separation of these enzymes makes ammonia metabolism more efficient.
Liver damage causes changes in the metabolic functions of the liver (Gebhardt and
Reichen 1994; Fleming and Wanless 2013). Hepatic encephalopathy is a condition where
liver damage leads to an accumulation of potentially neurotoxic factors in the blood,
impairing cognitive function (Butterworth 2015). Liver cirrhosis has been shown to cause
changes in the activities of CPS1 and GLUL (Gebhardt and Reichen 1994; Fleming and
Wanless 2013). When these enzyme activities are altered, the rate at which ammonia
metabolism occurs is altered as well, leading to higher levels of ammonia in the blood of
patients with liver damage (Butterworth 2003). The higher levels of blood ammonia in
those with hepatic encephalopathy cause neural dysfunction, leading to the clinical
symptoms of disease.

Effects of Blood Ammonia on Neural Cells
Most ammonia (NH3) becomes protonated at physiological pH and is present in the
body as the ammonium ion (NH4+). For simplicity, “ammonia” is used in this dissertation to
include both chemical species unless otherwise noted. Uncharged ammonia can passively
cross the blood-brain barrier (BBB), while the charged ammonium ion cannot (Auron and
Brophy 2012). Because the brain has a lower pH than blood, once ammonia passes through
the BBB and becomes protonated, it does not pass back through so easily, leading to a
higher concentration of ammonium ions in the brain compared to the blood (Auron and
Brophy 2012). Once in the brain, ammonia can cause damage to neural cells and interrupt
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cognitive function in a variety of ways. First, ammonia can directly exert toxicity on
neurons and glia. Studies have demonstrated that increased ammonia levels cause
increased reactive oxygen and nitrogen species production (Bobermin et al. 2015), leading
to oxidative damage. Furthermore, ammonium ions compete with potassium for transport
into astrocytes and neurons, leading to problems with inhibitory neurotransmission in the
cortex (Rangroo Thrane et al. 2013). Next, high ammonia levels disrupt the glutamateglutamine balance in the brain (Braissant et al. 2013). Glutamate is an excitatory
neurotransmitter involved in learning and memory (Esposito et al. 2013). Disruption of
glutamate metabolism and signaling by high ammonia levels could lead to some of the
symptoms of neurological diseases. Either too much or too little glutamate signaling has
been shown to have negative effects on the brain (Myhrer 1998). The results of Specific
Aim 2 add further evidence that increased ammonia levels resulting from
pathophysiologically relevant enzyme activity changes are directly toxic to neurons.
Because of these results and the established role of glutamate signaling in neuronal
function and AD, I investigated a potential connection between ammonia metabolism genes
and three neurological and metabolic diseases: AD, major depressive disorder (MDD), and
type-2 diabetes (T2D).

Specific Aim 3
To determine if there is an association between single nucleotide polymorphisms
(SNPs) in the GLS, CPS1, and GLUL genes and AD, MDD, and T2D, and to predict the effects
of any associated SNPs in the disease processes. This aim addresses hypothesis (B) where I
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suggest that altered ammonia metabolism stimulates neuropathology on a molecular and
cellular level.

Ammonia Metabolism Could Play a Common Role in AD, T2D, and MDD
Proper organismal ammonia metabolism is critical for normal physiology, but it is
especially important for brain function. Because of its very high toxicity and its production
by a central metabolic pathway, ammonia metabolism may be altered in a variety of
diseases where central metabolism is altered. Therefore, we hypothesized that ammonia
and glutamate metabolism may play a role in the pathogenesis of AD, MDD, and T2D. While
these diseases have many differences, cortical thinning has been associated with all three
diseases (Du et al. 2007; Tu et al. 2012; Yoon et al. 2017). Memantine is one of the handful
of drugs available for the treatment of AD. It is an NMDA receptor antagonist, so it reduces
glutamate excitotoxicity in neurons. Overactivation of NMDA receptors results in the
excessive opening of plasma membrane calcium channels, resulting in calcium-induced cell
death. Memantine has been shown to slightly slow the progression of AD, reinforcing that
glutamate signaling is important in AD pathogenesis. However, memantine administration
has also been shown to have positive effects in patients with MDD (Amidfar et al. 2017)
and in a mouse model of T2D (Iwanami et al. 2014; Huang et al. 2017). Since memantine
may be effective against all three of these diseases, there are likely common features of
pathogenesis among them. Exploring common disease features may lead to better
treatments for patients with a variety of diseases. This suggests that drugs targeting
ammonia and glutamate metabolism and signaling may be worthwhile pharmacological
interventions.
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In addition to the link between AD, MDD, and T2D and glutamate and ammonia
metabolism and signaling, the comorbidity of the three diseases suggests a possible link
among them. For example, T2D nearly doubles the risk of developing MDD (Anderson et al.
2001; Ali et al. 2006), and those with a history of depression have an increased risk of
developing AD (Geerlings et al. 2008). Furthermore, a strong link between T2D and AD
appears to be established (Ott et al. 1999; Luchsinger et al. 2005; Gudala et al. 2013; Li et
al. 2015). Ammonia metabolism and its role in glutamate signaling may partially explain
the comorbidity, the benefit of NMDA receptor antagonists, and the similar tissue
pathology of these diseases with neurological components. Furthermore, since each of
these diseases has a heritable component (Gatz et al. 1997; Sullivan et al. 2000; Willemsen
et al. 2015), investigating genetic abnormalities in ammonia metabolism genes in
individuals with these diseases may further support a causative role for dysfunctional
ammonia and glutamate metabolism in the onset and progression of the disorders.

Amino Acid and Ammonia Metabolism in AD. Since 1992, Abeta has been a major
focus of AD research (Hardy and Higgins 1992). However, Abeta is likely not the only factor
involved in AD pathogenesis. The year after the amyloid hypothesis was proposed, Seiler
proposed the ammonia hypothesis of AD (Seiler 1993). However, due to the popularity of
the amyloid hypothesis, it has received little attention although the data that support it are
strong. In light of the numerous failed AD drug trials that sought to prevent Abeta
fibrilization or remove fibrils that were already present, many researchers have suggested
that the investigation of other hypotheses of AD pathogenesis is warranted (Herrup 2015).
Of the drugs currently approved to treat AD, none of them targets Abeta, but memantine
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alters glutamate signaling. Therefore, strategies targeting ammonia and glutamate
metabolism may lead to more effective treatments. Seiler has reviewed the body of
evidence that supports the role of ammonia in AD (Seiler 2002). Briefly, subjects with AD
tend to have high levels of ammonia in their plasma (Fisman et al. 1985), cerebrospinal
fluid (CSF), and autopsied brains than age-matched controls (Hoyer et al. 1990). The
cognitive symptoms of those with CPS1 deficiency or hepatic encephalopathy (although not
identical with AD) demonstrate the effects of hyperammonemia on the CNS (Raabe 1987).
Together, this evidence warrants further research.
In addition to increased ammonia levels in AD patients, amino acid level changes in
those with AD have also been thoroughly investigated. Several amino acids have altered
concentrations in blood, CSF, or autopsied brain tissue of AD patients (Chapter 5). Because
amino acids release ammonia when catabolized and are precursors for the synthesis of a
variety of metabolites, their altered levels in AD patients could lead to a variety of disease
symptoms. The changes in amino acid levels in AD patients and animal models are
thoroughly reviewed in Chapter 5.

Ammonia Metabolism in MDD and T2D. Ammonia and glutamate metabolism have
also been linked to MDD and T2D. In addition to the positive effects of memantine on the
symptoms of MDD patients and in a mouse model of T2D, some studies have reported
associations between ammonia metabolism genes and MDD and T2D. Changes in the
activity of GLS in a diabetes rat model were found (Ardawi 1987), and it is also known that
glutamate signaling pathways are altered in those with MDD (Bernard et al. 2011).
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Overview of the Dissertation
In the first part of this dissertation, I discuss the results of studies seeking to find
similarities among amyloidogenic proteins by combining 3D structural analysis with RIN
analysis. Amyloidogenic lysozyme was used as a model of an amyloidogenic protein to
demonstrate the usefulness of combining 3D structural data and RIN data in the study of
primary nucleation (Chapter 2). Next, a group of amyloidogenic proteins was compared to
random network controls and a group of real proteins to detect similarities among the
amyloidogenic proteins (Chapter 3). Then, Abeta, as an example from a prevalent disease,
was explored in more detail to find novel residue interactions that may be involved in
primary nucleation of amyloid fibrils (Chapter 3).
In the second part of this dissertation, the results of the studies aimed at
investigating the potential role of ammonia in a variety of neurological diseases are
discussed. First, a computational model was built to investigate the interactions among the
activities of enzymes involved in ammonia metabolism, dietary protein intake, and blood
ammonia levels and their potential role in hepatic encephalopathy (Chapter 4). Next, the
literature on amino acid and ammonia metabolism changes that occur in AD was
thoroughly reviewed (Chapter 5). Finally, single nucleotide polymorphisms (SNPs) in
ammonia metabolism genes were found to be linked to AD, MDD, and T2D, suggesting the
potential for altered ammonia metabolism to play an important role in a variety of diseases
with neurological symptoms (Chapter 6). By combining the study of amyloid forming
proteins such as Abeta in Alzheimer’s disease and ammonia metabolism in hepatic
encephalopathy, AD, MDD, and T2D, a more complete understanding of diseases with
neurological and metabolic components has been obtained.
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Abstract
Amyloidogenic proteins are most often associated with neurodegenerative diseases
such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, but there are
more than two dozen human proteins known to form amyloid fibrils associated with
disease. Lysozyme is an antimicrobial protein that is used as a general model to study
amyloid fibril formation. Studies aimed at elucidating the process of amyloid formation of
lysozyme tend to focus on partial unfolding of the native state due to the relative instability
of mutant amyloidogenic variants. While this is well supported, the data presented here
suggest the native structure of the variants may also play a role in primary nucleation.
Three-dimensional structural analysis identified lysozyme residues 21, 62, 104, and 122 as
displaced in both amyloidogenic variants compared to wild type lysozyme. Residue
interaction network (RIN) analysis found greater clustering of residues 112-117 in
amyloidogenic variants of lysozyme compared to wild type. An analysis of the most
energetically favored predicted dimers and trimers provided further evidence for a role for
residues 21, 62, 104, 122, and 112-117 in amyloid formation. This study used lysozyme as a
model to demonstrate the utility of combining 3D structural analysis with RIN analysis for
studying the general process of amyloidogenesis. Results indicated that binding of two or
more amyloidogenic lysozyme mutants may be involved in amyloid nucleation by placing
key residues (21, 62, 104, 122, and 112-117) in proximity before partial unfolding occurs.
Identifying residues in the native state that may be involved in amyloid formation could
provide novel drug targets to prevent a range of amyloidoses.
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Background
Amyloidoses are a group of diseases defined by the formation of protein aggregates
characterized by stacks of cross-beta sheets (Greenwald and Riek 2010). There are dozens
of different amyloid diseases caused by a variety of both wild type (WT) and mutant forms
of proteins (Knowles et al. 2014). Some of the most well-known amyloidoses are
neurodegenerative diseases such as Alzheimer’s disease (involving amyloid-beta peptide)
and Parkinson’s disease (involving alpha-synuclein protein). However, not all amyloid
diseases affect the brain. Lysozyme amyloidosis is a rare disease characterized by the
deposition of amyloid fibrils of the enzyme lysozyme. Lysozyme was discovered by
Alexander Fleming in 1922 (Fleming 1922) and is an antimicrobial enzyme synthesized by
hepatocytes, cells of the gastrointestinal system, and macrophages (Granel et al. 2006).
Lysozyme amyloidosis has no known effective treatment and leads to lysozyme amyloid
deposits typically concentrated in the liver (Harrison et al. 1996), spleen, gastrointestinal
tract (Granel et al. 2002), and kidneys (Gillmore et al. 1999). Lysozyme amyloidosis is
thought to be largely caused by subtle structural changes of the protein caused by genetic
mutations that lead to pockets of local instability and a greater likelihood of partial
unfolding (Canet et al. 1999). The Online Mendelian Inheritance in Man (OMIM) database
(Amberger et al. 2015) entry for lysozyme (OMIM ID 153450) reports four lysozyme
variants that are associated with the disease: I56T (Pepys et al. 1993), D67H (Pepys et al.
1993), W64R (Valleix et al. 2002), and F57I (Yazaki et al. 2003).
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Lysozyme has long been used as a model for studying protein structure and folding.
Since lysozyme is structurally and functionally well-characterized, the protein provides a
useful model for understanding the complex process of amyloid fibril formation (Merlini
and Bellotti 2005). Several studies have investigated the role of amyloidogenic mutations
on lysozyme amyloid formation with a focus on the first identified mutations, I56T and
D67H. Studies that examined the crystal structure of the WT and I56T variant suggest very
little difference in the native structure of these enzymes (Funahashi et al. 1996). The D67H
variant, however, destroys the hydrogen bonds that stabilize the beta domain, leading to
the displacement of a long loop of residues (Booth et al. 1997). Because the obvious loop
displacement between the WT and D67H mutant is not present in the I56T mutant, it is
thought that this change is not responsible for amyloidogenesis. Instability of the I56T
variant may be caused by subtle changes in bonding between alpha and beta domains of
lysozyme; similar bonding changes are also evident in the D67H variant (Booth et al. 1997).
Since the structure of proteins in amyloid plaques are different from the native
structure, amyloidogenic proteins must at least partially unfold during amyloidogenesis.
Most studies focus on the unfolding process of lysozyme instead of differences in the native
structure. The amyloidogenic proteins likely spend more time partially unfolded, providing
more opportunities for unfolded segments to interact and aggregate in the form of amyloid
plaques (Canet et al. 1999). The importance of the partially unfolded state for lysozyme
amyloidosis has been demonstrated in vitro with the use of antibodies that stabilize the
protein (Dumoulin et al. 2003; Chan et al. 2008). Studies have also shown that both the
I56T and D67H mutants are less stable than WT lysozyme when heated (Booth et al. 1997),
and the I56T mutant is also less stable than WT at low pH (Funahashi et al. 1996; Booth et
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al. 1997; Morozova-Roche et al. 2000; Buell et al. 2011), further supporting a role for
instability. However, other factors besides regions of protein instability may be involved in
amyloidogenesis. Further studies that examine primary nucleation from different
perspectives could provide more insight into this important process that is associated with
a variety of diseases.
Residue interaction networks (RIN) abstract protein structure into a network of
likely side-chain interactions with residues represented as nodes and interactions
represented as edges, the connections between the nodes (Di Paola et al. 2013). Several
metrics are available for studying networks and identifying subnetworks of interest
(Junker and Schreiber 2008; Estrada 2012; Scardoni and Laudanna 2012). Many network
features have been associated with and applied to protein structural and functional
characteristics (Liu and Hu 2011; Scardoni and Laudanna 2012; Hu et al. 2014; Emerson
and Louis 2015), demonstrating the relevance of RINs to structural biology. Clusters are
particularly interesting in RIN analysis because they identify areas with many chemical
interactions, suggesting structural rigidity or functional importance (Vishveshwara et al.
2002). RIN analysis is most useful when combined with 3D structural analysis (Amitai et al.
2004). This study uses the two-pronged approach of combining 3D structural analysis with
RIN analysis to identify residues in the native structure that are likely involved in amyloid
formation.
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Methods
Three-Dimensional Structure Visualization and Structure Comparison
The Online Mendelian Inheritance in Man (OMIM) database (Amberger et al. 2015)
was searched for mutations in lysozyme that have been associated with amyloidosis. The
Protein Data Bank (PDB) (Berman et al. 2000) was then searched for human lysozyme
structures with these mutations, resulting in a dataset of WT human lysozyme (PDB ID:
1REX, (Muraki et al. 1996)) and two amyloidogenic variants, I56T (PDB ID: 1LOZ, (Booth et
al. 1997)) and D67H (PDB ID: 1LYY, (Booth et al. 1997)). The 3D protein structure
coordinates were downloaded from the PDB and visualized using UCSF Chimera v1.11.2
software (Pettersen et al. 2004). The 3D structures were overlapped using the MatchMaker
application (Meng et al. 2006) in UCSF Chimera with default settings, and the root mean
square deviations (RMSDs) for the full residues from the wild type (1REX) structure of
lysozyme were calculated in the Multialign Viewer (Meng et al. 2006). Side chains that had
a different location when compared to WT lysozyme in both amyloidogenic variants were
selected for further study. Because the resolution of the PDB files used for the comparison
was less than or equal to 1.8 angstroms, only residues with a RMSD from WT greater than
or equal to 1.9 angstroms were considered.

Generating Residue Interaction Networks and Calculating Clusters and Metrics
To detect network clusters in the proteins, the PDB files were converted to GML
format using the Protein Graph Converter software from the Protein Graph Repository
(PGR) (Dhifli and Diallo 2016). Each alpha carbon was considered a node, and an edge was
drawn between every alpha carbon within seven angstroms of another. The GML files were
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then analyzed for clusters using the MCODE application in the network analysis software
Cytoscape v3.4.0 (Shannon et al. 2003). Only clusters with MCODE scores greater than or
equal to 5.00 were selected for further analysis. The residues involved in the clusters in the
amyloidogenic mutants were compared to those identified in WT lysozyme. As with the 3D
structure comparison, cluster changes that are in common between the amyloidogenic
mutants and different from WT lysozyme were selected for further analysis. UCSF Chimera
was used to calculate the average residue B-factor for each of the clusters. The Pearson
correlation of MCODE scores for the selected clusters of each of the lysozyme PDB files with
the average B-factor for the clusters was calculated using GraphPad Prism 7, and a p-value
of < 0.05 was considered significant.

Generating Predicted Dimer and Trimer Structures and Calculating Interprotein Bond
Number and Energies
ClusPro v2.0 software (Kozakov et al. 2017) was used to generate predicted
structures of homodimers, homotrimers, and heterodimers for WT lysozyme and the
amyloidogenic variants. After multimer generation, the resulting PDB files for the top
predicted dimer and trimer structures were edited so that each lysozyme protein was
given a unique name. Next, the edited PDB files were uploaded to the Residue Interaction
Network Generator (RING) v2.0 software (Piovesan et al. 2016), and residue interaction
networks were created using a strict distance threshold between the closest atoms of
residues separated by at least two other residues. Multiple edges per residue pair were
allowed but only one edge per interaction type. The resulting graph files were analyzed for
the number of interactions and overall bonding energy occurring between lysozyme
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proteins in dimers or trimers. The number and bond energies of the interprotein
interactions were analyzed for the whole complexes and the residues of interest to provide
information about the relative importance of the residues of interest to the formation of
dimers and trimers.

Results
Three-Dimensional Structural Comparison of Lysozyme
Three-dimensional structure overlaps from the MatchMaker software revealed
residues of the amyloidogenic variants that differed from WT lysozyme. The D67H variant
diverges more from WT lysozyme than the I56T variant. However, there are only four
residues with a RMSD greater than or equal to 1.9 angstroms that were shared by both the
I56T and the D67H amyloidogenic lysozyme variants: residues 21, 62, 104 and 122. In all
four cases, the structural changes are in proximity to each other in the 3D structure (Figure
2.1).

Figure 2.1: Three-dimensional overlap of lysozyme structures 1REX (WT, tan), 1LOZ (I56T,
orange), and 1LYY (D67H, blue). The side chains of residues 21, 62, 104, 112-117, and 122
are shown and outlined in green.
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Residue Interaction Network Clustering Analysis of Lysozyme Structures
The 3D structure of lysozyme and its resulting PGR residue interaction network
(RIN) representation are shown in Figure 2.2. The MCODE application in Cytoscape
revealed four clusters in each of the lysozyme structures that had an MCODE score of
greater than 5.00. Some of the clusters in each of the lysozyme variants involved similar or
identical sets of residues. As before, we focused on the differences from the WT clusters
that were present in both amyloidogenic proteins. The most robust and consistent
difference was the cluster around residues 112-117. The MCODE score for the cluster
containing these residues in WT lysozyme was 5.11, but it increased in both amyloidogenic
variants to 6.00. Residues 104 and 106-108 are clustered with 112-117 in WT lysozyme
but not in I56T and D67H. The average B-factors of the clusters containing residues 112117 also decreased in both amyloidogenic variants compared to WT lysozyme. These
results are shown in Table 2.1. Residues 112-117 are shown in Figure 2.1. There was a
statistically significant negative correlation (r2 = 0.44, p = 0.0184) between MCODE scores
for the top four clusters in each of the three lysozyme network structures and the average

B-factor for each cluster. The residues are in proximity to the other residues of interest as
shown in Figure 2.1.
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Figure 2.2: Three-dimensional and network structures of lysozyme. A) The threedimensional structure of WT lysozyme, PDB 1REX. B) Network representation of WT
lysozyme with amino acids represented as nodes and edges drawn between alpha carbons
within seven angstroms of each other. Residue numbering starts at zero only for this image.
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Table 2.1: RIN clusters in WT and amyloidogenic variants of lysozyme
Lysozyme Cluster MCODE Score Residues Involved
Average Residue
Structure
Rank
B-Factor
WT
14.88
1
6.36
92-103
12.35
2
6.00
32-37
11.71
3
5.60
7-13, 19, 23-29, 31
9.72
4
5.11
104, 106-108, 112-117
19.09
I56T
16.06
1
6.00
112-117
17.53
2
6.00
92-98
10.54
3
5.60
7-13, 19, 23-29, 31
10.39
4
5.00
122-126
29.15
D67H
13.24
1
6.50
92-100
7.83
2
6.00
112-117
14.99
3
6.00
32-37
8.21
4
5.75
7-13, 17-19, 23, 25-29, 31 8.12

Interprotein Bonds Involving Residues 21, 62, 104, 112-117, and 122 in Predicted
Lysozyme Dimers and Trimers
The top-rated ClusPro models of dimer and trimer structures for each of the
variants of lysozyme are shown in Figure 2.3 (homodimers), Figure 2.4 (homotrimers), and
Figure 2.5 (heterodimers). The number of interprotein residue interactions and the
strength of the bonding energy for these interactions for all residues and for the residues of
interest were quantified using RING 2.0 software, and the results are shown in Table 2.2
(homodimers), Table 2.3 (homotrimers), and Table 2.4 (heterodimers).
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Figure 2.3: Predicted 3D structures of WT or mutant lysozyme homodimers. A) WT: WT, B)
I56T: I56T, and C) D67H: D67H. The side chains of residues 21, 62, 104, 112-117, and 122
are shown and outlined in green.
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Figure 2.4: Predicted 3D structures of WT or mutant lysozyme homotrimers. A) WT: WT:
WT, B) I56T: I56T: I56T, and C) D67H: D67H: D67H. The side chains of residues 21, 62,
104, 112-117, and 122 are shown and outlined in green.
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Figure 2.5: Predicted 3D structures of heterodimers of each of the amyloidogenic lysozyme
variants with WT lysozyme. A) WT: I56T, B) WT: D67H. The side chains of residues 21, 62,
104, 112-117, and 122 are shown and outlined in green.
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Table 2.2 ClusPro predicted interprotein binding energies for WT and mutant lysozyme homodimers
Lysozyme
Number of Interprotein Residue Interactions Interprotein Bond Energy (kJ/mol)
Structure
Total
Residues of Interest
Total
Residues of Interest
(% of Total)
(% of Total)
WT
100
36 (36 %)
1019
398 (39.1 %)
I56T
71
35 (49.3 %)
768
442 (57.6 %)
D67H
61
18 (29.5 %)
594.6
246 (41.4 %)

Table 2.3 ClusPro predicted interprotein binding energies for WT and mutant lysozyme homotrimers
Lysozyme
Number of Interprotein Residue Interactions
Interprotein Bond Energy (kJ/mol)
Structure
Total
Residues of Interest
Total
Residues of Interest
(% of Total)
(% of Total)
WT
89
2 (2.2 %)
824.8
12 (1.5 %)
I56T
133
74 (55.6 %)
1392.8
817 (58.7 %)
D67H
108
24 (22.2 %)
1060.8
320 (30.2 %)

Table 2.4 ClusPro predicted interprotein binding energies for WT and mutant lysozyme heterodimers
Lysozyme
Number of Interprotein Residue Interactions
Interprotein Bond Energy (kJ/mol)
Structures
Total
Residues of Interest
Total
Residues of Interest
(% of Total)
(% of Total)
WT: I56T
48
25 (52.1 %)
481
238 (49.5 %)
WT: D67H
49
27 (55.1 %)
482.6
289.6 (60.0 %)
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For homodimers, residues of interest made up 36% of the number of interprotein
residue interactions in WT lysozyme, contributing to 39.1% of the predicted interprotein
bonding energy. The overall number of interprotein residue interactions increased to
49.3% of the total in the I56T variant, but it decreased to 29.5% of the total number in the
D67H variant. However, the total percentage of interprotein bonding energy contributed by
the residues of interest increased for both amyloidogenic variants even though the total
interprotein bonding energy for dimers was less than WT dimers.
Trimers showed different trends from the homodimers (Table 2.3). The total
number of interprotein residue interactions increased for I56T (133 interactions) and
D67H (108 interactions) compared to WT (89 interactions). The contribution of the
residues of interest to the total number of interprotein residue interactions increased from
2.2% for the WT to 55.6% for the I56T variant and 22.2% for the D67H variant.
Interprotein bonding energy showed similar trends. The total interprotein bonding energy
increased from 824.8 kJ/mol in the WT to 1392.8 kJ/mol in the I56T variant and 1060.8
kJ/mol in the D67H variant. Residues of interest contributed 1.5% of the total interprotein
bonding energy in the WT but 58.7% in the I56T variant and 30.2% in the D67H variant.
Heterodimers (WT: I56T and WT: D67H) showed fewer and less energetic
interprotein interactions than homodimers (Table 2.4). The WT: I56T variant heterodimer
had 48 interprotein interactions and 481 kJ/mol interprotein bonding energy, and the WT:
D67H variant heterodimer had 49 interprotein interactions and 482.6 kJ/mol bonding
energy. In both cases, there was a high reliance on the residues of interest for the bonding.
The residues of interest made up more than 50% of the number of interprotein bonding
interactions and nearly 50% of the interprotein bonding energies of both heterodimers.
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Discussion
Three-Dimensional Structural Comparison Suggests Residues 21, 62, 104, and 122 May Be
Involved in Lysozyme Amyloidogenesis
Comparing 3D protein structures revealed that both amyloidogenic variants of
lysozyme analyzed differ from WT lysozyme in the location of residues 21, 62, 104, and
122. Following the reasoning of Booth and colleagues (Booth et al. 1997), because these
differences are common to both amyloidogenic variants, they suggest these residues may
play a role in the formation of amyloid fibrils. The four residues (21, 62, 104, and 122) are
in proximity to each other in all three variants (Figure 2.1). As discussed above, the
prevailing hypothesis for lysozyme amyloidosis is that the mutations disrupt the hydrogen
bonds near the residues between alpha and beta domains, leading to partial unfolding
followed by fibril formation (Canet et al. 1999; Johnson et al. 2005; Buell et al. 2011);
interprotein interactions between the native structures are not thought to play a large role
in unfolding. However, the consistency of the structural changes observed in both
amyloidogenic variants compared to WT hints at a role for these residues in amyloidosis.
We hypothesized that these residues may facilitate an interprotein interaction between
native state amyloidogenic lysozyme proteins, contributing to the first steps of amyloidosis.
To gather further support for this hypothesis, we examined the structures for network
cluster changes.

Residues 112-117 May Also Be Involved in Lysozyme Amyloidogenesis
In addition to the 3D structural changes described above, amyloidogenic variants of
lysozyme were associated with changes in network clusters. The network cluster
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consisting of residues 112-117 in the I56T and the D67H variants had the greatest and
most consistent cluster changes, showing an increased MCODE score in both variants
compared to WT (Table 2.1). Residues 104 and 106-108 were included in the cluster
containing residues 112-117 in WT lysozyme only, so the loss of this part of the cluster may
also be important for the structural changes observed. More clustering has been shown to
be associated with greater structural stability (Kannan and Vishveshwara 2000;
Vishveshwara et al. 2002), so we hypothesized that residues 112-117 have greater
structural stability in the amyloidogenic variants compared to WT lysozyme. To test this
hypothesis, we used UCSF Chimera to calculate the average B-factor for each of the residues
in each of the PDB files. The B-factor is a measure of flexibility where a lower B-factor
indicates greater stability (Yuan et al. 2005). Even in our relatively small data set of three
lysozyme structures, we found a statistically significant negative correlation (r2 = 0.44, p =
0.0184) between MCODE scores and average B-factors for the top four clusters of each of
the PDB files shown in Table 2.1. Consistent with the hypothesis of greater cluster stability,
residues 112-117 had smaller average B-factors in amyloidogenic variants compared to the
cluster containing these residues in WT lysozyme. Because most studies focus on the
instability caused by amyloidogenic mutations, disrupting this cluster while stabilizing
other regions may provide a novel therapeutic approach. The side chains of residues 112117 are shown in Figure 2.1 along with the other residues of interest (21, 62, 104, and 122)
from the 3D structural comparison. Residues 112-117 are in proximity to the residues
identified through the 3D structural comparison. Therefore, residues 112-117 may also be
involved in facilitating interactions between different lysozyme molecules and possibly
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contribute to the primary nucleation of amyloid fibrils. To test this hypothesis, we
simulated intermolecular interactions between native state structures.

Predicted Dimer and Trimer Structures Provide Further Evidence for the Involvement of
Residues 21, 62, 104, 112-117, and 122 in Lysozyme Amyloidogenesis
To test the hypothesis that residues 21, 62, 104, 112-117, and 122 in the structure
of amyloidogenic lysozyme variants are involved in primary nucleation, we used ClusPro
docking software to predict the 3D structure of dimers and trimers of lysozyme for the PDB
files. While ClusPro generates the structures of many predicted dimers and trimers, we
only analyzed the top-ranked structures. Visual inspection of the predicted homodimers
(Figure 2.3) suggested some of the residues of interest may be involved in dimer
interactions. To test this hypothesis, we examined the number and strength of interprotein
residue interactions (Table 2.2). The number of interprotein bonds was less for
amyloidogenic variant homodimers, and there was no consistent trend with the percent
contribution of the residues of interest to the number of interprotein bonds in the dimers.
Both amyloidogenic variant homodimers had overall less bonding energy. However, the
residues of interest contributed to a greater degree to the interprotein bonding energy
compared to WT lysozyme. Overall, the contribution of the residues of interest to lysozyme
homodimer formation in amyloidogenic variants was not as convincing as the evidence for
their role in simulated trimer formation.
Visual inspection of the predicted trimer structures of lysozyme suggested a greater
role for the residues of interest in interprotein interactions of amyloidogenic variants than
WT lysozyme (Figure 2.4). When examined quantitatively, both amyloidogenic variants
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had stronger and more numerous bonds between proteins compared to WT (Table 2.3).
This suggests the residues of interest may be largely facilitating the predicted sharp
increase in interprotein interactions, supporting the important role predicted for these
residues by 3D structural analysis and network analysis.

A Role for Mutant Native Structure in Enhancing Lysozyme Amyloid Fibril Formation?
Taken together, these data support the hypothesis that residues 21, 62, 104, 112117, and 122 in the mutant native states are involved in lysozyme amyloid primary
nucleation. While the instability of amyloidogenic variants of lysozyme is almost certainly
the most important factor for fibril formation (Dumoulin et al. 2005), it may not be the only
factor involved. The greater interprotein interactions predicted to occur between trimeric
amyloidogenic mutants compared to WT lysozyme may lead to amyloidogenic variants
oligomerizing more readily before unfolding. We hypothesize these aggregates are
composed of mostly mutant proteins because heterodimers with WT lysozyme have less
interprotein bonding energies than mutant homodimers. This suggests when one of the
lysozyme variants partially unfolds, it may already be in proximity to or bound by another
mutant molecule, leading to a greater probability of amyloid nucleation. The sequence of
events of the unfolding process for WT lysozyme and the I56T variant are consistent with
our hypothesis. It has been demonstrated that lysozyme alpha helices A, B, and D
(Moraitakis and Goodfellow 2003) are some of the last regions to unfold (Dhulesia et al.
2010). All the residues identified in this report except residue 62 are in or near regions of
the protein that unfold later in the unfolding process, so these positions have a greater
chance of maintaining their structure to facilitate intermolecular interactions during this
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process. Residues 21, 62, 104, and 122 do not appear to be involved in increasing the
flexibility of lysozyme in the amyloidogenic mutants because the total predicted bond
energies from RING analysis for monomers do not suggest consistent and structurally
important differences when compared to WT. Furthermore, the average B-factors for these
residues in mutant lysozyme do not consistently differ from WT. It has been suggested that
residues not present in the partially unfolded region can be altered without affecting the
process of amyloid fibril formation (Ahn et al. 2012), but our data challenge this
suggestion. It has been noted that lysozyme amyloid plaques are nearly entirely composed
of the amyloidogenic variant free from WT protein (Morozova-Roche et al. 2000). This may
be due not only to the greater instability of amyloidogenic proteins, but also due to the
predicted favored intermolecular interactions of mutant homodimers and homotrimers
compared to heterodimers with WT molecules (Table 2.4). A better understanding of the
process of amyloidogenesis for lysozyme could yield insights into treatments for many
different types of amyloidoses.

Study Limitations and Future Studies
Data from various computational approaches in this study support a role for
lysozyme residues 21, 62, 104, 112-117, and 122 in lysozyme amyloidosis. However, this
study has several limitations. The most obvious limitation is the small sample size of 3D
structures used. Unfortunately, the study is limited by the availability of PDB files of human
amyloidogenic lysozyme variants. We draw our conclusions from three PDB files, making
this a preliminary study. The findings reported here may not be shared by all
amyloidogenic variants of lysozyme. To increase confidence in our conclusions, further
59

studies should explore the structures of WT and amyloidogenic lysozyme under various
experimental conditions. Furthermore, these hypotheses need to be experimentally tested
to verify the importance of these residues for amyloidogenesis. Lysozyme mutants with
smaller side chains or nonpolar side chains at the residues of interest could be created and
the fibril formation kinetics studied. Data from studies of double mutants may also be
useful. Future studies could be performed where residues 21, 62, 104, 112-117, or 122 are
mutated in combination with I56T or D67H and tested for altered fibril formation kinetics.
However, it may be most useful to mutate residue 21 and a residue in 112-117 or 122
because residues 32 through 108 have been shown to form the core of the lysozyme fibril
(Frare et al. 2006). Therefore, mutating these residues may interfere with amyloid
formation after unfolding.

Conclusions and Testable Hypotheses Generated
This preliminary study used a combination of 3D structural and residue interaction
network analyses to support roles for residues 21, 62, 104, 112-117, and 122 in lysozyme
amyloidosis. By comparing two amyloidogenic variants to WT lysozyme, we were able to
identify network and 3D structural changes that were shared between the amyloidogenic
variants. Modeling dimer and trimer interactions further supported a role for these
residues. These residues appear to be especially important for trimer formation. This study
generates several hypotheses that can be experimentally tested. 1) Residues 112-117 are
less flexible in amyloidogenic variants of lysozyme than in the WT. 2) Residues 21, 62, 104,
112-117, and 122 are involved in the primary nucleation of lysozyme by facilitating
intermolecular interactions between mutant lysozyme molecules. 3) Trimers of lysozyme
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are more stable than dimers. 4) Lysozyme mutant molecules favor self-interactions over
interactions with WT molecules. 5) Interprotein interactions in or close to the native state
likely play a larger role in amyloid formation in general than previously hypothesized. This
study demonstrates the utility of combining 3D structural and network analysis for
understanding amyloid formation. Furthermore, it provides insight into lysozyme amyloid
formation that may be applicable to the study of many other amyloidoses.
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Abstract
Amyloid plaques are known to contribute to the pathogenesis of a variety of
diseases, but few 3D structural or sequence similarities among these proteins have been
found. Here we report similarities in the residue interaction networks (RINs) of unrelated
non-amyloid forms of amyloidogenic proteins. RINs for amyloidogenic proteins, nonamyloidogenic proteins, and random network controls were created, and various network
metrics were calculated to test for differences in network structures. After finding
differences in the RINs between a set of control proteins and a set of amyloidogenic
proteins, we found differences in network structures when comparing amyloidogenic
variants to non-amyloidogenic variants of the same proteins. Next, we focused on amyloidbeta (1-42) (Abeta42) because of its likely involvement in the pathogenesis of Alzheimer’s
disease (AD). Abeta42 is more amyloidogenic and therefore more likely to form amyloid
plaques in aqueous environments than nonpolar environments that resemble cell
membranes. We examined the network and structural differences in Abeta42 in a more
polar versus a relatively nonpolar solvent and found some of the network features of
amyloids were only present when Abeta was in the more polar environment. Insights from
the combined use of network analysis and structural data suggest that the interaction
between Val24 and Ile31 in Abeta42 in more nonpolar environments may be involved in
preventing amyloidogenesis. This in silico study generates hypotheses that could provide
insight into amyloid primary nucleation.
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Background
In many neurodegenerative diseases such as Alzheimer’s disease (AD) and
Parkinson’s disease, specific proteins are known to aggregate into cross-β sheet structures
called amyloid fibrils (Makin and Serpell 2005). There are dozens of these diseases,
collectively called amyloidoses, that affect several physiological systems (Greenwald and
Riek 2010). Amyloid fibrils are thought to contribute to disease processes (Knowles et al.
2014). The protein monomers that form fibrils associated with diseases are diverse, and
there are few structural and sequence similarities among them (Tzotzos and Doig 2010).
Further understanding the similarities among amyloidogenic proteins that are present
could provide insight into the first steps of nucleation, when two or three molecules of the
same protein interact to form oligomers that may continue aggregating to form fibrils
(Knowles et al. 2014). To investigate the molecular properties of amyloidogenic proteins
that lead to plaque formation, we examined the residue interaction networks (RINs). RINs
represent the residue interactions that are likely to occur as determined by the protein
structure and are reviewed by Di Paola et al. (Di Paola et al. 2013). Each amino acid is
represented as a node, and edges are drawn between residues that are likely to interact
(Figure 3.1). Various metrics have been devised to mathematically describe the network
size and the connections within a network (Estrada 2012), and many of these metrics have
biological interpretations useful for analyzing protein structure (Amitai et al. 2004;
Scardoni and Laudanna 2012) (Table 3.1). It has even been found that 3D structural
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analysis techniques such as normal mode analysis reveal features that are largely
determined by RINs (Bahar et al. 2010). RINs are powerful tools because they examine
proteins from the perspective of a whole system rather than using a reductionist approach.
This information complements more traditional structural and sequence studies, adding
another layer to the understanding of protein function. RIN observations indicate residues
that are important to the network (Estrada 2012); if a residue is important to the network,
it is likely important to the 3D structure of the protein. This study investigates associations
between RINs and amyloidogenicity to provide novel insights into common 3D structural
features of non-amyloid forms of amyloidogenic proteins. If the non-amyloid forms of
amyloidogenic proteins have similar features distinct from nonamyloidogenic proteins,
these features may predispose the proteins to nucleate and fibrillize into amyloids.

Figure 3.1: Three-dimensional and network structures of β-2-microglobulin. Residue
interaction networks (RINs) abstract a 3D protein structure (left) into a network (right) of
nodes (representing residues) and edges (representing potential residue bonds). This
structure and network is for β-2-microglobulin (PDB ID: 5CSB). The numbering of residues
in the network begins at zero in this figure only.
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Table 3.1: Network metrics and their interpretations
Metric
Interpretation of Metric
Average Clustering Coefficient Average connectedness of a node’s neighbors
Centralization

Describes how much the network relies on hubs

Average Shortest Path Length

Mean minimum number of edges between one node
and any other node

Density

Describes how connected the network is compared to a
fully connected network

Average Number of Neighbors

Mean number of edges connected to a node

Highest MCODE Score

Describes the “strength” of the top cluster

Average of Top 3 MCODE
Scores

Describes the average “strength” of the top three
clusters

Clusters per Node

How many clusters are in a network (corrected for
network size)

Number of Nodes

Total number of nodes in a network

Betweenness

Describes the extent to which a node is in the shortest
path between other node pairs

Residue Centrality

Change in mean shortest path length after removing a
node and its edges

Amyloid-beta (1-42) (Abeta42) is a 42 amino acid peptide that is hypothesized to be
a causative factor in Alzheimer’s disease (Hardy and Higgins 1992). As discussed above,
Abeta42 forms amyloid fibrils and plaques in the brains of AD patients. Many drug
candidates have been designed to reduce the amount of amyloid plaques in the AD brain,
but these efforts have been largely ineffective in treating AD in human trials (Herrup
2015). If blocking oligomerization and amyloidogenesis of Abeta42 can lead to treatments
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for AD, a better understanding of the primary nucleation of this peptide could lead to more
effective drugs.
Abeta is a well-studied peptide, and there are many reports describing the
relationship between fibrillization and the Abeta sequence. However, Abeta contains
amino and carboxyl terminal regions of intrinsic disorder, and therefore detailed structural
studies of the full-length peptide have proven challenging. The central hydrophobic cluster
(CHC), consisting of residues 17-21, has been shown to be important for fibrillization
(Wurth et al. 2002). Studies with fragments containing the CHC reveal that replacing any of
the five residues prevents fibrillization (Wood et al. 1995). Several other studies have also
found the CHC to be important for fibrillization (Hilbich et al. 1991; Hilbich et al. 1992;
Esler et al. 1996; Wurth et al. 2002). However, the CHC is not the only region suspected to
be involved in fibril formation. Scanning proline mutagenesis of Abeta40 identified
residues 24-26 and 31-34 as important for fibrillization (Williams et al. 2004). The Nterminal 10 to 15 residues have not been found to have much effect on amyloid formation
(Sánchez De Groot et al. 2005).
While some amyloidogenic proteins have regions that lack clearly defined structure,
there is much evidence using different experimental conditions that Abeta is not
completely disordered, and that the structured regions that are present play a role in
nucleation and fibril formation. Studies have detected secondary structure in Abeta40 or
Abeta42 dissolved in hexafluoroisopropanol (HFIP) (Crescenzi et al. 2002; Tomaselli et al.
2006), aqueous solvent with and without trifluoroethanol (TFE) (Soto et al. 1995),
aqueous sodium dodecyl sulfate (SDS) micelles (Coles et al. 1998; Shao et al. 1999),
aqueous urea solutions (Chen and Glabe 2006), and aqueous glycine solutions (Kirkitadze
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et al. 2001). HFIP and aqueous SDS micelles are used to model a phospholipid membrane
environment (Shao et al. 1999; Crescenzi et al. 2002), so protein structures in these
solutions are likely similar to the in vivo membrane structures. Studies have shown that
some secondary structure is necessary for Abeta amyloid formation because Abeta
fibrillization was decreased following the near complete denaturation of Abeta by urea
(Chen and Glabe 2006).
While the presence of secondary structure in Abeta dissolved in several different
solvents has been described, there is not much consensus on the structural details. For
example, while several studies have provided support for the existence of a turn region in
Abeta, there are conflicting reports about where the turn occurs and even how many turns
there are. These inconsistencies are likely due to different solvent conditions and peptide
fragments used for these experiments. Williams et al. report two turn regions around
residues 22-23 and 29-30 (Williams et al. 2004), whereas Morimoto et al. report only one
turn around residues 22-23 (Morimoto et al. 2004), and Lazo et al. found evidence of one
turn near residues 24-28 (Lazo et al. 2009). More data will likely help clarify these
inconsistencies reported for Abeta structure, allowing for more precise drug targeting.
In this study we used both RINs and structural data to provide novel insights into
the primary nucleation of Abeta42 and the role of solvent polarity in nucleation. We found
that amyloidogenic proteins tend to be smaller, denser, and more centralized when
compared to non-amyloidogenic controls. These features indicate networks that are more
reliant on hubs. Potential binding pockets including these hub amino acids could prove
useful as drug targets. Furthermore, our data suggest that when Abeta42 is present in a
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more nonpolar solvent or membrane environment the interactions between Val24 and
Ile31 in Abeta42 may play a role in preventing primary nucleation.

Methods
Creating Residue Interaction Networks from PDB Files
3D structure files for amyloidogenic proteins available in the Protein Data Bank
(PDB) (Berman et al. 2000) (Table 3.2) and proteins not known to form amyloid fibrils in
disease (Real Protein Controls, Table 3.3) were downloaded. The PDB files were uploaded
to the Protein Graph Repository Converter (PGR Converter) (Dhifli and Diallo 2016 Jan 24)
and used to create RINs. A node was considered to be the alpha carbon and an edge was
drawn between every alpha carbon within 7 Å. The networks were exported from PGR
Converter as GML files and then imported into Cytoscape v3.4.0 (Shannon et al. 2003) for
visualization and network analysis.
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Table 3.2: Network metrics of amyloidogenic proteins
PDB
Name
SCOP Class Closest
ID
Match
1ZEH Insulin
Small Protein α
1IYT
Amyloid-β (1-42)
Peptide
α
1QLX Human Prion Protein α+β
α+β
1XQ8 α-Synuclein
Coiled Coil
α
2KB8 Amylin
NA
α
1LOZ Lysozyme (I56T)
α+β
α+β
4IP8
Serum Amyloid-α
α
α
5CSB β-2-Microglobulin
NA
β
(D76N)
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Nodes
102
42
104
140
37
130
420
100

Density Clusters
per Node
0.074
0.069
0.168
0.119
0.070
0.115
0.046
0.100
0.188
0.108
0.060
0.092
0.021
0.074
0.073
0.090

Centralization
0.056
0.054
0.047
0.019
0.095
0.049
0.015
0.049

Table 3.3: Network metrics of real protein controls
SCOP Protein Control PDB IDa
Nodes Density Clusters Centralization
Class
Number
per Node
1
1A6M
151
0.052
0.073
0.028
α
2
1ALL
321
0.026
0.059
0.015
3
1B33
2060
0.004
0.064
0.002
4
1C75
71
0.114
0.099
0.103
5
1DLW
116
0.067
0.086
0.038
6
1DO1
153
0.052
0.092
0.034
7
1DWT
152
0.052
0.079
0.035
8
1FPO
499
0.015
0.060
0.009
9
1FXK
349
0.023
0.049
0.012
10
1G08
572
0.014
0.068
0.009
11
1H97
294
0.028
0.071
0.017
12
1HBR
572
0.014
0.072
0.009
13
1IDR
253
0.030
0.087
0.022
14
1IRD
287
0.028
0.077
0.017
15
1KR7
110
0.070
0.091
0.041
16
1KPT
334
0.025
0.078
0.014
17
1LIA
664
0.012
0.062
0.009
18
1MWC
306
0.026
0.059
0.017
19
1NEK
1068
0.008
0.073
0.005
20
1PHN
334
0.024
0.072
0.015
21
1ALC, 1AVP
168.5
0.051
0.105
0.036
α+β
22
1BRN, 1CNS
351
0.026
0.081
0.016
23
1CQD, 1EUV
582
0.018
0.079
0.013
24
1F13, 1GCB
946.5
0.012
0.082
0.008
25
1GOU, 1IWD
216.5
0.036
0.081
0.027
26
1K3B, 1LNI
272
0.031
0.098
0.025
27
1LSD, 1ME4,
1MZ8, 1PPN
245
0.039
0.101
0.031
28
1QMY, 1QSA,
1UCH, 2ACT
377.5
0.026
0.084
0.019
29
1AUN, 1BEH,
β
1BHU, 1DMH,
1DO6
308.6
0.039
0.090
0.030
30
1F35, 1F86,
1G13, 1HOE,
1I9R
569
0.038
0.091
0.023
31
1IAZ, 1IFR,
1JK6, 1KCL,
1KNB
299
0.041
0.097
0.030
32
1SFP, 1SHS,
1SLU, 2MCM,
2HFT
338.4
0.042
0.082
0.033
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Creating Real Protein Controls
The proteins selected for the real protein controls were based on the protein control
groups created by Bagler (Bagler and Sinha 2005; Bagler 2006) and Sinha (Bagler and
Sinha 2005). The Bagler and Sinha protein library consists of 20 proteins each of the α, β,
α+β, and α/β structural classes as defined by the Structural Classification of Proteins
(SCOP) (Murzin et al. 1995) for a total of 80 protein control entries. We searched the
amyloidogenic proteins in SCOP, and, if they were assigned to a protein structure class that
was not α, β, α+β, or α/β, we classified them as α, β, α+β, or α/β based on the closest best
fit determined by visual inspection (Table 3.2). If a protein was not included in SCOP, we
searched for structural matches in SCOP and used the class of the closest match. The
resulting amyloidogenic group was 62.5 % α-class, 12.5 % β-class, 25 % α+β-class, and 0 %
α/β class. The real protein control group was adjusted to reflect the structural class
composition of the amyloidogenic group by averaging metrics from random subgroups of
real protein control entries in the same class to condense the 20 protein entries in each
group so we could create a control group with 20 entries from the α-class, 4 entries from
the β-class, and 8 entries from the α+β-class. This method yielded a control group with the
same percent composition of protein classes as the amyloidogenic protein group. The
averaged random subgroups and the resulting control group are included in Table 3.3.

Creating Random RIN Controls
The RIN metrics from the amyloidogenic proteins were compared to the real protein
controls. However, the real protein controls generally consisted of larger networks (Table
3.3). To determine if differences between groups are due to network size or network
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connections, we created a random network control group of the amyloidogenic proteins
(Table 3.4). To create the random protein controls, we retained the number of nodes and
edges from each RIN for the amyloidogenic proteins, but the connections between them
were randomized using the Network Randomizer application (Tosadori et al. 2016) in
Cytoscape. For each amyloidogenic protein RIN, fifty random networks were created. The
RIN metrics were calculated for each of the networks, and then the mean of the fifty
resulting metric values for each type of metric was used as the randomized metric value for
the random control of a single amyloidogenic protein. This process was repeated for each
amyloidogenic protein.

Table 3.4: Average metrics of randomized networks of amyloidogenic proteins
PDB Name
Nodes Density Clusters
Centralization
ID
per Node
1ZEH Insulin
102
0.074
0.033
0.074
1IYT Amyloid-β (1-42)
42
0.168
0.056
0.142
1QLX Human Prion Protein
104
0.070
0.031
0.070
1XQ8 α-Synuclein
140
0.046
0.019
0.051
2KB8 Amylin
37
0.188
0.056
0.154
1LOZ Lysozyme (I56T)
130
0.060
0.028
0.062
4IP8
Serum Amyloid-α
420
0.021
0.011
0.024
5CSB β-2-Microglobulin (D76N) 100
0.073
0.033
0.071

Calculating RIN Metrics
Local RIN metrics were calculated in Cytoscape using the Network Analyzer
application (Assenov et al. 2008). The MCODE application (Bader and Hogue 2003) in
Cytoscape was used to calculate the number of clusters in a network. Centrality measures
of Abeta42 included betweenness and residue centrality. Residue centrality was calculated
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as by Hu et al. (Hu et al. 2014) by taking the average path length for the whole Abeta42
network, deleting a single node, recalculating the average path length for the resulting
network, and then finding the absolute value of the change in average path length from the
whole network. This was repeated for every node in the Abeta42 network. These values
were used to determine which nodes have the highest betweenness values and which
nodes are the most critical for maintaining the average path length. We then calculated
betweenness values for residues in Abeta42 and Abeta40 in more polar and more nonpolar
solvents (PDB structure files 1IYT (Crescenzi et al. 2002); 1Z0Q (Tomaselli et al. 2006);
1BA4 (Coles et al. 1998); 2LFM (Vivekanandan et al. 2011)). Next, we averaged the
betweenness values for residue regions of interest in Abeta and compared them across all
four structures.

Overlapping Abeta42 Structured Regions and Analyzing Residue Interactions
The PDB files for Abeta42 were visualized using UCSF Chimera v1.11.2 (Pettersen et
al. 2004). The unstructured regions of each of the PDB files as determined by visual
inspection (residues 1-9 and 33-42) were trimmed off, and then the two structures were
overlapped using the MatchMaker application (Meng et al. 2006) in UCSF Chimera. The
structural data for the PDB files for Abeta42 are from NMR experiments, so there is
information for multiple models in each file. To determine the residue interactions
occurring in each model, each chain was individually input into the Residue Interaction
Network Generator (RING) (Piovesan et al. 2016), and networks were created using the
alpha carbons as nodes and by drawing a single undirected edge for each type of
interaction between two residues. The resulting networks were each analyzed for the
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presence of edges between the residues of interest identified from the betweenness and
residue centrality measures.

Analyzing Predicted Abeta42 Trimer Interactions
To determine the potential differences of contributions of the residues of interest to
the energy of interpeptide bonding in a solvent, we used ClusPro (Kozakov et al. 2017) to
predict the trimer structure of Abeta42 in a nonpolar or a polar solvent. The resulting PDB
file for the ClusPro top-rated predicted structure was input into RING, and networks were
created as described above. Bonding information was exported to Microsoft Excel and the
predicted bond energies for interpeptide interactions were summed for each condition.

Statistical Analysis of Data
All statistical analyses were completed with GraphPad Prism v7.0, and p-values <
0.05 were considered significant.

Comparing Amyloidogenic Proteins, Real Protein Controls, and Random Network
Controls. The data was tested for normality using the D’Agostino-Pearson normality test.
When the data distribution was normal, and the groups had equal variance as determined
by Bartlett’s test, a one-way ANOVA with Tukey’s post hoc test was performed. This was
the case for comparing the RIN metric clusters per node. If data was not normally
distributed but had equal variance, the Kruskal-Wallis test with Dunn’s multiple
comparisons was performed. This was the case for number of nodes and centralization. If
data was not normal and did not have equal variance, it was transformed by taking the
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square root of each value and then rechecked for normality. We then performed a one-way
ANOVA with Tukey’s post hoc test. This was the case for network density.

Analyzing Abeta42 Centrality Metrics. To determine which residues had high
centrality values, we checked the data for normality using the D’Agostino-Pearson
normality test before calculating the z-score for each of the residues. Betweenness values
were normalized by taking the square root of each value, and residue centrality values
were normalized by taking the cube root. Z-score absolute values ≥ 2 were considered
statistically significant. For both betweenness and residue centrality, Val24 and Ile31 had
z-score absolute values ≥ 2.

Comparing Average Betweenness Values of Regions in Abeta. The arithmetic mean
for betweenness was calculated for regions of interest of different lengths across several
PDB structures of Abeta. These average betweenness values of regions were compared to
the average betweenness of the entire structure using a paired one-way ANOVA with
Tukey’s post hoc test.

Results
RINs of Amyloidogenic Proteins Have Unique Features Compared to Controls
Of the RIN metrics analyzed (average clustering coefficient, centralization, average
shortest path length, density, average number of neighbors, highest MCODE cluster score,
average of top 3 MCODE cluster scores, clusters per node, and number of nodes), four
metrics showed significant differences when comparing amyloidogenic proteins to the
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controls (Figure 3.2). The eight amyloidogenic proteins in our data set are shown in Table
3.2. If the amyloidogenic protein group differs from the real protein controls in the same
direction and magnitude as the random controls, then the differences are due to network
size and not wiring (the specific connections between nodes). If both the amyloidogenic
protein group and the random control group differ from the real protein controls and differ
from each other, then at least some of the differences are due to network wiring. First,
compared to real protein controls, amyloidogenic proteins tend to have fewer nodes
(Figure 3.2A) and a higher density (Figure 3.2B). These metrics are a measure of network
size rather than connections. However, some measures related to network wiring also
showed significant differences. Amyloidogenic proteins had 1) slightly greater numbers of
clusters per node (Figure 3.2C) compared to real protein controls or random networks.
Furthermore, 2) the centralization of amyloidogenic RINs was greater than real protein
controls but less than random network controls (Figure 3.2D).
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Figure 3.2: Comparing network metrics for amyloidogenic proteins (APs), real protein
controls (Real Protein Ctrl), and random network controls (Random Ctrl). # indicates p ≤
0.05, ## indicates p ≤ 0.01, ### indicates p ≤ 0.001, and #### indicates p ≤0.0001 when
compared to Real Protein Ctrl.

RINs of Amyloidogenic Variants of Proteins Show Similar Patterns as When Comparing
Amyloidogenic RINs to Real Protein Controls
We compared the RINs of wild type (WT) variants to amyloidogenic variants of the
same proteins. The findings are reported in Table 3.5 for lysozyme (an α+β class protein)
and Table 3.6 for β-2-microglobulin (a β-class protein). Lysozyme and β-2-microglobulin
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were chosen because they both had WT and amyloidogenic variant structures available in
the Protein Data Bank (Muraki et al. 1996; Booth et al. 1997). For centralization but not for
density or clusters per node the amyloidogenic lysozyme variants I56T and D67H showed
similar differences from the WT protein as the group of amyloidogenic proteins showed
when compared to real protein controls. For centralization and density only D76N β-2microglobulin showed similar differences from the WT protein as the group of
amyloidogenic proteins showed when compared to real protein controls.

Table 3.5: Effects of amyloidogenic mutations of lysozyme (α+β class) on RIN
metrics
Network Metric WTa
I56Tb D67Hc Consistent with Group Trends?
Centralization
0.049
0.049 0.050
Yes
Density
0.0604 0.0602 0.0598 No
Clusters per Node 0.108
0.092 0.115
No
a
PDB ID 1REX
b
PDB ID 1LOZ
c
PDB ID 1LYY

Table 3.6: Effects of amyloidogenic mutations of β-2-microglobulin (β-class) on RIN
metrics
Network Metric WTa
D76Nb Consistent with Group Trends?
Centralization
0.040
0.049 Yes
Density
0.072
0.073 Yes
Clusters per Node 0.10
0.09
No
a
PDB ID 5CS7
b
PDB ID 5CSB
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RINs of Abeta40 and Abeta42 Show Similar Patterns as When Comparing Amyloidogenic
RINs to Real Protein Controls
We compared the RINs from Abeta42 in 20% H2O, 80% hexafluoroisopropanol
(v/v) (Crescenzi et al. 2002), a more nonpolar solvent (predicted to make Abeta less
amyloidogenic), to those in 70% H2O, 30% hexafluoroisopropanol (v/v) (Tomaselli et al.
2006), a more polar solvent (predicted to make Abeta more amyloidogenic), and found that
the centralization was different and changed in a direction consistent with the trends
described above for real protein controls versus amyloidogenic proteins. However,
clusters per node or density did not follow these trends (Table 3.7). We found similar
results when comparing the RINs of Abeta40 in nonpolar and polar solvents (Table 3.8).

Table 3.7: Effects of solvent conditions on amyloid-beta (1-42) RIN metricsa
Network Metric Nonpolarb Polarc Consistent with Group Trends?
Centralization
0.054
0.063
Yes
Density
0.168
0.159
No
Clusters per Node 0.119
0.095
No
a
Amyloid-beta (1-42) tends to form amyloid plaques in polar solvents
(Crescenzi et al. 2002).
b
PDB ID 1IYT
c
PDB ID 1Z0Q
Table 3.8: Effects of solvent conditions on amyloid-beta (1-40) RIN metricsa
Network Metric Nonpolarb Polarc Consistent with Group Trends?
Centralization
0.069
0.086
Yes
Density
0.165
0.123
No
Clusters per Node 0.125
0.125
No
a
Amyloid-beta (1-42) tends to form amyloid plaques in polar solvents
(Crescenzi et al. 2002).
b
PDB ID 1BA4
c
PDB ID 2LFM
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RINs of Abeta40 and Abeta42 Reveal Higher Mean Betweenness Values for the CHC
The central hydrophobic cluster (CHC) in the Abeta40 and Abeta42 peptides spans
residues 17-21. Compared to the average betweenness of each of the entire structures, the
CHC had a significantly higher average betweenness (Figure 3.3). Because betweenness
can indicate structurally important residues, this agreed with the visual examination of the
3D structure of Abeta40 and Abeta42 in each solvent where it is visually evident that the
CHC largely retains its structure.

Figure 3.3: Average betweenness of regions of Abeta40 and Abeta42 compared to the
average betweenness of the entire node set. # indicates p ≤ 0.05 and ## indicates p ≤ 0.01.

Val24 and Ile31 Have Significantly Higher Centrality Values
The betweenness (Figure 3.4A) and residue centrality (Figure 3.4B) measures for
each residue in Abeta42 in the more nonpolar solvent are shown. In each case, the values
for Val24 and Ile31 were higher than the value for the average node in the network, and
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each has a z-score absolute value of ≥ 2.0, so they were significantly different from the
values of the other residues. Structural data indicated that Val24 and Ile31 were likely to
form hydrophobic interactions in 3 of 10 NMR models in the PDB 1IYT structure file (more
nonpolar solvent), but no hydrophobic interactions between these residues were predicted
in any of the 30 models in the PBD 1Z0Q structure file (more polar solvent). The structures
in the more nonpolar and more polar environments for representative NMR models are
shown in Figure 3.5.

Figure 3.4: Betweenness and residue centrality values for each residue in Abeta42 in a
more nonpolar solvent (1IYT). * indicates a z-score ≥ 2.0.
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Figure 3.5: Structured regions of Abeta42 in a more nonpolar solvent (tan, 1IYT) and a
more polar solvent (blue, 1Z0Q). The side chains of Val24 and Ile31 are shown highlighted
in green in each case.

Predicted Trimers of Abeta42 Suggest Greater Interpeptide Bonding Energy in More Polar
Solvents
The PDB files of the predicted trimers with the top ClusPro ranking for 1IYT
(showing the possible Val24-Ile31 hydrophobic interaction) and 1Z0Q (showing no Val24Ile31 hydrophobic interaction) were used to generate RINs, and the predicted bonding
energies were analyzed (Figure 3.6). The total bonding energy between chains was larger
for the predicted trimer with no hydrophobic Val24-Ile31 interaction (1Z0Q PDB file).
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Figure 3.6: Predicted trimer structures of Abeta42. UCSF Chimera predictions of trimer
formation for Abeta42 in a more nonpolar solvent (left, 1IYT) and a more polar solvent
(right, 1Z0Q). The side chains of Val24 and Ile31 are shown highlighted in green in each
case.

Discussion
RINs From Amyloidogenic Proteins Suggest Similarities in Structure
By comparing non-amyloidogenic protein RINs to those of amyloidogenic proteins,
differences unique to amyloidogenic proteins were detected. When interpreted in the light
of structural data, the results could be important for understanding the amyloidogenic
process and developing strategies to prevent it. RIN metrics have important biological
interpretations, allowing for structural and functional predictions (Amitai et al. 2004;
Scardoni and Laudanna 2012). Compared to real protein controls, amyloidogenic proteins
tended to be more centralized, smaller, denser, and had more clusters per node (Figure
3.2). The network metric differences due to differences in network wiring provide novel
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insight into the structure of amyloids. Amyloidogenic proteins had more clusters per node.
A cluster is a group of nodes that is highly connected (Bader and Hogue 2003), indicating
the potential for many residue interactions. This suggests a greater number of local areas
of higher stability in amyloidogenic proteins compared to non-amyloidogenic proteins.
This does not contradict the well-established finding that destabilizing mutations increase
amyloidogenesis because the amyloidogenic proteins could be globally less stable while
having a few local areas of higher stability. Amyloidogenic proteins were also more
centralized. Centralization describes the “star-like” character of a network (Pavlopoulos et
al. 2011), which can also be described as reliance on hubs. A reliance on hubs makes
proteins more robust against random “attacks” such as random amino acid substitutions
caused by DNA mutations, but it leaves them more susceptible to targeted attacks (Albert
et al. 2000; Oltvai et al. 2000), such as those that can occur when groups of amino acids
including hubs are targeted by rational drug design. Drugs targeting these hub regions are
more likely to greatly disrupt or stabilize peptide structure than drugs targeting other
regions of the protein. Network metrics revealed common features in amyloidogenic
proteins that have not previously been described. These common features may enhance
our understanding of the pathogenesis of amyloidoses.

Some of the Network Differences Observed for Amyloidogenic Proteins as a Group Are
Robust Enough to Be Observed in Mutant Variants of the Same Protein
This study reports significant network differences between an amyloidogenic
protein group and a group of non-amyloidogenic proteins. We also investigated whether
the differences between amyloidogenic proteins and real protein controls held when
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examining different mutant variants of the same protein. Lysozyme (an α+β class protein)
has been extensively studied as a model of amyloidogenesis because it has mutant variants
that differ by a single residue that are much more likely to form amyloid plaques
(Swaminathan et al. 2011). We compared WT lysozyme network metrics to those of two
different amyloidogenic variants and observed similar changes in centralization as when
comparing amyloidogenic proteins to real protein controls (Table 3.5). The protein β-2microglobulin (a β-class protein) also had a WT structure and an amyloidogenic variant for
comparison. The expected trends held for centralization and density for β-2-microglobulin
(Table 3.6). The network metric differences were understandably small because we
analyzed networks that only had a single amino acid change. Because increased
centralization was present in the amyloidogenic variants of proteins from these two
classes, increased centralization may be a more robust difference between amyloidogenic
proteins and non-amyloidogenic proteins than other network metrics tested. Therefore,
drugs could be designed to target the regions of the peptide that include the hubs that
amyloidogenic proteins appear to rely on most heavily for network structure.

Network Variations Can Be Observed for the Same Protein in Different Solvents
Some of the differences observed when comparing amyloidogenic proteins to real
protein controls were observed even when comparing the networks of the same protein in
different solvents. Abeta42 structures in HFIP were used because HFIP is a model for
hydrophobic membrane environments (Crescenzi et al. 2002). While HFIP likely
exaggerates the alpha helicity of Abeta (Pachahara et al. 2015), it is still a relevant model
for Abeta structure in vivo because alpha helical Abeta likely plays a role in
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amyloidogenesis (see Background). The two concentrations of HFIP used for structural
studies also allow for a direct comparison to determine the effects of solvent polarity on
Abeta structure. We examined network properties of Abeta42 dissolved in a more nonpolar
solvent where it is less amyloidogenic and those present when it is dissolved in a more
polar solvent where it is more amyloidogenic (Crescenzi et al. 2002). Interestingly, we
found the Abeta42 network when the more polar solvent was used to be more centralized
than that for Abeta42 when the more nonpolar solvent was used (Table 3.7). We observed
the same trend when comparing Abeta40 dissolved in the more nonpolar and more polar
solvents (Table 3.8). Because this trend was also found when comparing the amyloidogenic
variants of lysozyme and β-2-microglobulin with their WT variants, increased
centralization appears to be a consistent feature of amyloidogenic proteins. As discussed
above, increased centralization could indicate the presence of effective drug targets in
amyloidogenic proteins because of the increased reliance on hubs.

Results from RIN Metrics Support a Role for the CHC in Abeta Fibrillization
Amyloid-beta is a well-studied protein with much known about its structure. The
CHC has been identified as an important region of Abeta for fibrillogenesis (Wurth et al.
2002). Consistent with these studies, we found that the CHC has significantly higher
average betweenness values compared to the average betweenness values of the entire
networks (Figure 3.3). Betweenness describes the frequency with which a node occurs in
the shortest path length between any two other nodes (Chakrabarty and Parekh 2016).
Betweenness is used as a metric to identify residues that are important for the overall
network (Steuer and Lopez 2008) and therefore for the 3D structure. The significantly
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higher average betweenness values for the CHC indicate that it is an important region for
the structure of Abeta monomers. This agrees well with several other studies (Hilbich et al.
1991; Hilbich et al. 1992; Esler et al. 1996; Wurth et al. 2002), providing support for the
usefulness of RINs in the study of protein structure and function.

Disrupting the Predicted Interaction Between Val24 and Ile31 in Abeta42 in a More
Nonpolar Solvent May Facilitate Primary Nucleation
Because increased centralization suggests reliance on hubs, we analyzed network
and structural data to identify the key residues for network structure of Abeta42 when
dissolved in a more nonpolar solvent where it is less amyloidogenic. We calculated the
betweenness and residue centrality values for each residue in the structure (Figure 3.4),
and residues Val24 and Ile31 were shown to have significantly higher values than the other
residues. Therefore, two separate methods for identifying key residues support the
conclusion that the interaction between Val24 and Ile31 is important for overall network
structure in Abeta42 when it is dissolved in a more nonpolar solvent.
Residue interaction network data is most useful when combined with sequence and
structural data (Amitai et al. 2004), so we examined the 3D structure of Abeta42 when it is
dissolved in a more nonpolar solvent to determine the effects that these residues may exert
on the overall structure (Figure 3.5). When dissolved in the more nonpolar solvent,
Abeta42had a noticeable turn near Val24 and Ile31, so we hypothesized the presence of a
hydrophobic interaction between them. To test this hypothesis, we uploaded the PDB file
to RING which predicted the interactions that occur within the structures. The predicted
interaction between Val24 and Ile31 in a nonpolar environment may be important for
92

maintaining the less-amyloidogenic structure of Abeta42. The involvement of Val24 and
Ile31 in Abeta fibrillization has previously been identified by scanning proline mutagenesis
(Williams et al. 2004). To our knowledge, we are the first to predict an interaction between
Val24 and Ile31 in Abeta42 to be important for preventing fibrillization.
To further determine why Abeta42 is more likely to engage in primary nucleation in
more polar solvents compared to more nonpolar solvents, software was used to predict
Abeta42 trimer formation under both solvent conditions, and interpeptide bonding energy
was calculated (Figure 3.6). Evidence has shown that oligomers are the form of Abeta that
is most toxic to neurons (Sakono and Zako 2010), so even if trimers only exist transiently
on the path to fibril formation, structural studies of trimers are important. However, there
is experimental evidence that relatively stable trimers and tetramers of Abeta exist (Chen
and Glabe 2006). The interpeptide bonding energy was much higher for Abeta42 when
dissolved in the more polar solvent. Increased bonding energy suggests tighter binding
between the individual components of an Abeta42 trimer when dissolved in the polar
solvent compared to the nonpolar solvent. We hypothesize that the lack of an interaction
between Val24 and Ile31 allows for a more linear conformation, facilitating tighter bonding
and primary nucleation. Therefore, drugs designed to stabilize the interaction between
Val24 and Ile31 may prevent primary nucleation and reduce the number of toxic Abeta42
oligomers.

Study Limitations
While there are several dozen amyloidogenic proteins in the human proteome, our
experimental group only contained eight due to the limited availability of PDB data files.
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The relatively small size of the amyloidogenic protein group is a limitation of this study.
Second, our conclusions regarding Abeta42 structural differences are based on only two
structures. More structural data for Abeta42 in monomeric form in different solvent
conditions would increase our confidence in the conclusions. Third, some of the effect sizes
are relatively small. It is not entirely clear if these small effects could lead to functional
differences between the groups. Finally, the hypotheses generated from the data presented
here need to be experimentally tested to verify the validity of our conclusions. Sciarretta
and colleagues created a lactam link between two different residues of Abeta40 to test the
effects of conformational changes on the nucleation of beta-amyloid (Sciarretta et al. 2005).
A similar method covalently linking Val24 to Ile31 in an aqueous solvent and comparing
nucleation to an unlinked peptide could be used to test our hypothesis. However, the
predicted Val24-Ile31 interaction is likely only one of several interactions necessary to
prevent oligomerization.

Conclusions
Metrics from residue interaction network structures of amyloidogenic proteins
were statistically different from those of a group of non-amyloidogenic control proteins.
These differences included increased centralization and clusters per node. Increased
centralization implies the presence of residues that act as hubs in the network, making the
protein more susceptible to targeted attacks such as those occurring from rationally
designed drugs. Some of these differences were observed even when comparing
amyloidogenic variants to the WT non-amyloidogenic variant of the same protein.
Furthermore, increased centralization was observed when comparing the structure of
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Abeta42 in a more nonpolar solvent to that in the more amyloid-friendly polar solvent. The
local RIN metrics of betweenness and residue centrality identified residues 24 and 31 as
hubs. Combining this data with structural analysis suggests stabilizing the interaction
between Val24 and Ile31 may help prevent oligomerization of Abeta42. Combining the use
of network analysis and structural data produces novel insight that can be used for the
design of drugs for the treatment of amyloidoses.
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Abstract
After proteolysis, the majority of released free amino acids from dietary protein are
transported to the liver for gluconeogenesis or to peripheral tissues where they are used
for protein synthesis and eventually catabolized, producing ammonia as a byproduct. High
ammonia levels in the brain are a major contributor to the decreased neural function that
occurs in several pathological conditions such as hepatic encephalopathy. Therefore, it is
important to gain a deeper understanding of human ammonia metabolism. The objective
of this study was to predict changes in blood ammonia levels resulting from alterations in
dietary protein intake or from liver disease and to determine the toxicity of ammonia on
differentiated SH-SY5Y neuroblastoma cells. A simple mathematical model was created
using MATLAB SimBiology and data from published studies. Simulations were performed
and results analyzed to determine steady state changes in ammonia levels resulting from
varying dietary protein intake and varying liver enzyme activity levels to simulate liver
disease. As a toxicity reference, viability was measured in SH-SY5Y neuroblastoma cells
following differentiation and ammonium chloride treatment. Results from simulations
yielded physiological steady state blood ammonia levels and reasonably approximated
pathophysiological steady state levels resulting from liver cirrhosis or a genetic carbamoyl
phosphate synthetase I (CPS1) deficiency. A pathophysiological level of ammonium
chloride (90 µM) decreased the viability of differentiated SH-SY5Y cells by 14%. Data from
the model suggest decreasing protein consumption may be one simple strategy to decrease
blood ammonia levels and minimize the risk of developing encephalopathy for some liver
disease patients.
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Background
Protein is an abundant part of the human diet. It is recommended that humans
consume 0.8 g of protein per kg body mass per day. For a male of average weight (88.7 kg)
(Fryar et al. 2012), this is equivalent to 71 g of protein per day. When amino acids are
consumed at a faster rate than they are used for protein synthesis, they are metabolized as
an energy source, typically accounting for roughly 15%-20% of the energy supply. The
liver breaks down nearly half of the amino acids in the human diet as substrates for
gluconeogenesis (Jungas et al. 1992). Amino acid catabolism first relies upon the transfer
of the amino group by aminotransferases to a ketoacid, often to alpha-ketoglutarate to form
glutamate, and then by the deamination of glutamate by glutamate dehydrogenase which
produces ammonia (NH3). Roughly 12.5% of nitrogen intake is excreted from the digestive
tract (Tome and Bos 2000). Because ammonia is relatively toxic (Auron and Brophy 2012),
systems such as the urea cycle are in place primarily in the liver to convert it into a less
toxic form that can be readily removed from the circulation and excreted.
The liver is the main organ responsible for filtering ammonia and other nitrogen
sources such as glutamine from the blood to synthesize urea, the major form of excreted
nitrogen in mammals. Urea is a relatively nontoxic waste product that safely stores
nitrogen until it can be removed from the body. However, when ammonia is not
successfully removed from the blood due to impaired or overwhelmed removal
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mechanisms, the plasma ammonia concentration increases, which may cause deleterious
effects such as neural impairment (Ott and Vilstrup 2014). As part of the process of
nitrogenous waste removal, nitrogen-rich blood enters through the hepatic portal vein and
is eventually filtered through the acinus, the functional unit of the liver, before draining out
of the central vein. The acinus is divided into three zones (Brosnan and Brosnan 2009).
Zone 1 is the closest to the hepatic portal vein, and zone 3 is the closest to the central vein.
The hepatocytes spanning these three zones do not all perform the same metabolic
functions (Häussinger et al. 1992); rather, different branches of nitrogen metabolism are
localized to specific zones. Zones 1 and 2 contain the enzymes of the urea cycle (Moorman
et al. 1989) as well as glutaminase (Moorman et al. 1994), an enzyme that removes
nitrogen from glutamine to yield ammonia and glutamate. However, zone 2 has less
glutaminase activity than zone 1. Zone 3 contains glutamine synthetase (Gebhardt and
Mecke 1983), an enzyme that combines ammonia and glutamate to produce glutamine and
is also called glutamate-ammonia ligase (GLUL).
Liver disease can change the activities of several key enzymes involved in nitrogen
metabolism. For example, liver cirrhosis results in decreased expression of GLUL and the
urea cycle enzyme CPS1 (Gebhardt and Reichen 1994; Fleming and Wanless 2013).
Mutations in the CPS1 gene can lead to individuals born with a deficiency in mitochondrial
carbamoyl phosphate synthetase activity (Klaus et al. 2009). Because CPS1 catalyzes the
first committed step of the urea cycle, this can have serious consequences on nitrogen
metabolism. The increase in the number of individuals with liver disease in recent years
(Mokdad et al. 2014) combined with an average protein intake in the U.S. that is about 40%
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above the recommended value (NHAHES 2006) creates the need for understanding the
effects of increased protein intake on blood ammonia levels.
Increased blood ammonia levels are a causative agent in hepatic encephalopathy
(HE) (Butterworth 2003), but increased ammonia levels have also been implicated in other
neural disorders such as Alzheimer’s disease (Seiler 2002), amyotrophic lateral sclerosis
(Parekh 2015), and Huntington’s disease (Chen et al. 2015). HE results from liver damage
leading to cognitive impairment. Liver disease also increases the blood levels of other
potentially neurotoxic factors such as manganese and pro-inflammatory cytokines
(Butterworth 2015) that may contribute to the encephalopathy as well. Between 30% and
45% (Poordad 2007) of the more than 600,000 patients (Scaglione et al. 2015) with liver
cirrhosis each year will develop hepatic encephalopathy, resulting in a cost of nearly $1
billion per year (Poordad 2007). Most treatments aim to reduce the level of circulating
ammonia (Butterworth 2003). Due to challenges in reliably assaying ammonia due to its
reactivity (Goggs et al. 2008; Blanco Vela and Bosques Padilla 2011), there are not many
studies that measured the effects of dietary alterations on blood or tissue ammonia levels.
Our model provides further insight into how changes in dietary protein intake may affect
blood ammonia levels to better direct these treatment strategies.
We used data from the literature to create a computational model that simulates
ammonia metabolism and predicts blood ammonia levels based upon the amount of
protein consumed and upon the degree of liver dysfunction. Results from the model agree
relatively well with measured physiological and pathophysiological steady state metabolite
levels, and several insights were made from varying our initial conditions to investigate the
role of key enzymes in human organismal nitrogen metabolism. Cell culture studies were
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used to extend the model and establish the toxicity of pathophysiological concentrations of
ammonia on differentiated SH-SY5Y neuroblastoma cells in culture.

Methods
Description of the Model
This model describes the changes in ammonia, urea, and glutamine in the blood with
the following ordinary differential equations:

𝑑[𝑁𝐻3 ]
𝑑𝑡
𝑑[𝑈𝑟𝑒𝑎]
𝑑𝑡
𝑑[𝐺𝑙𝑛]
𝑑𝑡

= 𝑉𝑁𝐻3 𝑎𝑏𝑠 + 𝑉𝐺𝐿𝑆 − 𝑉𝑈𝑟𝑒𝑎 𝑓𝑜𝑟 𝐵𝑎𝑙𝑎𝑛𝑐𝑒 − 𝑉𝐶𝑃𝑆1 − 𝑉𝑁𝐻3 𝑒𝑥 − 𝑉𝐺𝐿𝑈𝐿

(1)

= 𝑉𝐶𝑃𝑆1 − 𝑉𝑈𝑟𝑒𝑎 𝑒𝑥

(2)

= 𝑉𝐺𝐿𝑈𝐿 − 𝑉𝐺𝐿𝑆

(3)

The overall reaction scheme is shown in Figure 4.1. Equations for reaction velocities
in Equations 1, 2, and 3 are shown in Table 4.1. Carbamoyl phosphate synthetase 1 (CPS1)
catalyzes the first committed step in the urea cycle, so this is the only enzyme of the cycle
incorporated into the model for simplicity. Other model parameters are shown in Table
4.2. Mammalian enzymes from liver tissue were used when the data was available (see
Table 4.1). No distinction is made between NH3 and NH4+ in this study unless otherwise
noted. N-acetyl-glutamate (NAG) is a CPS1 activator that increases in concentration when
more protein is consumed (Morimoto et al. 1990). To model the effects of NAG on CPS1
activity, we interpolated data on CPS1 activity changes from a study that included the
effects of changes in hepatic mitochondrial NAG levels due to diet (Morimoto et al. 1990)
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(about 11% in this study). The maximally activated activity of CPS1 (Pierson and Brien
1980) was adjusted to reflect the reduced activity at physiological NAG concentrations
(McGivan et al. 1976; Caldovic and Tuchman 2003) for all the protein diets and liver
conditions used in the study. The adjusted CPS1 values for individuals on the three diets of
differing protein content are as follows: 71 g protein per day, 8.05 mmoles/min; 100 g
protein per day, 8.47 mmoles/min; 122 g protein per day, 8.78 mmoles/min. Adjustments
for liver conditions are described below.

Figure 4.1: Model of nitrogen metabolism and excretion. NH3 in the figure includes both
ammonia and ammonium ions. Circles represent reactions (see Table 4.1 for reaction
equations) and ovals represent reactants and products. A) Conceptual framework of the in
vivo physiology simulated including the many tissues and subcellular compartments
involved. B) The system is modeled in silico considering only the concentrations of
metabolites in the blood. Abbreviations are as follows: GLUL, glutamine synthetase; Gln,
glutamine; GLS, glutaminase; CPS1, carbamoyl phosphate synthetase 1; Urea ex, urea
excreted; NH3 abs, ammonia absorbed; NH3 ex, ammonia excreted.
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Table 4.1 Values for reaction velocities scaled to average healthy male liver mass with healthy
protein diet
Reaction Velocities
Parameters from the
Organism and Parameters Scaled
Literature
Tissue
to Liver
VNH3 abs = 0.492 mmol/mina
VGLS = (Vmax GLS[Gln])/
(Km Gln + [Gln])

VCPS1 = (Vmax CPS1[NH3])/
(Km NH3 + [NH3])

Vmax GLS = 91.4
nmole/min per mg
(McGivan et al. 1991)

Rat Liver

Km Gln = 4.0 mM
(DeLaBarre et al. 2011)

Human
Recombinant

Vmax CPS1 = 45
nmole/min per mg
(Pierson and Brien
1980)

Human Liver

Km NH3 = 0.35 mM
(Ahuja and Powers-Lee
2008)

Human
Recombinant

Vmax GLUL = 0.47
µmole/15 min per mg
(Tate et al. 1972)

Rat Liver

Km NH3 = 0.15 mM
(Listrom et al. 1997)

Human
Recombinant

Ki Gln = 0.6 mM (Wray
and Fisher 2005)

Bacillis
subtilis

Vmax GLS = 28.54
mmol/min

Km Gln = 4.0 mM

Vmax CPS1 = 8.05
mmol/minab

Km NH3 = 0.35
mM

VNH3 ex = 0.004 mmol/mina
VGLUL = (Vmax GLUL[NH3])/
(Km NH3{1 + ([Gln]/Ki Gln)}
+ [NH3])

Vmax GLUL = 12.3
mmol/minb

Km NH3 = 0.15
mM

Ki Gln = 0.6 mM
VUrea ex = 0.244 mmol/mina
a
These values change with protein diet. See methods and discussion for details.
b
These values change with liver condition. See methods and discussion for details.
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Table 4.2 Parameter values used in nitrogen metabolism model
Parameter Name
Value
References
a
Blood Volume
6.59 L
Average Liver Mass
1561 g
(Molina and DiMaio 2012)
Average Human Mass, Male
88.7 kg
(Fryar et al. 2012)
Time Through Sinusoid
4.3 s
(Schwen et al. 2015)
Initial Urea
5.5 mM
Initial Ammonia
0 µM
Initial Glutamine
0 mM
Recommended Daily Protein
71 g
(2005)
a
Blood volume is about 5.2 L for a 70 kg individual (Wicker 2015). The value used above was
determined by assuming a linear relationship of blood volume with body mass for an individual
weighing 88.7 kg. This is the volume of the blood compartment used to calculate metabolite
concentrations.

Because all the chemical species under consideration are present in the blood
compartment, it is the only compartment where the volume affects simulation results. The
other compartments in Figure 4.1 are used to organize the model components for
conceptualization. We assume free diffusion across membranes. The volume was
determined by assuming a linear relationship between body mass and blood volume and
taking 5.2 liters to be the blood volume of a 70 kg male (Wicker 2015). Blood in the model
is assumed to be well mixed. Published enzyme activities were scaled up to the average
liver size (1561 g, see Table 4.2) by adjusting the units to mmol/(min*1561 g). For
example, McGivan et al. (McGivan et al. 1991) report glutaminase activity as 91.4 nmoles
per minute per mg protein, which converts to 0.0914 mmoles per minute per g protein. If
we assume 20% protein content in the cultured hepatocytes, it takes 5 g of tissue to yield 1
g protein. Adjusting for protein content and multiplying by a liver weight of 1561 g yields
an enzyme activity of 28.54 mmoles/min/liver. Because of the slightly higher protein
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content of liver tissue compared to isolated hepatocytes (Berry et al. 1991), we used a
tissue protein content value of 25% when scaling up parameters from a study that reports
enzyme activity from liver tissue. Similar calculations were performed for each of the liver
enzymes. Changes in enzyme activity due to diet and liver conditions are summarized in
Table 4.3.

Table 4.3 Parameter changes with protein diet and liver condition
Parameter
Protein Diet
Healthy
Early Cirrhosis
Late Cirrhosis
Name
(g per day)
(mmoles/min)
(mmoles/min)
(mmoles/min)
Urea ex
71
0.244
100
0.343
122
0.417
NH3 ex
71
0.004
100
0.008
No change with liver condition
122
0.012
NH3 abs
71
0.492
100
0.693
122
0.845
Vmax CPS1
71
8.05
5.64
5.64
100
8.47
5.93
5.93
122
8.78
6.146
6.146
Vmax GLUL
No change
12.3
2.46
0.246
with diet

The complete urea cycle uses two nitrogen atoms to synthesize each molecule of
urea in one turn of the cycle. However, CPS1 incorporates one nitrogen atom per turn of
the cycle. A second nitrogen enters into the cycle from aspartate when argininosuccinate
synthetase catalyzes the reaction of aspartate with citrulline. To balance the stoichiometry
of the reaction series and to simplify the model, a second reaction equal to CPS1 was
created with the product not considered in the simulation results (“Urea for Balance” in
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Figure 4.1). Therefore, two nitrogen atoms per unit time are used to produce one urea
molecule, satisfying the stoichiometry of the overall reaction series for this simplified
model. The rate of nitrogen absorption is based upon the daily amount of nitrogen
consumed. The mass of protein ingested is adjusted to the molar amount of nitrogen
ingested (16% of the mass of protein ingested) and for the 12.7% loss of nitrogen in feces
(Tome and Bos 2000). The remaining molar amount of nitrogen is assumed to be absorbed
linearly over a period of 24 h. For example, if 71 grams of protein is ingested, 16% of that
amount (11.36 grams) is nitrogen. Assuming a 12.7% loss in feces, this leaves 9.92 grams
of nitrogen available for absorption. Because there are 14 grams of nitrogen per mole,
there are 0.708 moles of nitrogen available for absorption per day, or 0.49 millimoles of
nitrogen per minute. The absorption rate was recalculated using the same method for each
of the three protein diets modeled. The ranges of the amounts of ammonia and urea
excreted in urine over a 24 h period have been reported (Bingham et al. 1988; Bankir et al.
1996), and in the model we assumed the average values to be excreted linearly over the 24
h period. When modeling altered protein intake, the rates of ammonia and urea excretion
were adjusted as well. For the high protein diet, we used the upper values of the reference
ranges reported for the amounts of ammonia and urea excreted instead of the average
values. This was accomplished by assuming daily nitrogen balance and using calculations
similar to those used above to equate molar amounts of nitrogen to grams of protein. For
example, using the lower values for the reference ranges of daily ammonia and urea
excretion and assuming daily nitrogen balance suggest a dietary intake of about 60 g of
protein per day. Ammonia and urea excretion rates were scaled to the dietary protein
intake by assuming a linear relationship between the two. Excretion rates that were used
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in the model are as follows: for the 71 g per day protein diet, 0.004 mmoles ammonia are
excreted per minute and 0.244 mmoles urea are excreted per minute; for the 100 g per day
protein diet, 0.008 mmoles ammonia are excreted per minute and 0.343 mmoles urea are
excreted per minute; and for the 122 g per day protein diet, 0.012 mmoles are ammonia
excreted per minute and 0.417 mmoles urea are excreted per minute. Changes with
protein diet are summarized in Table 4.3.
We modelled the spatial separation of enzymes by acinus zones by translating
spatial separation into temporal separation. The time a red blood cell takes to travel
through a sinusoid has been calculated to be 4.3 seconds (Schwen et al. 2015). Assuming a
constant rate and equal division of zones, this is about 1.43 s per zone. By using event
functions in the SimBiology software, the enzyme activities of CPS1 and glutaminase were
turned on for 2.87 s and then off for 1.43 s while GLUL was turned on. This change in
enzyme activities combined with the well-mixed assumption approximates the spatial
enzyme separation found in the liver because blood is exposed to CPS1 and glutaminase for
twice as long and just prior to exposure to GLUL activity before repeating the cycle. This
cycling was repeated for 774 seconds during simulations (Figure 4.2A), yielding a pattern
of peaks and valleys in the simulation results that is a mathematical artifact of modeling
spatial separation as temporal separation.
Steady state levels for ammonia were calculated following model simulations for
different levels of protein in the diet (healthy, 71 g per day; average, 100 g per day; high,
122 g per day) and liver conditions (healthy, “early cirrhosis”, “late cirrhosis”, and 50%
CPS1 activity) for 12 conditions total. Simulation results were exported to Microsoft Excel,
and steady state levels were determined from the data points corresponding to the top of
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the resulting ammonia concentration curve. Steady state was defined as the concentration
when blood ammonia levels were changing less than 0.002% per second.
Several assumptions and simplifications were used in the model. The urea cycle is
simplified to the first committed step and an extra CPS1 reaction was added to maintain the
stoichiometry of the entire urea cycle (“Urea for Balance” in Figure 4.1). Other molecular
species involved in the included reactions that are not included in the model are assumed
to be in abundance, blood is assumed to be well-mixed, and we used temporal separation of
enzymes to model spatial separation of enzymes in the liver acinus. Furthermore, GLS
activity is the same in zones 1 and 2 in the model, but it may be slightly decreased in zone 2

in vivo. We recognize that blood is heterogeneous and blood ammonia levels may be
concentrated in some compartments compared to others. For example, arterial blood has
been shown to have higher ammonia levels than venous blood in dogs with liver disease
(Rothuizen and van den Ingh 1982). This difference of concentrations could limit systemic
effects of blood ammonia. However, this was not included in the model. We also assume a
continuous nutritional supply for simplicity. Furthermore, the model does not account for
the activities of transporters but often assumes free passage of small molecules. There is
also evidence for positive cooperativity for the binding of some of the species to enzymes in
the model. For example, there is evidence of cooperativity for glutamine binding (Hill
coefficient of 1.8) in the kinetics of the glutaminase enzyme (Szweda and Atkinson 1989)
and possible glutaminase upregulation by a high protein diet (Ewart and Brosnan 1993)
that was not included in the model. However, sensitivity analysis suggests that increases in
glutaminase and GLUL activity will not have much effect on ammonia steady state levels.
Even with these simplifying assumptions, the model results agree relatively well with the
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available clinical data. However, the available clinical data is sometimes incomplete, so
further validation is not currently possible.

Sensitivity Analysis
To determine the relative effects of altering enzyme kinetic parameters on the
steady state blood ammonia levels, each of the parameters was individually increased or
decreased by 50% under the normal simulation conditions for a healthy liver and a protein
diet of 71 g per day. The simulations were run under these altered conditions and the
steady state levels of ammonia were compared to those under normal conditions. Results
are reported in Table 4.4 as percent change.

Table 4.4 Sensitivity analysis for kinetic parameters.
Enzyme
Parameter Percent Parameter Blood Ammonia
Change
Percent Change
CPS1
Vmax
150%
-35.4
50%
110.3
Km
150%
52.6
50%
-50.3
Glutaminase Vmax
150%
0.6
50%
-2.9
Km
150%
-1.1
50%
1.1
Glutamine
Vmax
150%
4.6
Synthetase
50%
-4.6
Km
150%
-2.9
50%
7.4
Ki
150%
0.6
50%
-0.6
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SH-SY5Y Culture, Differentiation, and Treatment
SH-SY5Y cells were cultured in a 1:1 mixture of DMEM (high glucose) and Ham’s F12 medium. The medium contained 2.44 g/L sodium bicarbonate, 30 mg/L penicillin, 50
mg/L streptomycin, and 10% FBS. The cells were seeded at a concentration of 1,000 cells
per well in 96-well plates and treated with retinoic acid (10 µM) for 4 days with the
medium changed every two days. Next, ammonium chloride was added to the medium at
the indicated concentrations and the cells were incubated for 24 additional hours.

Protein Assay
After 24 h of treatment with ammonium chloride, the cells were washed in PBS and
then lysed with RIPA buffer (50 µl per well for three wells per condition). The lysate was
pooled in a microcentrifuge tube and the Pierce BCA Protein Assay was performed in
triplicate per manufacturer’s instructions.

Software and Statistical Methods
The model was built and simulated using the MATLAB R2016a SimBiology software
package. Data was analyzed using Microsoft Excel and GraphPad Prism v7.0. For cell
culture studies, three independent experiments were performed and data was analyzed
with a repeated measures one-way ANOVA with Fisher’s post hoc test.
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Results
Model Results Approximated Physiological Steady State Ammonia Levels
A computational model estimating blood ammonia levels in healthy individuals and
those with liver disease was constructed. The model was first simulated using the
parameters for a healthy liver and a healthy, moderate protein diet to determine if the
resulting steady state levels were consistent with clinical data. The healthy protein diet
was taken to be 71 g per day. The reference range for healthy blood ammonia levels was
taken to be 11-32 µM (Hawke 2012). Healthy blood urea levels are considered to be 3.67.1 mM (Pagana and Pagana 2009). The initial conditions in this study are 0 µM ammonia
and 5.5 mM urea. Figure 4.2A shows the results of 774 s of simulation of our model. The
steady state ammonia level was 17.5 µM (Figure 4.2A), and the steady state urea level
remained around 5.5 mM (Figure 4.2A), both values well within the healthy range.

Enzyme Activity Changes Had Different Effects on Ammonia and Urea Levels
To investigate the relative influences of CPS1 and GLUL on blood ammonia levels,
enzyme activities were individually varied stepwise in the model for a healthy individual
on a healthy protein diet, and steady state levels of ammonia were determined. The results
show an inverse, non-linear relationship between CPS1 activity and ammonia levels (Figure
4.2B). The steady state urea level did not show much change under any conditions tested
likely because much larger changes are necessary to cause differences in the millimolar
concentrations of urea compared to the micromolar concentrations of ammonia.
Decreasing GLUL activity had almost no effect on steady state levels of ammonia (Figure
4.2B). However, decreasing GLUL activity does affect the kinetics of ammonia formation.
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Eliminating GLUL activity caused the simulation to reach steady state ammonia levels much
more quickly. In a healthy individual, the rate of ammonia formation for the first 12.9
seconds of the simulation was 0.55 µmoles per second, but this rate increased to 0.83
µmoles per second when GLUL activity was inactivated (Figure 4.2C). A sensitivity analysis
(Table 4.4) of the kinetic parameters revealed that, as expected, changes in CPS1 activity
have by far the strongest effect on blood ammonia levels of any enzyme in the model.

Figure 4.2: Model simulation results for a healthy individual on a healthy protein diet. A)
Simulation results for a healthy individual with the recommended daily protein intake.
Note the break in the scale of the y-axis. B) Ammonia steady state levels from simulations
varying enzyme activities of CPS1 and GLUL. C) Simulation results showing changes in
ammonia kinetics with changes in GLUL activity.
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Changes in Enzyme Activities Caused by Liver Cirrhosis Affected Blood Ammonia Levels
Liver cirrhosis has been shown to decrease the activities of two of the enzymes in
the model, so decreasing the Vmax values accordingly can create a simple model of liver
cirrhosis at different stages. As mentioned above, a healthy, moderate protein diet for a
typical adult male is 71 g of protein per day. The average American diet is about 100 g of
protein per day, and a high protein diet in our model was taken to be 122 g of protein per
day. The amount of protein in the high protein diet was calculated by using the highest
values of ammonia and urea excretion in the published reference ranges (Bingham et al.
1988; Bankir et al. 1996) and assuming nitrogen balance (see Methods). To model early
stage liver cirrhosis, the Vmax of CPS1 was reduced to 70% of the normal value and the Vmax
of GLUL was reduced to 20% of the normal value (Gebhardt and Reichen 1994). Late stage
liver cirrhosis was modeled by changing the Vmax values for CPS1 and GLUL to 70% and 2%
of the normal values, respectively (Fleming and Wanless 2013). Following simulation, the
steady state ammonia and urea levels were determined as described above. The steady
state ammonia levels under the various conditions are shown in Figure 4.3A. Ammonia
levels progressively increased with increased dietary protein intake and with decreased
liver function.

Decreased CPS1 Activity Led to Increased Blood Ammonia Levels
Based upon the population frequency of the genetic disorder CPS1 deficiency, there
are likely many heterozygous individuals with decreased CPS1 activity (see Discussion).
To investigate the consequences of decreased CPS1 activity on blood ammonia and urea
levels, the Vmax for CPS1 was reduced by 50% and different protein levels in the diet were
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compared (Figure 4.3B). Decreased CPS1 activity (50% below normal, as present in a
heterozygous individual with a complete loss of function from one of the two alleles) led to
about a 20 µM increase in blood ammonia levels, greater than the levels present in the early
or late stage liver cirrhosis models for each of the diets examined.

Figure 4.3: Ammonia levels changed with dietary protein levels, progression of liver
cirrhosis, and CPS1 activity. A) The steady state ammonia concentration in the blood
increases with increased ammonia absorption due to increases in dietary protein (See
Table 4.1) and declining liver function. B) When CPS1 activity is reduced by half, steady
state ammonia levels are higher than those in a healthy individual. This effect increases
with increased ammonia absorption due to increased dietary protein levels (See Table 4.1).
Cirr-E, early liver cirrhosis; Cirr-L, late liver cirrhosis.

Ammonium Chloride Treatment Decreased Viability of Differentiated SH-SY5Y Cells
To test whether the increased ammonia levels observed in the simulations could be
neurotoxic in vitro, we administered ammonia to differentiated human neuroblastoma
cells. Retinoic acid-treated SH-SY5Y cells treated with 90 µM ammonium chloride showed
14% decreased viability as measured by protein content from cells attached to the plate
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after a PBS wash. Ammonium chloride concentrations of 30 µM or 60 µM showed no
statistically significant effect on viability (Figure 4.4).

Figure 4.4: Ammonium chloride (90 µM) decreased the viability of retinoic aciddifferentiated SH-SY5Y neuroblastoma cells in culture. * indicates that p = 0.01 compared
to 0 µM NH4Cl added. Bars represent mean ± SEM, and n = 3 independent experiments.

Discussion
A simple mathematical model of human organismal nitrogen metabolism is
presented that uses published parameters for physiological inputs to give physiologically
relevant outputs consistent with the available experimental data. While other models exist
for ammonia metabolism in humans (Ohno et al. 2008; Drasdo et al. 2014; Schliess et al.
2014), this is the first to model the effects of altered levels of dietary protein intake on
blood ammonia levels. Increased protein intake led to increased blood ammonia levels
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across all conditions. However, blood ammonia levels remained in the healthy range when
simulating a healthy liver. The simulation results showed that low GLUL activity can lead
to more rapid changes in blood ammonia levels. The model highlights the effects of diet on
ammonia levels in disease conditions. Our results indicate that increased protein intake
likely causes blood ammonia to rise above healthy levels in some patients with cirrhosis.

Altering Dietary Protein Consumption in Cirrhosis Patients
Because relative energy expenditure per kg body mass is increased in some cirrhotic
patients (Merli et al. 1985), some sources recommend a high protein diet (1.8 g/kg per
day) for these patients to maintain muscle mass if they do not already have HE (Nielsen et
al. 1995). Others suggest a normal, moderate intake of 0.8 g to 1.0 g of protein per kg per
day (Riordan and Williams 1997). Data has shown that high protein intake exacerbated
encephalopathy in 35% of patients with cirrhosis (Seymour and Whelan 1999). Reduced
protein intake was first shown to protect from encephalopathy in cirrhotic patients in 1952
(Phillips et al. 1952). In 2004, a study was performed with cirrhosis patients where
protein was completely removed from the diet for three days and then slowly increased
over 12 days back to the normal level (Córdoba et al. 2004). At the end of the study, blood
ammonia levels were non-significantly 17% lower in the patients with the restricted
protein diet compared to patients on a normal protein diet of 1.2 g/kg per day, roughly
equivalent to the average American protein diet in this model. However, the methods used
in that study have been critiqued and questioned (Nguyen and Morgan 2014). A larger
patient group size and earlier measurements of blood ammonia levels would help to clarify
if blood ammonia levels are indeed decreased by a low protein diet. If the findings of no
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significant effects do prove to be robust and highly reproducible, this leaves the possibility
that a high protein diet may play a role in the development of HE, but a low protein diet is
not normally helpful in its resolution. Even though several studies have suggested that
restricting dietary protein intake below the recommended amount for a healthy individual
may not be therapeutic for the roughly 60% of cirrhosis patients who suffer from
malnutrition, other studies over the past 65 years on HE patients who can maintain a
proper energy balance have consistently shown benefits of protein restriction (Nguyen and
Morgan 2014). We acknowledge the large heterogeneity in patient responses to changes in
the level of dietary protein (Gheorghe et al. 2005) and suggest that monitoring the
cirrhosis patient’s energy balance will help determine the proper dietary protein level for
that individual.
Previous research has shown that there was an 80% reduction in GLUL activity and
a 30% reduction in CPS1 activity in a rat model of liver cirrhosis (Gebhardt and Reichen
1994). As the disease progressed, GLUL activity dropped even further (Fleming and
Wanless 2013). Results from adjusting the model to these parameters suggest that
ammonia levels will increase as liver cirrhosis develops. Furthermore, a high protein diet
may exacerbate these effects. We recognize that liver cirrhosis is a complex disease with
many changes besides altered CPS1 and GLUL activity, so this model is a simplified
representation of liver cirrhosis. Using an upper limit of 32 µM for the reference range of
healthy blood ammonia levels, the model indicates that a high protein diet with early or
late cirrhosis will result in blood ammonia levels that are at least 20% higher (40.3 µM and
41.3 µM, respectively) than the upper limit for the healthy range (32 µM). These elevations
may contribute to HE. The model suggests that controlling protein intake could be one
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method to slightly reduce the likelihood of developing HE in some patients with liver
cirrhosis.

Plasma Ammonia Levels Likely Rise in Healthy Individuals After a Meal
Our model predicts that blood ammonia levels will rise slightly by consumption of a
high protein diet. Surprisingly, we could not find many studies in the literature examining
dietary-induced changes in blood ammonia levels in healthy humans. One study found
increased blood ammonia levels in women following consumption of a test drink
containing whey protein. The ammonia level peaked at a value 20% higher than the initial
level at 90 minutes after consumption (Chungchunlam et al. 2015). Another study found
increasing breath ammonia levels after a high protein challenge; ammonia levels plateaued
roughly 5 hours after the dietary challenge (Spacek, M.L. Mudalel, et al. 2015). However,
breath ammonia levels do not always correlate well with blood ammonia levels (Spacek, M.
Mudalel, et al. 2015). A further study using Huntington’s disease patients who were put on
a high (26.3%) protein diet did not find any association between the high protein diet and
blood ammonia levels (Chen et al. 2015).
In studies with mice placed on a high protein diet ammonia levels increased from
210 µM to 245 µM at night when the mice were active and feeding. Likewise, a high fat/low
protein diet decreased ammonia levels from 170 µM to 130 µM when measured at night
(Nohara et al. 2015). When rats were switched from a 20% protein diet to a 58% protein
diet, colonic venous ammonia maximally increased from 100 µM to 340 µM two days after
the switch in diet, which dropped to 170 µM after a week on the diet (Mouillé et al. 2004).
Another study using rats trained on a 6% protein diet showed that blood ammonia levels
122

increased from 60 µM to 120 µM when they were given a 44% protein meal, and ammonia
levels were maintained at that elevated level for at least 24 hours (Semon et al. 1988).
There is also evidence of increases in blood ammonia levels in pigs after a protein meal
(Welters et al. 1999; Liu et al. 2015). The limited data above suggest that systemic
ammonia levels likely increase slightly following a meal, especially if the meal is high in
protein, but more experiments should be performed to verify these initial findings and to
determine the extent of brain ammonia level changes under the same conditions. In
addition, more detailed studies using human subjects would help to better characterize the
time dependency of elevated ammonia levels as well as to discern differential effects in
patients with liver disease.

Variability in the Correlation between Blood Ammonia Levels and the Severity of HE
While there is a correlation between blood ammonia levels and HE severity (Ong et
al. 2003), the exact blood concentration that leads to impairment may be different for
individuals based on their specific nitrogen balance and the release of other neurotoxic
factors from the liver. Some patients with hyperammonemia present with 100-200 µM
blood ammonia levels and remain asymptomatic, while others such as infants with GLUL
deficiency have severe encephalopathy with blood ammonia levels fluctuating between 100
and 150 µM (Häberle 2013). However, decreased blood glutamine levels may also
contribute to the encephalopathy in GLUL deficiency. Maintained blood ammonia levels
over 300 µM are considered severe and invariably lead to encephalopathy. However, some
newborns have been shown to have no lasting impairment by temporary blood ammonia
concentrations up to 2 mM for a day or two (Whitelaw et al. 2001). In contrast with this
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data, blood ammonia levels (< 50 µM) that border the healthy range have also been linked
to HE (Ong et al. 2003). These variabilities do not affect the validity of the model because
the model represents the blood ammonia level changes for an average person.
To investigate the roles of CPS1 and GLUL in ammonia metabolism, enzyme
activities were varied in the model with otherwise healthy parameters (Figure 4.2B, Table
4.4). CPS1 activity levels relevant to the model had a non-linear effect on ammonia
concentrations. GLUL activity, however, had very little effect on ammonia steady state
levels. Simulating early liver cirrhosis (70% CPS1, 20% GLUL) resulted in an average
ammonia increase of 43% across all diets. Simulating late liver cirrhosis (70% CPS1, 2%
GLUL) resulted in an average ammonia increase of 47%. GLUL activity appears to slow
changes in blood ammonia levels. Since muscles may help metabolize some ammonia
(Dejong et al. 1992), slowing the rate of change may give the body time to adapt to the
larger ammonia levels. These results are consistent with the known role of CPS1 together
with the rest of the urea cycle to be a low affinity, high capacity system for removing
ammonia, while GLUL is a high affinity, low capacity enzyme for removing ammonia
(Häussinger 1986).

Ammonia Levels in Individuals Deficient in GLUL
Human subjects with decreased GLUL activity have been shown to have blood
ammonia levels of 100-150 µM (Häberle 2013), while mice with liver-specific GLUL
knockout showed a blood ammonia level of roughly 150 µM (Qvartskhava et al. 2015). Our
model, under otherwise normal healthy conditions, shows no change in ammonia steady
state levels when GLUL is reduced (Figure 4.2B). This is a limitation of the study possibly
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due to the enzyme kinetics data available, but it could also be due to the way we have
modeled the hepatic acinus, the functional unit of the liver. The ratio of CPS1 to GLUL
activity or the amount of time that ammonia is associated with CPS1 activity compared to
GLUL activity may be too high in our model, resulting in deviations from in vivo results.
This suggests that some of the changes in ammonia levels observed in our model may be
too conservative.

Ammonia Levels in Individuals Deficient in CPS1
CPS1 deficiency is a rare autosomal recessive genetic disorder that results in very
little CPS1 activity (McReynolds et al. 1981). Individuals experience extreme
hyperammonemia and the many detrimental effects that come with it (Klaus et al. 2009).
The prevalence of CPS1 deficiency is about 1 in 800,000 (Nagata et al. 1991). Assuming
strict Mendelian inheritance, if a mother and father each are heterozygous and have
decreased CPS1 activity, there is a 1 in 4 chance that their children will have CPS1
deficiency. Working backwards from this assumption, the odds that both parents are
heterozygous are 1 in 200,000. The odds that one parent is heterozygous is roughly 1 in
447. Therefore, heterozygosity for disease-causing CPS1 mutations is almost as prevalent
as liver cirrhosis. However, regulatory effects may partially compensate for CPS1
heterogeneity, a scenario not explored is this study. The model predicts that individuals
with CPS1 activity 50% of normal levels (currently thought to have no detrimental effect)
will have high blood ammonia levels. Many people may be unaware that they carry a
mutation in one CPS1 allele that likely results in higher than normal levels of blood
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ammonia. Lifelong exposure to high levels of blood ammonia may have unknown,
deleterious effects on neural function.

Relatively Low (90 µM) Brain Ammonia Levels May Affect Neural Cell Viability or Function
It is hypothesized that the increased levels of ammonia in liver disease interfere
with the glutamine-glutamate balance involved in neurotransmission (Butterworth 2014),
which can lead to increased production of reactive oxygen and nitrogen species (Bobermin
et al. 2015). Increased brain ammonia levels also block potassium uptake in astrocytes,
which causes increased potassium uptake in neurons that compromises inhibitory
neurotransmission in the cortex, leading to seizure (Rangroo Thrane et al. 2013).
Cell culture experiments using retinoic acid-differentiated SH-SY5Y cells revealed
that viability was decreased by relatively low concentrations (90 µM) of ammonium
chloride. The ability of such a low concentration of brain ammonia to cause toxicity was
surprising given that most cells (Schneider et al. 1996) including rodent primary cortical
and cerebellar granule cells and undifferentiated human SH-SY5Y cells require low (1-10)
millimolar concentrations of ammonium chloride before toxicity is observed (Bobermin et
al. 2015). Ammonia has been reported to be slightly more toxic to neuroblastoma cells
than to primary neurons (Haghighat et al. 2000), partially accounting for the lower toxicity
threshold. Furthermore, the retinoic acid-mediated differentiation procedure we used
likely sensitized the cells to ammonia toxicity as it is known to increase reactive oxygen
species production (Kunzler et al. 2016).
The ability of uncharged NH3 to cross the blood brain barrier and the limited ability
of the charged, protonated form NH4+ to cross the barrier combined with the difference in
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pH between the brain and the blood allows higher total ammonia levels to accumulate in
the brain (Auron and Brophy 2012). The model predicts serum (pH ~ 7.4) levels of
ammonia/ammonium in healthy individuals will be 17.5 µM; since the brain has a pH of
about 7.0 (Shi et al. 2014; Ren et al. 2015), applying the Henderson-Hasselbalch equation
implies a total ammonia/ammonium concentration in the brain of 44 µM for a healthy
individual on a healthy protein diet, more than twice the blood ammonia/ammonium
concentration. The following diet combinations and liver conditions are predicted from the
model results to have brain ammonia/ammonium concentrations of > 90 µM: high protein
diet/early cirrhosis (101 µM), high protein diet/late cirrhosis (104 µM), healthy protein
diet/decreased CPS1 activity (92 µM), average protein diet/decreased CPS1 activity (127
µM), and high protein diet/decreased CPS1 activity (152 µM). Combining the experimental
data with the computational results suggests that many of the diet and liver condition
combinations could negatively affect neuronal function. Mouse studies showing that high
protein diets are associated with decreased lifespan (Solon-Biet et al. 2014) should
stimulate further research into the mechanisms involved. Adhering to the recommended
protein diet may help cirrhosis patients and CPS1 heterozygotes avoid high blood and brain
ammonia levels and any associated cognitive problems.

Conclusions
The following testable hypotheses have been generated using this model: 1)
Increasing dietary protein consumption increases blood ammonia levels in healthy
individuals. 2) A low protein diet is beneficial for liver cirrhosis patients who have a
normal energy balance. 3) Heterozygosity for CPS1 complete loss of function mutations
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leads to elevated blood ammonia levels. 4) Chronic but low-level hyperammonemia has
negative effects on neurons and astrocytes such as sensitizing them to further toxic insults.
5) Increased blood ammonia levels contribute to the decreased lifespan of mice on a high
protein diet (Solon-Biet et al. 2014).
This model describes physiological and pathophysiological human nitrogen
metabolism in blood and liver using published parameters. It suggests that the diet and the
level of progression of liver cirrhosis contribute to blood ammonia levels, and experimental
results suggest that these blood ammonia levels could affect neural functioning. Since high
blood ammonia levels are associated with diseases such as HE, the model can be used to
predict the conditions in which HE may develop. Furthermore, the model predicts that a
50% reduction in CPS1 activity, an activity level likely present in thousands of individuals
worldwide, can lead to high blood ammonia levels. Limiting protein intake may be one
effective way for some of these individuals to decrease blood ammonia levels and possible
associated pathologies.
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Abstract
There is a dire need to discover new pathways to target for Alzheimer’s disease
(AD) drug development. The decreased neuronal glucose metabolism that occurs in AD
brain could play a central role in disease progression. Little is known about the
compensatory neuronal changes that occur to attempt to maintain energy homeostasis. In
this review using the PubMed literature database, we summarize evidence that amino acid
oxidation can temporarily compensate for the decreased glucose metabolism, but
eventually altered amino acid and amino acid catabolite levels likely lead to toxicities
contributing to AD progression. Because amino acids are involved in so many cellular
metabolic and signaling pathways, the effects of altered amino acid metabolism on AD are
far-reaching. Possible effects resulting from changes in the levels of several important
amino acids are discussed. Urea cycle function may be induced in endothelial cells of AD
patient brains, possibly to remove excess ammonia produced from increased amino acid
catabolism. Studying AD from a metabolic perspective provides new insights into AD
pathogenesis and may lead to the discovery of dietary metabolite supplements that can
partially compensate for alterations of enzymatic function to delay AD or alleviate some of
the suffering caused by the disease.
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Background
There are currently about 24 million cases of Alzheimer’s disease (AD) worldwide,
and that number is expected to continue to increase for at least the next few decades as
better treatments for other diseases such as heart disease and cancer extend average
human longevity (Reitz et al. 2011). In addition to human suffering, Alzheimer’s disease
and other dementias cost the United States about $172 billion in 2010 (2010). To date,
most research has focused on the amyloid cascade hypothesis that emphasizes the role of
amyloid-β protein aggregation in the pathogenesis of AD. However, growing evidence
suggests that the amyloid cascade hypothesis does not encapsulate the complex
symptomology of AD (Herrup 2015). Two decades of researching the amyloid cascade
hypothesis have not yielded the treatments that were predicted in the early 1990s. The
other major histological hallmark of AD in addition to amyloid plaques is the
neurofibrillary tau tangle pathology present in neurons (Herrup 2015). It is possible that
tau-based therapies will not fare better in clinical trials than amyloid-based therapies.
Another promising alternative is to view Alzheimer’s disease as a metabolic disease in
attempt to shed novel insight into its etiology. In this regard, it is known that neurons in
AD brain show large deficits in glucose metabolism, so alternative energy sources may help
to prevent the neuronal death characteristic of the disease. Treating AD as a metabolic
disorder would lead to further research into dietary supplementation of metabolites and
enzyme cofactors that show depletion in AD brain as possible treatments. Neurons lack the
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enzymes for beta-oxidation of fatty acids, but other possible neuronal energy sources
include amino acids, ketone bodies, citric acid cycle intermediates, pyruvate, and lactate.
Because many recent metabolomics investigations have shown large changes in the levels
of several amino acids in AD brain and plasma, it is important to consider whether changes
in amino acid metabolism are a driving force for AD progression.
Amino acids in the form of proteins are a large part of the human diet. The
recommended daily allowance of protein is 0.8 grams per kilogram body mass (2005); in
an average adult this amounts to roughly 71 grams of protein per day. This high protein
consumption dictates that amino acids will be present at levels that far exceed their
requirements as the building blocks for protein synthesis, and that much of the protein
consumed will be broken down for energy generation. Processing these amino acids for
energy generation requires the disposal of nitrogenous waste, a process carried out mostly
in the liver and small intestine by the urea cycle. Disrupted amino acid and nitrogen
metabolism is associated with neurological defects and in some cases dementia (Wiesinger
2001; Gropman et al. 2007; Coloma and Prieto-Gonzalez 2011; Esposito et al. 2013; P. Liu
et al. 2014). In addition to these primary routes of amino acid usage, amino acids and their
metabolic derivatives are also involved to a lesser extent in cell signaling and in many
diverse metabolic pathways.

Amino Acid Metabolism in the AD Brain
Many studies have shown altered amino acid levels in serum and brain in AD
patients or in AD model mice, but whether these changes contribute to disease
pathogenesis is not yet known. Because glutamate is an excitatory neurotransmitter and
139

two of its metabolites, gamma-aminobutyric acid (GABA) and glycine, are inhibitory
neurotransmitters (Esposito et al. 2013), changes in glutamate metabolism in AD brain
could greatly affect neural functioning. GABA can also be synthesized from arginine in
astrocytes and increased GABA levels synthesized through this pathway have been shown
to play a role in cognitive dysfunction in an AD mouse model (Jo et al. 2014). Changes in
the levels of enzymes involved in amino acid metabolism have also been observed in AD
brain (Jęśko et al. 2016), further suggesting a role for metabolic dysregulation in AD
pathogenesis. For example, alterations in the levels of glutamine synthetase and urea cycle
enzymes and intermediates have been observed in AD brain. This is of concern because
nitrogenous waste in the form of ammonia from amino acid catabolism has adverse effects
on neural cells if not properly cleared from the brain.
A healthy individual is able to process the excess amino acids consumed into other
useful metabolites or oxidize them for energy production. To use them as fuel, the carbon
skeletons are oxidized in the citric acid cycle to produce carbon dioxide, and the excess
nitrogen is disposed of as the relatively non-toxic nitrogenous waste product urea.
However, when neurons cannot catabolize glucose efficiently such as during AD, they likely
become partly reliant upon amino acid oxidation for energy. If neuronal amino acids
become depleted or if the machinery used to metabolize amino acids becomes
dysregulated, the neurons may die, contributing to disease progression. However, even if
amino acid oxidation is able to maintain neuronal energy levels, the increased amounts of
ammonia released during amino acid catabolism could lead to neuronal cell death because
a complete urea cycle that is needed to detoxify ammonia is not present in neurons.
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Instead, astrocytes contain the glutamine synthetase enzyme to sequester ammonia into
glutamine, which can be released from the brain.

Amino Acid Level Changes Examined in Control, MCI, and AD Populations
Identifying amino acid changes in patients with mild cognitive impairment (MCI) is
important as these changes may be upstream changes leading to the onset of AD, and the
downstream changes that occur during AD may be a result of the body adapting to the
insults that occurred during MCI. In one report, a metabolomics analysis was performed on
the cerebralspinal fluid (CSF) of patients with mild cognitive impairment (MCI), AD, or
healthy aged-matched controls. Results showed that the metabolites dimethylarginine,
arginine, valine, proline, serine, histidine, choline, creatine, carnitine, and suberylglycine
were possible disease progression biomarkers (Ibáñez et al. 2012). Another group
studying potential CSF biomarkers for AD concluded that changes in methionine,
tryptophan, tyrosine, and purine metabolism pathways occurred in both MCI and AD
subjects. Methionine levels increased in MCI while tryptophan levels decreased
(Kaddurah-Daouk et al. 2013). Levels of the tripeptide glutathione also decreased in AD.
Another study found increased cysteine levels in CSF from AD subjects (Czech et al. 2012)
while another identified altered tryptophan and phenylalanine levels in plasma from both
MCI and AD subjects compared to controls; tryptophan levels were also distinct when
comparing MCI to AD subjects (Y. Liu et al. 2014). A further metabolomics study of plasma
found altered arginine metabolism and polyamine metabolism in MCI and AD subjects
(Graham et al. 2015). Another study found that glycine and valine levels were altered in
AD plasma (Klavins et al. 2015), but the authors warned that plasma amino acid levels
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show large variability depending upon the amount of fasting the subjects had undergone
prior to donating blood (Mathew et al. 2014) and that phospholipids may be more reliable
plasma biomarkers.
A comprehensive metabolomics study of both plasma and CSF from control, MCI,
and AD subjects found that tryptophan and arginine metabolism were altered in both CSF
and plasma from MCI subjects (Trushina et al. 2013). Lysine metabolism was decreased in
the CSF, but not plasma, from the MCI subjects. This study also found increased methionine
levels in the CSF of MCI subjects. Methionine, histidine, and lysine levels were increased in
AD plasma. The pathways affected in AD in both CSF and plasma included beta-alanine,
aspartate and asparagine, alanine, cysteine, methionine, methionine-cysteine-glutamate,
and arginine and lysine metabolism. Phenylalanine, lysine, and leucine were three of six
metabolites in plasma that could be used to discriminate between the MCI subjects and
controls (Trushina et al. 2013). A salivary metabolomics analysis found that taurine and
several dipeptides including Ser-Ser, Phe-Pro, and Arg-Leu were decreased in abundance in
MCI patients (Zheng et al. 2012). From the summation of these results one can discern that
there are many alterations in amino acid metabolism in MCI and AD patients, but the
results are not very consistent from study to study likely due to the different
methodologies and instrumentation used.

An Overview of Select Amino Acids by Class
In AD and MCI patients, some amino acids showed increased levels while most
showed decreased levels, especially in the brain, consistent with their oxidation as a
neuronal energy source. This information is summarized in Table 5.1. There are several
142

possible connections described in detail below through which disruption of normal amino
acid metabolism may lead to pathogenicity.
Table 5.1: Amino acids of interest in neurodegeneration
Amino Acids
of Interest

Tissue

Increase or
Decrease in
AD

Leucine

Valine

Plasma
(GonzalezDominguez
et al. 2015)

Decrease
(GonzalezDominguez et
al. 2015)

Isoleucine

Points of Interest

Effects of
Addition

Led to persistent
mTOR activation
(Lynch and Adams
2014); Metabolites
led to metabolic
dysfunction
(Amaral et al.
2010; Lynch and
Adams 2014;
Wisniewski et al.
2016)

Metabolite led to
mitochondrial
dysfunction in rat
neurons (Amaral et
al. 2010); BCAAs
increased mean
lifespan in male
mice (D’Antona et
al. 2010)

0.592

Led to persistent
mTOR activation
(Lynch and Adams
2014); Metabolites
led to metabolic
dysfunction
(Lynch and Adams
2014)

BCAAs increased
mean lifespan in
male mice
(D’Antona et al.
2010)

0.559

Led to persistent
mTOR activation
(Lynch and Adams
2014); Metabolites
led to metabolic
dysfunction
(Lynch and Adams
2014)

BCAAs increased
mean lifespan in
male mice
(D’Antona et al.
2010)

0.684

Phenylalanine

Serum
(GonzalezDominguez
et al. 2015);
Brain
(Nilsen et al.
2014; Xu et
al. 2016)

Decrease
(GonzalezDominguez et
al. 2015);
Increase
(Nilsen et al.
2014; Xu et al.
2016)

Metabolized in
absence of tyrosine
(Fernstrom and
Fernstrom 2007)

Tryptophan

Serum
(GonzalezDominguez
et al. 2015);
Brain (Xu et
al. 2016)

Decrease
(GonzalezDominguez et
al. 2015);
Increase (Xu
et al. 2016)

Metabolites led to
metabolic
dysfunction
(Bonda et al. 2011)
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DataWarrior
Drug Score*

0.579

Metabolite
increases nitric
oxide synthetase in
cell culture (PérezSeveriano et al.
1998)

0.661

Tyrosine

Serum
(GonzalezDominguez
et al. 2015)

Decrease
(GonzalezDominguez et
al. 2015)

Decreases could
disrupt
catecholamine
production

Improved memory
and cognitive
function in humans
(van de Rest et al.
2013)

Glutamine

Serum
(GonzálezDomínguez
et al. 2015);
Brain (Gueli
and Taibi
2013)

Decrease
(GonzálezDomínguez et
al. 2015);
Increase
(Gueli and
Taibi 2013)

0.573

Aspartic Acid

Brain (Gueli
and Taibi
2013; Xu et
al. 2016);
Serum
(GonzalezDominguez
et al. 2015)

Decrease
(Gueli and
Taibi 2013;
GonzalezDominguez et
al. 2015; Xu et
al. 2016)

0.593

Glutamic
Acid

Serum (G.
Wang et al.
2014); Brain
(Gueli and
Taibi 2013;
Xu et al.
2016)

Increase (Xu
et al. 2016);
Decrease
(Gueli and
Taibi 2013; G.
Wang et al.
2014)

Lysine

Brain (Xu et
al. 2016)

Decrease (Xu
et al. 2016)

0.499

Histidine

Serum
(GonzalezDominguez
et al. 2015)

Decrease
(GonzalezDominguez et
al. 2015)

0.835

Cysteine

Serum
(GonzálezDomínguez
et al. 2014;
Hu et al.
2016); Brain
(Hu et al.
2016; Xu et
al. 2016);
CSF (Czech
et al. 2012)

Decrease (Hu
et al. 2016);
Increase
(Czech et al.
2012;
GonzálezDomínguez et
al. 2014; Xu et
al. 2016)

Excitotoxicity led
to neuronal death
(Mattson et al.
1992; Hynd et al.
2004)

Involved in
glutathione
synthesis
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0.584

0.531

Decrease in mTOR
activity in rats
(Gomez et al. 2015)

0.493

Serum
Decrease
Increased amyloid0.578
(González(Gonzálezbeta and p-tau in
Domínguez
Domínguez et
mice (Tapia-Rojas
et al. 2014)
al. 2014)
et al. 2015)
*Structures were drawn using DataWarrior software using their most prevalent charge states at pH 7.4. A
higher Drug Score value indicates a better drug candidate.
Methionine

Branched Chain Amino Acids, mTOR, and AD
The branched chain amino acids (BCAAs) include leucine, valine, and isoleucine.
BCAAs compete with the aromatic amino acids phenylalanine, tyrosine, and tryptophan for
entry into the brain. Therefore, altering plasma BCAA levels can affect the levels of the
neurotransmitters serotonin, dopamine, epinephrine, and norepinephrine in the brain
(Fernstrom 2005). Unlike most amino acids which are metabolized to a large extent by
first pass hepatic metabolism, BCAAs are not metabolized there to a large degree, so their
concentration in blood often directly reflects the level of dietary consumption. Protein
restriction has been shown to decrease tau hyperphosphorylation and increase cognition in
an AD mouse model (Parrella et al. 2013). A BCAA-restricted diet has been shown to
induce similar protective metabolic effects on peripheral glucose and insulin levels as a
protein restricted diet (Fontana et al. 2016). However, whether the neuroprotective effects
of protein restriction are mediated by decreased BCAA levels is not yet known because
methionine restriction can also induce protective metabolic effects (Sanchez-Roman and
Barja 2013).
Some researchers suspect a link between increased BCAA levels and AD
pathogenesis (Morabito et al. 2014). Increasing BCAA levels through dietary
supplementation in rats led to a decrease in neural growth factor (NGF) in the
hippocampus (Scaini et al. 2013), a part of the brain involved in memory formation and
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known to shrink due to neuronal loss in AD patients. Administration of the leucine
metabolite α-ketoisocaproic acid also decreased NGF as well as brain-derived neurotrophic
factor (BDNF) (Wisniewski et al. 2016). However, the role of BCAAs in AD is not clear-cut.
The level of one of the BCAAs, valine, was found to be decreased in the plasma of AD
patients (Gonzalez-Dominguez et al. 2015). Furthermore, there are several studies that
link increased levels of BCAAs to indicators of increased health such as increased muscle
protein synthesis (Rennie et al. 2006), mitochondrial biogenesis (D’Antona et al. 2010),
and mTOR signaling (Tokunaga et al. 2004). A beneficial role of mTOR signaling in AD has
been hypothesized due to the fact that insulin is neuroprotective (Felice 2013; Cai et al.
2015), and insulin can activate mTOR kinase through PI3K (Um et al. 2006; Vergès and
Cariou 2015). mTOR activity has also been found to be neuroprotective under other
experimental conditions. For example, increased mTOR activation was associated with
decreased Aβ pathology in brains from the 5XFAD mouse model (Avrahami et al. 2013).
However, these effects may be related to the particular model or to the length of time of
mTOR activation. In the short term, it appears mTOR activation can lead to improved
insulin secretion (Rachdi et al. 2008), whereas chronic mTORC1 activation may lead to
exhaustion of β-cells in the pancreas (Shigeyama et al. 2008), decreasing the levels of
neuroprotective insulin. Somewhat contrary to the findings of mTOR being
neuroprotective is the finding that increased mTOR activation is frequently found in the
brains of AD model mice (Caccamo et al. 2011) and human AD patients (Li et al. 2005).
Increased amyloid-beta levels lead to increased mTOR activation which increases protein
translation to increase levels of tau protein, the main component of the neurofibrillary
tangles pathologically found in AD neurons (Jahrling and Laberge 2015). The increased
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rate of translation induced by mTOR activation may be partially responsible for the
decreased levels of amino acids measured in AD brain. Increased mTOR activity can also
stimulate mitochondrial electron transport chain activity (Schieke et al. 2006), perhaps
leading to increased mitochondrial catabolism of amino acids. The increased mTOR
activity also decreases the rate of autophagy, leading to the build-up of toxic amyloid-beta
peptides. Consistent with these findings, treatment of PDAPP or 3xTg-AD mice with
rapamycin, an mTOR inhibitor, reduced amyloid-beta and tau levels and restored cognitive
function (Caccamo et al. 2010; Spilman et al. 2010). These data suggest that diets
containing low protein levels or low levels of the potent mTOR activators leucine and
arginine may prove beneficial for AD patients (Hara et al. 1998), although decreasing the
levels of all three BCAAs together was more potent than decreasing only leucine levels on
enhancing peripheral metabolism in mice (Fontana et al. 2016).
Since a portion of the protective effects of mTOR inhibition by rapamycin treatment
in AD model systems is likely caused through a decreased rate of translation, other
therapies which decrease the rate of translation in the hippocampus may also be
therapeutic. With this in mind, decreased or unbalanced amino acid levels have also been
shown to decrease the rate of translation through the general control nonderepressible 2
(GCN2)-eIF2α kinase pathway. GCN2 kinase senses uncharged tRNAs and then
phosphorylates the translation initiation factor eIF2α to slow the rate of translation. Many
amino acids, for example BCAAs and aromatic amino acids, share the same amino acid
transporter for transport across the blood brain barrier. Therefore, supplementation with
high levels of one particular amino acid may competitively decrease the rate of transport of
others into the brain to decrease the levels of one or more of these other amino acids. This
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could create imbalanced amino acid levels in the brain to activate GCN2 and inhibit mTOR,
decreasing global translation rates and increasing autophagy to protect AD brains. Not all
mRNA transcripts show decreased translation under amino acid limitation. Some
transcripts, such as ATF4, show increased translation to mediate protective compensatory
responses. ATF4 is a transcription factor involved in the ER stress response that has been
shown to be upregulated during five conditions that extended mouse longevity (Li et al.
2014).
There are two prevalent hypotheses linking BCAAs to metabolic disease (Lynch and
Adams 2014). First, BCAAs, especially leucine, may directly lead to persistent activation of
mTORC1. Second, hyper-activation of BCAA catabolism can lead to increased BCAA
metabolites which lead to metabolic dysfunction. For example, adding the α-keto acid
catabolite of leucine, α-ketoisocaproic acid, to rat neurons led to mitochondrial dysfunction
(Amaral et al. 2010). The conflicting results of studies attempting to find correlations
between BCAA levels and disease suggest a complex role for BCAA levels in metabolism
that may vary depending on the model organism, disease state, and the length of time of
elevated BCAA and BCAA catabolite levels.
Few studies have examined the levels of BCAAs specifically in postmortem AD brain,
but it appears increasing certain BCAAs may be beneficial for the aging brain in specific
model systems. A diet high in BCAAs has even been shown to increase the mean lifespan of
male mice (D’Antona et al. 2010). Research into the role of BCAAs in AD is far from
complete. For example, there has been little study of the effects of isoleucine or valine
supplementation in AD patients or animal models. Since isoleucine and valine do not
stimulate mTOR activity as potently as leucine does (Xu et al. 1998) and are not broken
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down into neurotoxic α-ketoisocaproic acid, supplementation with these amino acids could
provide energy for the brain without activating potentially pathogenic signaling pathways.
Given the links between BCAAs, mTOR signaling, aging, and neurodegeneration, further
research will likely clarify these complex interactions. Furthermore, many of the same
correlations observed for BCAAs in insulin resistant individuals have also been observed
for aromatic amino acids, highlighting a complementary role for both of these classes of
amino acids in metabolism and disease (Newgard 2012).

Aromatic Amino Acids
Several studies have found that the levels of aromatic amino acids are frequently
altered in AD serum or brain. One research group found a decrease in all three aromatic
amino acids in the serum of AD patients (Gonzalez-Dominguez et al. 2015), while others
reported an increase in both phenylalanine and tryptophan in the brains of AD patients (Xu
et al. 2016). Researchers using AD model rats found an increase in phenylalanine in
different regions of the brain (Nilsen et al. 2014). Tryptophan has two different neural
fates; it can be metabolized into serotonin or it can enter the kynurenine pathway (KP)
where it is degraded to α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) which can
either be metabolized into quinolinic acid for NAD synthesis or into 2-aminomuconate for
entry into the TCA cycle. Serotonin plays a role in learning and cognition (Geldenhuys and
Van Der Schyf 2011), but enzymes involved in the KP are upregulated in AD (Bonda et al.
2011). There is evidence that quinolinic acid (QUIN) and other metabolic intermediates in
the KP pathway cause oxidative damage to the brain (Bonda et al. 2011). Increased QUIN
led to a concentration-dependent increase in ROS in the synaptosomes of rat brains and
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lipid peroxidation in the hippocampus (Santamaría et al. 2001). Researchers have also
shown that QUIN can increase nitric oxide synthase activity more than three-fold (PérezSeveriano et al. 1998). This enzyme produces nitric oxide, a vaso-relaxing free radical.
Amyloid-beta production increased the concentration of QUIN (Guillemin et al. 2003),
linking AD more directly to oxidative damage from amino acid metabolites. Moreover, a
shift in tryptophan degradation to the KP pathway diverts tryptophan from the serotonin
synthesis pathway. This could deprive the AD brain of serotonin, contributing to the
pathogenesis of AD. However, knowledge of aromatic amino acid metabolism and
signaling in AD brain is far from complete. Dietary tryptophan restriction has been shown
to extend the lifespan of rodents (Segall 1977), but the mechanism has not been
investigated. Acute tryptophan depletion leads to memory impairment (Riedel et al. 2002).
The amino acid tyrosine is important for synthesizing catecholamines, but there are
only a few studies measuring tyrosine levels specifically in AD brain, although several
studies have found that oral tyrosine administration improves memory and cognitive
function (van de Rest et al. 2013). Phenylalanine can be metabolized through the same
metabolic pathways as tyrosine but only when tyrosine levels are low (Fernstrom and
Fernstrom 2007), preventing firm conclusions regarding changes in phenylalanine levels in
AD brain until changes in tyrosine levels are measured as well. As a class, aromatic amino
acid metabolism is especially important for neural functioning, and more research is
needed to elucidate the relevance of the changes that occur in AD.
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Charged Amino Acids
The charged amino acids include the acidic (aspartate and glutamate) and basic
(arginine, lysine, and histidine) amino acids. Each of these appears to be decreased in AD
patient brain or plasma, with the possible exception of glutamate where the direction of
change may depend upon the brain region assayed. Glutamate (G. Wang et al. 2014),
histidine, and aspartate levels were decreased in serum from AD patients (GonzalezDominguez et al. 2015), while aspartate and glutamate levels were decreased in the
temporal lobe of the cerebral cortex of AD patients (Gueli and Taibi 2013). Xu et al.
measured a decrease in both lysine and aspartate levels in the brains from autopsied AD
patients, while glutamate levels increased (Xu et al. 2016). Glutamate’s interaction with
the NMDA receptor is critical for learning and memory formation (Esposito et al. 2013), but
glutamate excitotoxicity also leads to neuronal death in AD (Mattson et al. 1992; Hynd et al.
2004). As discussed below, aspartate and glutamate also play a role in transamination
reactions such as those occurring upstream of the urea cycle. As a group, the levels of
charged amino acids are altered in AD, suggesting specific perturbations in metabolism,
but more research needs to be done to determine the cause of the changes in amino acid
levels and the effects these have on the brain. Examining the activity of more enzymes
involved in amino acid metabolism and building computational models of amino acid
metabolism could help explain the alterations in amino acid levels in AD.

Glutamine
Glutamine is the most prevalent amino acid in plasma and, together with glutamate,
the most prevalent amino acids in human brain (Cooper and Jeitner 2016). Glutamate
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supplementation decreases tau phosphorylation and has shown other protective effects in
a mouse model of AD (Chen and Herrup 2012). It has been found that glutamine,
glutamate, aspartate, alanine, and purines are likely degraded as the top alternative energy
sources in neurodegenerative diseases such as AD when glucose metabolism is disturbed
(Kori et al. 2016). These amino acids are readily broken down because high levels of
aminotransferases for the initial step in the catabolism of alanine, aspartate, and glutamate
are present in brain (Cooper and Jeitner 2016). In AD patients, glutamine levels have been
shown to decline in the serum (González-Domínguez et al. 2015) but increase in the
temporal cortex of the brain (Gueli and Taibi 2013). Glutamine and alanine levels have
also been found to be decreased in the blood in transient global amnesia (Sancesario et al.
2013).
There has not been much data generated on how the brain maintains balances in
amino acid and total nitrogen levels during times of neuronal amino acid catabolism, but it
is likely that BCAAs can be taken up through the blood-brain barrier (BBB) and glutamate
can be released to maintain nitrogen balance (Hawkins and Viña 2016). BCAA-derived
carbons can then be fed into the citric acid cycle to form alpha-ketoglutarate, and then the
alpha-ketoglutarate can be transaminated to glutamate to maintain glutamate levels.
During times when ammonia levels increase in the brain, exporting a glutamine (containing
two nitrogen atoms) from the brain for every BCAA (or other amino acid containing a
single nitrogen atom) taken up would allow for a net efflux of nitrogen to lower the brain
ammonia levels (Cooper and Jeitner 2016).
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Sulfur-Containing Amino Acids
The sulfur containing amino acids are cysteine and methionine. Much research has
been performed on supplementation with cysteine and the more membrane permeable
form N-acetylcysteine (NAC) as cysteine levels limit the synthesis of glutathione, one of the
most important antioxidants in the body. NAC appears to cross the blood-brain barrier
slowly, so other therapies are under development to increase brain glutathione levels
(Bavarsad-Shahripour et al. 2014). There have been three small clinical trials of NAC
supplementation to AD patients with mixed results (Deepmala et al. 2015). Therefore,
more research is needed to clarify the effects of NAC on AD. There seems to be a disruption
in sulfur-containing amino acid metabolism in AD as serum and brain homocysteine levels
increase (Hu et al. 2016). Cysteine levels were also shown to be increased in the
hippocampus of autopsied AD patients (Xu et al. 2016). Homocysteine-cysteine disulfide
levels were also found to increase in AD patient serum while methionine levels decreased
(González-Domínguez et al. 2014). Increased homocysteine levels in the plasma is a known
risk factor for AD and other dementias (Seshadri et al. 2002). Dietary methionine
supplementation caused increased amyloid-beta and phosphorylated tau levels in brain
and cognitive impairment in wild-type mice (Tapia-Rojas et al. 2015). Dietary methionine
restriction led to decreased amyloid-beta levels and neuroprotection in APP-PS1 AD mice
(Sambamurti et al. 2015) and decreased mitochondrial complex I-mediated superoxide
production and increased lifespan in rats (Orentreich et al. 1993) while cysteine
supplementation led to a slight decrease in mTOR activity (Gomez et al. 2015). However,
cysteine supplementation prevented the decreased ROS production in methionine
restricted animals.
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Amino Acids as an Energy Source in AD Neurons
One of the hallmarks of AD is dysfunctional energy metabolism. Mitochondrialderived oxygen free radicals produced in AD brain are known to damage glycolytic
enzymes such as enolase (Butterfield and Lange 2009) and glyceraldehyde-3-phosphate
dehydrogenase (Butterfield et al. 2010), slowing glycolysis. This damage, combined with
decreased insulin signaling in AD brains (Calvo-Ochoa and Arias 2015), results in
decreased glucose uptake and metabolism which has been confirmed as an early event in
AD progression through the use of fluorodeoxyglucose (FDG)-PET scans (Mosconi et al.
2010). The decreased glucose metabolism results in decreased pyruvate production which,
combined with amyloid-beta-mediated mitochondrial complex IV inhibition (Wong-Riley et
al. 1997) and tau-mediated mitochondrial complex I inhibition (Rhein et al. 2009), results
in decreased mitochondrial energy metabolism and ATP levels. Most cells in the body
show metabolic flexibility and can increase mitochondrial fatty acid beta-oxidation when
glycolytic output decreases to maintain cellular ATP levels. Neurons contain very low
levels of fatty acid beta-oxidation enzymes (Panov et al. 2014), so they instead rely upon
ketone body catabolism, amino acid catabolism, or catabolism of lactate released from
astrocytes (Mächler et al. 2016) to maintain cellular ATP levels. Ketone body levels are
normally very low in the well-fed and unexercised human body (Sleiman et al. 2016).
Therefore, amino acid catabolism together with lactate metabolism and limited glucose
metabolism likely play essential roles in maintaining cellular ATP levels in AD neurons.
Data supporting this hypothesis come from clinical studies that show a 44% decrease in
glucose utilization in autopsied early-onset familial Alzheimer’s disease brain. The AD
brains showed no deficits in oxygen utilization as free amino acids (and perhaps lactate)
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were oxidized for energy generation in replacement of glucose, leading to decreased amino
acid levels (Hoyer et al. 1988). Once brain amino acid levels were depleted, brain ammonia
levels decreased as well. These data indicate that amino acid supplementation or high
protein diets may help to energize the AD brain.
The most abundant amino acids present in the human brain as a potential energy
source are glutamate and glutamine, present at roughly 7-8 mM, while the next most
abundant amino acids are aspartate and taurine which are present at roughly 1.2 mM, and
then serine, GABA, and glycine that are present at roughly 0.5 mM (Cooper and Jeitner
2016). The brain contains a glutamate-glutamine cycle where glutamate is released by
neurons into synaptic clefts; the glutamate is then taken up by astrocytes where some is
broken down for energy but most is converted to glutamine which is exported from the
astrocytes and taken up once again by neurons and converted back into glutamate. To
facilitate this cycle, the brain has been shown to possess high levels of two neuronal
glutaminase genes, GLS and GLS2 (phosphate-activated mitochondrial glutaminase), to
function in the breakdown of glutamine to glutamate that releases ammonia, but small
amounts of glutaminase (mostly GLS) have also been localized to astrocytes (Cardona et al.
2015). GLS2 activity is strongly upregulated by ADP (Masola and Ngubane 2010) and has
been shown to decline with aging (Walton and Dodd 2007), particularly in AD brain
(Akiyama et al. 1989).
Further release of ammonia in the brain can occur if glutamate is catabolized to
alpha-ketoglutarate by glutamate dehydrogenase. In addition to the normal mammalian
glutamate dehydrogenase gene, GLUD1, primates have a second glutamate dehydrogenase
gene, GLUD2, that is expressed in astrocytes and may be needed in those cells to preserve
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alpha-ketoglutarate levels in the presence of high glutamine synthetase activity (Spanaki
and Plaitakis 2012). Glutamine synthetase activity has been shown to decline in AD brain
(Smith et al. 1991). Mitochondrial GLUD1 is negatively regulated by the GTP formed from
citric acid cycle function, while GLUD2 is relatively unaffected by guanine nucleotides but is
positively regulated by ADP and branched chain amino acids (Zaganas et al. 2014). The
negative regulation of GLUD1 when energy levels are high allows for preservation of
glutamate levels needed for neurotransmission as well as prevents the toxic buildup of
ammonia. Glutamate can also be metabolized to alpha-ketoglutarate to fuel citric acid
cycle metabolism without the release of free ammonia through the function of the alanine,
aspartate, and branched chain aminotransferases (McKenna et al. 2016) if the
corresponding ketoacids are present in adequate amounts.
Normally both neurons and astrocytes oxidize glucose by glycolysis and the
resulting pyruvate by oxidative phosphorylation to maximize ATP yield (Patel et al. 2014).
However, there is much evidence that indicates astrocytes are more metabolically flexible
than neurons due to their slightly lower energy demands (Stobart and Anderson 2013).
Therefore, astrocytes can survive predominately by glycolysis with little oxidative
metabolism. In metabolically stressful times, such as in AD, astrocytes may convert the
pyruvate produced from glycolysis into lactate to maintain the cellular redox state and then
export the lactate which can then be taken up by neurons, converted back to pyruvate, and
used for oxidative energy metabolism, a process called the astrocyte-neuron lactate shuttle
(Pellerin and Magistretti 2012). Astrocytes may also be able to increase the amount of
glutamine released to neurons to be utilized as an energy source under these conditions
when neuronal glycolysis is impaired. Astrocytes possess some fatty-acid beta-oxidation
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capabilities (Panov et al. 2014) which likely becomes important during these times when
neuronal energy metabolism is impaired.
A study using AD mice found that a high protein/low carbohydrate diet resulted in a
5% reduction in the brain weight in AD mice, including decreased neuronal density and
volume in the CA3 region of the hippocampus that is important for memory (Pedrini et al.
2009). A high protein/low carbohydrate diet has also been associated with increased
excitotoxicity in the aged brain (Pal and Poddar 2008). These data suggest that high levels
of amino acids or products of their catabolism may contribute to neurodegeneration.
Consistent with this assessment, catabolism of branched chain keto acids by branched
chain ketoacid dehydrogenase (BCKDH) in mitochondria results in substantial production
of damaging superoxide radical (Quinlan et al. 2014). In addition, mice on a low
protein/high carbohydrate diet lived longer than those on a high protein/low carbohydrate
diet and had lower insulin levels and lower mTOR activation (Solon-Biet et al. 2014).
However, the health benefits of a low protein/high carbohydrate diet may only extend
through middle age as aged mice and humans on a high protein diet showed protection
from disease (Levine et al. 2014). Therefore, amino acid supplementation therapies may
best be explored as therapies for late-onset AD. Interestingly, plasma levels of all three
branched chain amino acids showed a positive correlation with dietary protein intake in
mice, while the plasma levels of most other amino acids showed a negative correlation with
dietary protein intake. Therefore, some of the beneficial health effects conferred by the low
protein diet in young and middle aged mice may be mediated by decreased plasma
branched chain amino acid levels.
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The Urea Cycle and AD
Amino Acid Metabolism, Ammonia, and the Urea Cycle
Proteins are digested in the stomach and intestine by a variety of peptidases into
free amino acids and dipeptides; the dipeptides are further catabolized into amino acids by
first pass hepatic metabolism. These amino acids are then transported by the blood to
other tissues where the amino acids are used for protein synthesis or broken down in
processes that produce ammonia when levels exceed their requirements. The α-amino
group of the amino acid is often transferred to α-ketoglutarate to form glutamate and an αketo acid. Glutamate can undergo oxidative deamination to form ammonia and αketoglutarate, or the amino group can be transferred to oxaloacetate to form aspartate and
α-ketoglutarate. Aspartate is required for urea cycle function. In the brain and muscle
(tissues normally lacking appreciable urea cycle function) aspartate can enter the purine
nucleotide cycle to release fumarate and ammonia. Other reactions produce ammonia as
well; histidine, serine, threonine, and tyrosine-derived catecholamine catabolism each
release ammonia through separate reactions. Ammonia is toxic and needs to be eliminated
quickly or converted to a less toxic form. Once ammonia and glutamate combine to form
glutamine through the action of the glutamine synthetase enzyme, the glutamine is
exported from the tissue and transported through the blood to the liver where the free
ammonia is released through the action of the glutaminase enzyme. The urea cycle can
then function to convert the ammonia to urea, which is excreted from the body.
The first and second steps of the urea cycle occur in the mitochondria, while the
other three steps occur in the cytoplasm. First, ammonia combines with CO2, H2O, and
HCO3- to form carbamoyl phosphate. N-acetylglutamate is required as a cofactor for this
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reaction to proceed. Carbamoyl phosphate reacts with ornithine to produce citrulline,
which is transported out of mitochondria and then reacts with aspartate to form
argininosuccinate. Arginosuccinate is converted by argininosuccinase into fumarate and
arginine. In the final step, arginase converts arginine into ornithine and urea. Figure 5.1
summarizes amino acid catabolism leading up to and including the urea cycle.

Figure 5.1: Overview of the urea cycle. Ammonia produced as a result of metabolic
processes involving amino acids and other biomolecules is converted into nontoxic urea in
the urea cycle for excretion. The intermediates are in boxes and the enzymes and other
necessary substrates are next to the arrows in lowercase. These intermediate metabolite
and enzyme levels are altered in the brain in Alzheimer’s disease.
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Changes in Components of the Urea Cycle in AD
Levels of enzymes and metabolic intermediates of the urea cycle are altered in
patients with AD. It is widely accepted that the urea cycle occurs almost exclusively in the
liver and intestines (Takiguchi and Masataka 1995). It has been shown that normal human
brain has low or no ornithine transcarbamoylase (OTC) activity, thus preventing urea cycle
activity (Bensemain et al. 2009). Carbamoyl phosphate synthetase activity is also low in
brain tissue. However, studies using autopsied brains from AD patients have challenged
this exclusive localization of the urea cycle. Hansmannel and colleagues identified mRNA
expression for all enzymes of the urea cycle in the brains of both normal adults and
patients with AD (Hansmannel et al. 2010). However, the mRNA levels of OTC were
extremely low in the non-AD subjects, and the normal cytoplasmic urea cycle enzyme
arginase I was extremely low in both populations. Arginase is one of the more studied
urea cycle enzymes that appears to be dysregulated in AD. Arginase converts arginine to
urea and ornithine (see Figure 5.1). Two groups, Lui et al. (P. Liu et al. 2014) and
Hansmannel et al. (Hansmannel et al. 2010), found the same trend of increased
mitochondrial arginase II (Arg2) levels in autopsied AD patient brain. Hansmannel et al.
used RT-PCR to find a 55% increase in Arg2 mRNA levels in AD patients compared to
controls (Hansmannel et al. 2010), whereas Lui et al. used Western blot to show an
increase in the total amount of Arg2 protein in two different brain regions with no change
in a third (P. Liu et al. 2014).
There are several important consequences of increased Arg2 expression in AD
brain. First, increased arginase activity increases urea and ornithine levels, the latter being
a precursor of polyamine synthesis. Polyamines can play an important neuroprotective
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role in the brain. Second, increased arginase activity decreases arginine levels, which can
lead to decreased mTOR activity. Arginine is also a substrate for nitric oxide synthase
which produces the vasorelaxing free radical nitric oxide that can increase
neuroinflammation. Therefore, transgenic overexpression of arginase I showed
neuroprotection in a tau-overexpressing model of AD (Hunt et al. 2015). However, an
arginase inhibitor showed neuroprotective effects in an amyloid-beta-producing mouse
model of AD (Kan et al. 2015). Therefore, it is possible that arginase expression has
different effects on amyloid and tau pathology. Arg2 is the main isoform in AD brain and is
highly expressed in endothelial cells. Therefore, it is also possible that arginase I activity is
neuroprotective while arginase II activity is neurotoxic due to expression in different cell
types or different subcellular localizations.
Bensemain et al. used RT-PCR to detect the transcription of the ornithine
transcarbamylase (OTC) gene and other enzymes of the urea cycle in AD brains as well
(Bensemain et al. 2009). OTC activity was exclusively localized to brain endothelial cells,
and its activity in cerebrospinal fluid was nearly 9 times higher in AD patients than in the
control group (Bensemain et al. 2009). It is interesting that OTC activity was concentrated
in the endothelia in the vasculature of the brain in AD (Bensemain et al. 2009); these areas
are severely affected by amyloid plaques (Koizumi et al. 2016). Taken together, these
results indicate that the urea cycle may occur in the endothelial cells of AD patients, but
this may rely upon the transport of arginine from the cytoplasm to the mitochondria to be
metabolized by arginase II. The mitochondrial ornithine carriers ORC1, ORC2, and
SLC25A29 are also able to transport arginine (Monné et al. 2015). ORC1 and ORC2 are
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expressed at very low levels in brain (Begum et al. 2002), but this may be enough to allow
low level urea cycle activity in the endothelial cells from AD patients.
Perhaps the most notable urea cycle metabolite change in the AD brain is in the level
of urea. The direction of the change in level of urea depends on the clinical or pathological
sample or the mouse model tested. Serum from human AD patients showed a 44%
decrease in urea levels when assayed using GC/MS (Gonzalez-Dominguez et al. 2015). The
same group found decreased urea in the serum of APP/PS1 AD model mice (GonzálezDomínguez et al. 2015). A decrease in urea in the hippocampus of the senescenceaccelerated SAMP8 mice was also measured (H. Wang et al. 2014). SAMP8 mice show
neurodegeneration similar to that observed in AD. The decreased urea levels are
consistent with decreased arginase levels found in APP/PS1 mouse brain (Tapia-Rojas et
al. 2015). Data collected from studies of human brain tell a completely different story. A
study by Gueli and Taibi using GC/MS on temporal lobe extracts demonstrated that urea
was increased in brain tissue of AD patients over 2-fold (Gueli and Taibi 2013). Xu and
colleagues measured urea in six different regions of the brain to find that urea was
increased in AD patients’ brains by an average of more than 5-fold (Xu et al. 2016). This
increase in urea levels is consistent with the increased Arg2 levels in human AD brain.
Interestingly, in the striatum of post-mortem Huntington’s disease brain, urea was found to
be the most decreased (3.2-fold) metabolite (Graham et al. 2016), but another study found
opposite results that urea was increased in all brain regions examined in post-mortem
Huntington’s patients (Patassini et al. 2015).
Ornithine levels were decreased in AD brain and serum (P. Liu et al. 2014; GonzalezDominguez et al. 2015; Xu et al. 2016). Although ornithine is the product of an enzyme that
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is upregulated (Arg2), the decrease is consistent with other findings because ornithine is
the substrate of OTC, another upregulated enzyme in AD brain (Bensemain et al. 2009),
and ornithine is a precursor for the production of polyamines that increase in abundance in
AD brain (Guerra et al. 2016). Citrulline, however, appears to remain unchanged in AD
brains (P. Liu et al. 2014; Pan et al. 2015). Citrulline is a strong antioxidant and citrulline
supplementation prevented age-related changes in lipid metabolism in mouse
hippocampus (Marquet-de Rougé et al. 2013). Aspartate reacts with citrulline to form
argininosuccinate. Aspartate levels are decreased in AD patient serum (GonzalezDominguez et al. 2015), and both aspartate and arginine levels are decreased in the brain
of AD patients (Gueli and Taibi 2013; Xu et al. 2016). Decreased levels of urea cycle
intermediates could indicate their efficient metabolism. Considering that different groups
have shown increased urea levels in biopsied AD brains as well as increased expression of
one or more urea cycle genes, current evidence suggests that urea cycle activity may be
induced in endothelial cells from AD patient brain. It is possible that a urea cycle
metabolite such as arginine that is produced in neurons and glia is imported into AD
endothelial cells where Arg2 levels are high and OTC is exclusively present to finish the
urea cycle there. The citrulline produced from endothelial cell OTC activity could also be
exported to neurons or glia to finish the urea cycle. However, it is also possible that the
higher urea levels found in AD brain are strictly due to increased Arg2 levels independent
of complete urea cycle function.
Increased urea levels in AD brain raises questions as to what could be leading to the
increased expression of OTC and arginase II. The main function of the urea cycle is to safely
dispose of nitrogenous waste from amino acid catabolism and other sources. Therefore, it
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has been hypothesized that abnormal nitrogen metabolism may play a role in the
pathogenesis of AD (Seiler 1993). One of the early hypotheses for the pathogenesis of AD,
proposed by Seiler in 1993, was the ammonia hypothesis; this posits that increased levels
of ammonia accumulate in and are toxic to the AD brain (Seiler 1993). However, the
amyloid cascade hypothesis was proposed the year before (Hardy and Higgins 1992), and
the ammonia hypothesis was not thoroughly investigated (Seiler 2002). The ammonia
hypothesis of AD was generated due to the following observations: increased ammonia
levels measured in the plasma from AD patients (Fisman et al. 1985; Hoyer et al. 1990),
decreased glutamine synthetase enzyme levels in AD astrocytes to scavenge ammonia
(Smith et al. 1991; Le Prince et al. 1995), increased adenosine deaminase activity in AD
brain (Sims et al. 1998), and increased monoamine oxidase activity in AD brain (Nakamura
et al. 1990; Jossan et al. 1991); the latter two enzymes produce ammonia. Ammonia has
also been implicated as a cause of oxidative damage in the brain as it was found to increase
reactive oxygen species levels in SH-SY5Y cells (Bobermin et al. 2015) and astrocytes
(Murthy et al. 2001) and lead to RNA oxidation in rats (Görg et al. 2008). Furthermore,
mitochondrial activity in rat and mouse models appears to be impaired by ammonia.
Ammonium acetate injection into rats led to decreased state III respiration (Kosenko et al.
1997), cytochrome c oxidase activity (Rama-Rao et al. 1997), and decreases in various
other respiratory complexes in isolated synaptic mitochondria (Qureshi et al. 1998).
Impaired mitochondrial function is often associated with increased oxidative damage. This
may in part explain the increase in reactive oxygen species in the presence of ammonia.
Increased ammonia production would either necessitate urea cycle function to metabolize
the toxic ammonia to urea or necessitate increased reaction of ammonia with glutamate
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catalyzed by astrocytic glutamine synthetase followed by export of glutamine from the
brain. Evidence from studies of the urea cycle and amino acid metabolism in AD subjects
and mouse models justifies further investigation into the production and detoxification of
ammonia in the AD brain.

Considerations for Dietary Metabolite Supplementation as a Treatment for AD
Increasing or decreasing the levels of specific amino acids and other metabolites in
the diet has shown some promise in improving markers of aging and longevity (Fernstrom
2005), so it is possible that nutrient supplementation or restriction may improve neural
functioning in AD patients as age is the major risk factor for AD. However, there are several
hurdles to overcome before an efficacious treatment can be formulated. For example,
studies on intestinal transport, bioavailability, hepatic metabolism and excretion, and
blood-brain barrier transport are needed in order to choose the optimal formulations.
Much of this information is present for a few commonly studied amino acids, but much of it
is absent for the vast majority of amino acids. From what is known, it appears that hepatic
metabolism, especially of amino acids, presents the greatest challenge to overcome for the
supplementation of many of the amino acids for their use in the treatment of
neurodegeneration, but intestinal transport may also become limiting in the elderly
(Levine et al. 2014). Several of the amino acids also have limited blood-brain permeability.
We will present one promising strategy taking these many challenges into consideration.
As mentioned above, intestinal uptake of amino acids declines past age 65. It has
been shown that the bioavailability of individual amino acids and dipeptides is slightly
better than that of amino acids consumed as polypeptides since the individual monomers
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can be absorbed quickly without the need for further enzymatic hydrolysis in the gut.
Therefore, dietary supplementation with individual amino acids or combinations of
individual amino acids would likely benefit the elderly in addition to a high protein diet
that promotes health in the elderly (Levine et al. 2014). The use of individual amino acids
also has the added benefit of being able to stimulate specific signaling pathways. Due to the
limited intestinal uptake of amino acids in the elderly, they may particularly benefit from
supplementation with hydrophobic, more membrane permeable forms of amino acids such
as amino acid ethyl esters or N-acetyl amino acids. These amino acid derivatives show a
greater probability of diffusion across membrane bilayers such as intestinal epithelia and
the capillary endothelia of the blood-brain barrier where the activity of specific membrane
transporters may be limiting. These more hydrophobic amino acid derivatives are cleaved
by esterases and other hydrolytic enzymes intracellularly or extracellularly to release the
free amino acid. This hydrolysis may occur to a large extent during first pass hepatic
metabolism.
Dietary aspartate, glutamate, and glutamine are oxidized as primary sources of fuel
for intestinal cells (Reeds et al. 2000). In addition, these amino acids, especially glutamate
and aspartate, are transported very poorly through the blood-brain barrier (Hawkins et al.
2006) even though they are present at high concentrations in the brain. Other amino acids
that are transported poorly through the blood-brain barrier include glycine, alanine,
proline, and GABA. Medium and large side chain, non-polar amino acids are transported
readily by the blood-brain barrier into the brain including aromatic amino acids, BCAAs,
methionine, histidine, and threonine (Smith 2000). These amino acids all compete for
transport through the L1 transport pathway. Glutamine and asparagine are also likely
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transported by this pathway. Another amino acid transporter called the y+ system
transports basic amino acids such as arginine, lysine, and ornithine as well as many neutral
amino acids such as serine through the blood brain barrier (Hawkins et al. 2006). One
potential therapeutic strategy for AD patients is to supplement their diets with high levels
of BCAAs, aromatic amino acids, and threonine. Through competition for the L1 amino acid
transport system, this therapy could limit the transport of methionine into the brain,
perhaps yielding the known metabolic and neuroprotective benefits of methionine
restriction (Sanchez-Roman and Barja 2013; Tapia-Rojas et al. 2015). However,
methionine is also transported into the brain to a limited extent through the y+ system; this
may hinder the effectiveness of this strategy. A second potential therapy is to omit leucine
and/or isoleucine from the previously mentioned supplementation strategy. These two
amino acids are not transported by the y+ system (Hawkins et al. 2006). Depletion of
leucine or isoleucine in the brain would lead to amino acid imbalance, activation of GCN2
kinase, and possibly the inhibition of mTOR kinase to slow protein translation rates that
may be beneficial for reducing the levels of neurofibrillary tangles formed from
hyperphosphorylated aggregates of tau protein. These amino acid supplementation
therapies could be combined with supplementation with other metabolic fuels such as Dbeta-hydroxybutyrate (a ketone body), citric acid cycle intermediates, pyruvate, and/or
lactate, which would decrease the reliance of AD neurons on the use of amino acids as a
fuel. Consumption of high levels of these alternative metabolic fuels may function to
restore neuronal amino acid levels.
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Summary and Conclusions
Dietary amino acids provide a large amount of carbon and nitrogen to the body that
can be metabolized by a myriad of biochemical pathways. Amino acids have roles in
neuronal signaling, energy production, and nitrogenous waste production and elimination.
These processes are important for normal physiology, so it is not surprising that disease
states result from major metabolic dysfunction, but whether relatively minor perturbations
of this metabolism contribute to neurodegeneration requires further study. Brains and
serum from AD patients have consistently shown alterations in amino acid levels and
metabolism that could provide a basis for some of the symptoms of the disease. These
individual changes may each play a different role in the disease, highlighting the complexity
that underlies AD pathology. An increase in urea in the brains of AD patients together with
the altered expression of urea cycle enzymes suggests that urea cycle activity is induced in
AD brain endothelial cells. Viewing AD as a metabolic disease provides valuable insight
into possible new targets for drug discovery in the AD research field. A summary of some
of the altered amino acid metabolism that occurs in AD is shown in Figure 5.2.
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Figure 5.2: Pathogenic processes and proposed physiological responses in Alzheimer’s
disease. A) An overview of the pathogenic processes of Alzheimer’s disease. B) An
overview of how the body may respond to AD to minimize damage by changing the
expression of enzymes involved in amino acid catabolism.

The measurement of metabolite levels provides a snapshot of a very dynamic
process. While this information is extremely useful, it is not sufficient by itself to
understand the pathological changes associated with AD. Further studies measuring
enzyme activities could provide complementary information about the dynamics of amino
acid metabolism in AD. In addition, studies overexpressing OTC and Arg2 to activate the
urea cycle in the brain endothelial cells of an AD mouse model would help clarify the effects
of endothelial urea cycle activity on brain physiology and cognitive function. Studying AD
from a metabolic perspective could lead to dietary supplementation therapies that could
delay disease progression or alleviate some of the suffering caused by the disease.
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Abstract
Ammonia is a toxic byproduct of protein catabolism and is involved in changes in
glutamate metabolism. Therefore, ammonia metabolism genes may link a range of diseases
involving glutamate signaling such as Alzheimer’s disease (AD), major depressive disorder
(MDD), and type 2 diabetes (T2D). We analyzed data from a National Institute on Aging
study with a family-based design to determine if 45 single nucleotide polymorphisms
(SNPs) in glutaminase (GLS), carbamoyl phosphate synthetase 1 (CPS1), or glutamateammonia ligase (GLUL) genes were associated with AD, MDD, or T2D using PLINK
software. HAPLOVIEW software was used to calculate linkage disequilibrium measures for
the SNPs. Next, we analyzed the associated variations for potential effects on
transcriptional control sites to identify possible functional effects of the SNPs. Of the SNPs
that passed the quality control tests, four SNPs in the GLS gene were significantly
associated with AD, two SNPs in the GLS gene were associated with T2D, and one SNP in
the GLUL gene and three SNPs in the CPS1 gene were associated with MDD before
Bonferroni correction. The in silico bioinformatic analysis suggested probable functional
roles for six associated SNPs. Glutamate signaling pathways have been implicated in all
these diseases, and other studies have detected similar brain pathologies such as cortical
thinning in AD, MDD, and T2D. Taken together, these data potentially link GLS with AD,

GLS with T2D, and CPS1 and GLUL with MDD and stimulate the generation of testable
hypotheses that may help explain the molecular basis of pathologies shared by these
disorders.
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Background
Excess dietary protein is catabolized to release ammonia. Because of the relative
toxicity of ammonia (Auron and Brophy 2012), it is removed from the body by the urea
cycle and excreted as the relatively non-toxic compound urea. The urea cycle is thought to
occur almost exclusively in the liver (Dimski 1994). However, certain types of ammonia
metabolism such as glutamate cycling can occur in other tissues. Among the enzymes
involved in ammonia metabolism are glutaminase (GLS, EC 3.5.1.2), carbamoyl phosphate
synthetase 1 (CPS1, EC 6.3.4.16), and glutamate-ammonia ligase (GLUL, EC 6.3.1.2), also
known as glutamine synthetase. CPS1 is the first committed step of the urea cycle.
Individuals who lack a functional CPS1 gene have severe hyperammonemia resulting in
cognitive impairment (Klaus et al. 2009). The majority of cells in the body (such as those in
the brain) that lack a functional urea cycle rely on GLUL to locally remove ammonia by
ligating it to glutamate to form glutamine (Cooper and Jeitner 2016). Glutaminase
catalyzes the reverse process, releasing ammonia from glutamine to form glutamate. The
human genome contains two glutaminase genes. Data from the Human Protein Atlas
(www.proteinatlas.org) suggest GLS is expressed primarily in the brain and kidney
(http://www.proteinatlas.org/ENSG00000115419-GLS/tissue) (Uhlén et al. 2015).
Because glutamate is an important neurotransmitter and signaling molecule, both GLUL
and GLS are necessary for proper neural functioning (Cooper and Jeitner 2016).
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Because (1) glutamine and glutamate are abundant and ubiquitous amino acids
involved in ammonia metabolism, (2) ammonia is a byproduct of protein catabolism, and
(3) glutamate is an important signaling molecule, we hypothesized that the CPS1, GLUL,
and GLS ammonia metabolism genes could influence various disease processes across a
range of tissues. Evidence for a link between ammonia metabolism genes and type 2
diabetes (T2D) includes studies that have found changes in GLS activity in a rat model of
diabetes (Ardawi 1987). In addition, a SNP in the GLUL gene has been associated with allcause mortality in individuals with T2D (Prudente et al. 2015), and a separate study has
found a transcriptomic link between T2D and GLUL (Mirza et al. 2014). Ammonia and
glutamate metabolism changes have also been linked to mood disorders such as major
depression. For example, glutamate signaling pathways have been shown to be altered in
major depressive disorder (MDD) (Bernard et al. 2011). Furthermore, GLUL expression
has been shown to be changed in individuals with MDD (Choudary et al. 2005; MiguelHidalgo et al. 2010; Bernard et al. 2011). However, one study reports no change in GLUL
activity in astrocytes from the brains of individuals with MDD (Chandley et al. 2013).
Further evidence supporting this connection is that researchers were able to induce
behaviors consistent with depression in mice by inhibiting enzymes involved in ammonia
and glutamate metabolism (Lee et al. 2013).
The potential link between ammonia metabolism and Alzheimer’s disease (AD) is
particularly well-supported. The amyloid cascade hypothesis is the dominant hypothesis
for the pathogenesis of AD (Hardy and Higgins 1992). However, increasing evidence
suggests increased amyloid-beta levels are only one facet of this complex disease (Herrup
2015). The ammonia hypothesis for the etiology of AD was first proposed in 1993 (Seiler
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1993), but it has not yet been thoroughly investigated. The ammonia hypothesis suggests
ammonia toxicity plays a causal role in AD. This is supported by several observations
reviewed by Seiler (Seiler 2002). Briefly, individuals with AD have been found to have
increased blood ammonia (Fisman et al. 1985) and cerebrospinal fluid ammonia levels.
The negative effects of ammonia on cognitive functioning are well documented (Raabe
1987), and studies have suggested that there are high ammonia concentrations in AD brain
(Hoyer et al. 1990). AD patients have also been shown to have increased plasma glutamate
compared to controls (Miulli et al. 1993). Further studies suggest changes in the activity of
ammonia metabolism genes may be involved in AD. Researchers have found changes in

GLUL expression in AD patients (Robinson 2000) as well as in mouse models of AD
(Kulijewicz-Nawrot et al. 2013). Changes in GLS expression in AD brains have been found
as well (Akiyama et al. 1989; McGeer et al. 1989; Burbaeva et al. 2014). The
aforementioned studies suggest an association between GLUL, GLS, and CPS1 genes and
disorders such as AD, T2D, and MDD. While all three of the genes of interest have not been
explicitly implicated in all three diseases, there is sufficient evidence for the involvement of
ammonia metabolism genes in the pathologies of these diseases to warrant further
investigation.
All three of these diseases have genetic heritability; AD is estimated to have a
heritability of 0.74 (Gatz et al. 1997), MDD of 0.37 (Sullivan et al. 2000), and T2D of 0.470.77 (Willemsen et al. 2015). There is also ample epidemiological evidence of associations
among MDD, T2D, and AD. T2D has been found in several studies to be linked to the
incidence of AD (Ott et al. 1999; Luchsinger et al. 2005; Gudala et al. 2013; Li et al. 2015).
Two separate analyses of a GWAS found SNPs that were associated with both T2D and AD
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(Hao et al. 2015; Gao et al. 2016), suggesting the possibility of a shared genetic etiology.
However, none of the hits from these studies were the genes we tested. There is also
epidemiological evidence of an association between AD and MDD. Individuals with a
history of depression were shown to have an increased risk for AD (Geerlings et al. 2008).
Finally, T2D has been shown by several studies to nearly double the risk of developing
MDD (Anderson et al. 2001; Ali et al. 2006). However, not every study supports a genetic
association amongst these diseases. A study of 32 genetic variants identified in GWAS
studies of individuals with T2D found no association with AD (Chung et al. 2015). Another
study also found no association between SNPs associated with T2D and risk of AD (Proitsi
et al. 2014). A third study found no common genetic variants between individuals with AD
and MDD (Gibson et al. 2017). Studies that continue to investigate the genetic component
of these diseases could help untangle knowledge of genetic associations and elucidate
targets for novel treatment strategies.
To investigate the potential association between these select ammonia metabolism
genes and AD, MDD, and T2D, we used data from a family-based study of Alzheimer’s
disease patients. The variations significantly associated with one or more of these diseases
were interpreted considering previously published experimental results and
bioinformatics analysis of possible effects of variants on gene expression. This study
generates several hypotheses useful for guiding future work into mechanisms of
pathogenesis of AD, MDD, and T2D and investigations into how these mechanisms may
interact and overlap.
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Methods
NIA-LOAD Family Study Subjects
Data for this study came from the National Institute on Aging—Late Onset
Alzheimer’s Disease Family Study: Genome-Wide Association Study for Susceptibility
Loci—Study Accession: phs000168.v1.p. There were 3,007 individuals selected consisting
of 1266 AD, 247 T2D, and 1688 MDD individuals, and 1279 non-AD individuals from 1386
pedigrees (589 nuclear families). Details on these subjects have been previously published
(Lee et al. 2008). Population stratification does not apply to a family-based study design.
The number of individuals in this data set with each type of disease and combinations of
co-occurrences are shown in Table 6.1.

Table 6.1 Number of individuals with co-occurrence of AD, MDD, and T2D in the data seta
AD and
AD and
MDD and
AD, MDD,
AD Only
MDD Only T2D Only MDD Only T2D Only T2D Only and T2D
166
877
16
372
32
93
46
a
Individuals with an unknown disease state for either AD, MDD, or T2D were not included in
this count

Analytic Procedures
A total of 45 SNPs in GLUL (4 SNPs), GLS (8 SNPs), and CPS1 (33 SNPs) were
available in the data set for association testing. A family-based association analysis for risk
of AD, T2D and MDD was performed using the PLINK DFAM procedure. Empirical p-values
for single marker analyses were calculated by 100,000 permutation tests using the Max (T)
permutation procedure implemented in PLINK v1.07 software
(http://zzz.bwh.harvard.edu/plink/index.shtml) (Purcell et al. 2007). Haplotype analysis
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was conducted in 2-SNP sliding windows using PLINK software to obtain p-values, chisquare values, and haplotype frequencies for affected and unaffected individuals.
HAPOVIEW v4.2 software (https://www.broadinstitute.org/haploview/haploview)
(Barrett et al. 2005) was used to determine minor allele frequencies (MAFs) and to test for
Hardy-Weinberg equilibrium (HWE) using all founders in the family-based dataset. The
quality control cutoff values for HWE and MAF are <0.001 and <0.05, respectively. The
linkage disequilibrium (LD) structure was constructed and r2 and D' values were
determined using HAPLOVIEW. To correct for multiple testing, the Bonferroni correction
(α=0.05/45=0.00111) was used.

Bioinformatics Analysis
Because the significantly associated SNPs were all intronic, the 11 SNPs associated
with AD, MDD, or T2D were input into the Human Splice Finder v3.0 program
(http://www.umd.be/HSF3/) (Desmet et al. 2009) to determine if any of the SNPs may
affect silencing and enhancing regions of the genes. The sequence immediately
surrounding the SNP was obtained from the NCBI dbSNP database
(https://www.ncbi.nlm.nih.gov/snp). PERFECTOS-APE was used to predict transcription
factor (TF) binding sites affected by the SNPs, and the hits were compared with the results
of database searches for transcription factors that have been experimentally determined to
be associated with the genes studied. We searched the transcription factor databases
Human Transcriptional Regulation Interaction Database
(http://www.lbbc.ibb.unesp.br/htri/) (Bovolenta et al. 2012) and RegNetwork
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(http://www.regnetworkweb.org/) (Liu et al. 2015) for transcription factors that have
been experimentally determined to interact with the genes of interest.

Results
Single Marker Analysis
PLINK single marker analysis revealed several SNPs associated with AD, MDD, and
T2D with an empirical p-value < 0.05.

Alzheimer’s Disease. There were four SNPs significantly associated with AD before
the Bonferroni correction (rs6758866, p = 0.00350; rs2355570, p = 0.03675; rs1921907;
p = 0.00334; and rs883844, p = 0.00163). All four of these SNPs are located in the GLS
gene on chromosome 2, and all have a HWE p > 0.001 and a MAF of p > 0.05, therefore,
they passed the quality control test. These results are shown in Table 6.2.

Table 6.2 SNPs associated with risk of AD
SNP
Position
Allelea
Gene
EMP1b
MAFc
HWEd
rs6758866
191464646
A
GLS
0.00350
0.440
0.1046
rs2355570
191489414
C
GLS
0.03675
0.258
0.3147
rs1921907
191493020
A
GLS
0.00334
0.437
0.1691
rs883844
191534014
T
GLS
0.00163
0.381
0.3054
a
Minor allele
b
Empirical p-value generated by 100,000 permutation tests using Max (T) permutation
procedure in PLINK
c
Minor allele frequency in founders
d
Hardy-Weinberg equilibrium p-value
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Major Depressive Disorder. Five SNPs were significantly associated with MDD
before the Bonferroni correction. Four of these SNPs (rs6749597, p = 0.02776;
rs9789405, p = 0.01283; rs2287602, p = 0.01692; and rs2302909, p = 0.02103) are
located in the CPS1 gene on chromosome 2, while one SNP (rs12735664, p = 0.03640) is
located in the GLUL gene. While each of these has a MAF > 0.05, rs2302909 failed to pass
the test for Hardy-Weinberg equilibrium (p = 2.0E-4). These results are shown in Table
6.3.

Table 6.3 SNPs associated with risk of MDD
SNP
Position
Allelea Gene
EMP1b
MAFc
HWEd
rs12735664
180622702
C
GLUL
0.03640
0.103
0.9515
rs6749597
211128370
T
CPS1
0.02776
0.138
0.4310
rs9789405
211131628
T
CPS1
0.01283
0.146
0.7266
rs2287602
211135486
C
CPS1
0.01692
0.150
0.0344
rs2302909
211211801
A
CPS1
0.02103
0.103
2.0E-4
a
Minor allele
b
Empirical p-value generated by 100,000 permutation tests using Max (T) permutation
procedure in PLINK
c
Minor allele frequency in founders
d
Hardy-Weinberg equilibrium p-value

Type 2 Diabetes. As shown in Table 6.4, three SNPs were significantly associated
with T2D before the Bonferroni correction, two in the GLS gene (rs1921915, p = 0.01794;
and rs1517354, p = 0.00072) and one in the CPS1 gene (rs2302909, p = 0.00647). All of
these SNPs have a MAF of > 0.05, but rs2302909 failed to pass the test for Hardy-Weinberg
equilibrium (HWE p = 2.0E-4).
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Table 6.4 SNPs associated with risk of T2D
SNP
Position
Allelea
Gene
EMP1b
MAFc
HWEd
rs1921915
191460572
G
GLS
0.01794
0.062
0.1093
rs1517354
191524111
C
GLS
0.00072
0.084
0.0066
rs2302909
211211801
A
CPS1
0.00647
0.103
2.0E-4
a
Minor allele
b
Empirical p-value generated by 100,000 permutation tests using Max (T) permutation
procedure in PLINK
c
Minor allele frequency in founders
d
Hardy-Weinberg equilibrium p-value

Two-SNP Haplotype Analysis
PLINK two-SNP haplotype analysis revealed several haplotypes associated with AD (one
haplotype), MDD (11 haplotypes), and T2D (15 haplotypes). The haplotypes with p < 0.05
are listed in Table 6.5 (AD), Table 6.6 (MDD), and Table 6.7 (T2D).

Table 6.5 Haplotype analysis of risk of AD based on PLINK in family-based study design
Haplotype
Gene
Affected
Unaffected
Chip value
Frequency (%) Frequency (%) square
rs883844
rs10932334 GLS/CPS1
C
T
14.34
30.55
3.894 0.0485

192

Table 6.6 Haplotype analysis of risk of MDD based on PLINK in family-based study design
Haplotype
Gene
Affected
Unaffected
Chip value
Frequency (%) Frequency (%) square
rs3856348
rs6725303 CPS1
T
C
27.91
18.57
7.005 0.0081
rs6725770
rs759688
CPS1
A
T
23.51
30.22
3.881 0.0488
rs918233
rs1509821 CPS1
A
G
56.22
47.8
4.545 0.0330
rs17773128 rs6749597 CPS1
C
T
14.64
8.242
5.459 0.0195
rs6749597
rs2887913 CPS1
T
C
14.64
8.242
5.459 0.0195
rs2887913
rs9789405 CPS1
C
T
15.52
8.242
6.748 0.0094
rs9789405
rs2287603 CPS1
T
T
15.42
8.171
6.723 0.0095
C
T
62.9
71.56
5.157 0.0232
rs2287603
rs2287602 CPS1
T
C
16.01
8.929
5.719 0.0168
T
T
61.72
69.64
3.925 0.0476
rs2287602
rs10515951 CPS1
C
G
15.95
8.929
5.644 0.0175
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Table 6.7 Haplotype analysis of risk of T2D based on PLINK in family-based study design
Haplotype
Gene
Affected
Unaffected
Chip value
Frequency (%) Frequency (%) square
rs1921915
rs6758866 GLS
T
G
47.95
56.67
4.034 0.0446
rs2355570
rs1921907 GLS
T
A
26.03
17.15
6.942 0.0084
rs1921907
rs17748089 GLS
A
G
51.37
42.8
3.894 0.0485
rs17748089 rs1517354 GLS
G
C
14.38
7.64
7.744 0.0054
rs1517354
rs883844
GLS
C
C
5.37
1.02
17.06 3.63E-5
rs1509821
rs981024
CPS1
G
C
41.78
50.64
4.105 0.0428
rs10515951 rs6714124 CPS1
T
C
2.74
7.06
3.957 0.0467
rs2371001
rs3821135 CPS1
A
C
2.14
6.87
4.822 0.0281
G
A
52.84
43.3
4.756 0.0292
rs3821135
rs7607205 CPS1
C
T
6.85
13.0
4.568 0.0326
rs7607205
rs12468557 CPS1
G
C
9.03
3.97
7.675 0.0056
rs12468557 rs2302909 CPS1
C
A
19.01
8.87
14.89 1.14E-4
C
C
46.05
55.59
4.751 0.0293
rs2302909
rs7599931 CPS1
A
G
5.43
2.27
5.155 0.0232
A
T
14.43
6.96
10.21 0.0014

LD Structure
The linkage disequilibrium (LD) structures for these genes are shown in Figure 6.1.
The GLS and CPS1 genes are located on chromosome 2 (2q32.2 and 2q34, respectively),
while the GLUL gene is located on chromosome 1 (1q25.3). SNP pairs with an r2 value >
0.5 and a D' value greater than 0.8 are listed in Table 6.8.
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Figure 6.1: Linkage disequilibrium structure of founders from the data set using HAPLOVIEW software.
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Table 6.8 Top linkage disequilibrium measures
SNP 1
SNP 2
D'
r2
rs10932334
rs3856348 1
0.979
rs6725303
rs6725770 1
0.951
rs6749597
rs9789405 1
0.941
rs6749597
rs2287602 1
0.937
rs6714124
rs7573258 1
0.718
rs2371000
rs2371001 1
0.71
rs6725770
rs918233
1
0.622
rs6758866
rs1921907 0.997
0.984
rs2012564
rs2887913 0.997
0.932
rs981024
rs2012564 0.997
0.929
rs7573258
rs2371001 0.996
0.703
rs2355570
rs883844
0.995
0.561
rs9789405
rs2287602 0.994
0.977
rs13010236
rs12997383 0.991
0.62
rs1921907
rs883844
0.99
0.777
rs1921915
rs1517354 0.988
0.707
rs6758866
rs883844
0.987
0.764
rs7573258
rs2371000 0.986
0.97
rs6714124
rs2371000 0.982
0.695
rs6714124
rs2371001 0.981
0.947
rs981024
rs2887913 0.98
0.958
rs6725303
rs918233
0.978
0.626
rs7607205
rs12468557 0.955
0.788
rs2371001
rs7607205 0.948
0.567
rs3856348
rs2887913 0.948
0.554
rs10932334
rs2887913 0.945
0.563
rs3856348
rs981024
0.939
0.543
rs10932334
rs981024
0.936
0.551
rs6714124
rs7607205 0.935
0.542
rs3856348
rs2012564 0.931
0.571
rs759688
rs10515951 0.922
0.631
rs10932334
rs2012564 0.906
0.551
rs2887913
rs6714124 0.885
0.501
2
SNP pairs with D'>0.8 and r >0.5
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Bioinformatics Analysis
All the SNPs tested are intronic. Of the 11 SNPs with a significant association with
AD, MDD, or T2D, bioinformatics analysis suggests a function for seven. Of these, only 6
SNPs are in HWE; the other SNP, rs2302909, will not be considered further. Three SNPs
(rs6758866, rs2355570, and rs1517354) were predicted to create enhancer sites, and one
SNP decreased the likelihood of the sequence binding to transcription factors that have
been experimentally determined to interact with the gene sequences of interest
(rs1921907). Another two SNPs (rs9789405 and rs2287602) both created an enhancer
site and decreased the likelihood of binding with a transcription factor. The details of these
results are presented in Table 6.9.

Table 6.9 Bioinformatics analysis predicted functional effects of SNPs
associated with AD, MDD, or T2D
SNP
Gene
Disease
Transcription Factor
Enhancer Site
Association
Binding Affected
Formation
rs6758866
GLS
AD
0
+
rs2355570
GLS
AD
0
+
rs1921907
GLS
AD
ETS1
0
rs883844
GLS
AD
0
0
rs1921915
GLS
T2D
0
0
rs1517354
GLS
T2D
0
+
rs12735664 GLUL MDD
0
0
rs6749597
CPS1
MDD
0
0
rs9789405
CPS1
MDD
E2F4
+
rs2287602
CPS1
MDD
FOXP3
+
rs2302909
CPS1
MDD/T2D
0
+
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Discussion
Alzheimer’s Disease
Because of the potential effect of ammonia levels on the onset and progression of AD
described above (Seiler 1993), we hypothesized that SNPs in the ammonia metabolism
genes GLUL, CPS1, and GLS may be associated with AD. However, single marker analyses
only found SNP markers statistically associated with AD in the GLS gene (Table 6.3) in this
current study. Bioinformatics analysis using the Human Splice Finder software and the
PERFECTOS-APE program suggest three of these intronic SNPs may have a direct
functional role in GLS regulation (Table 6.9). The minor alleles of SNPs rs6758866 and
rs2355570 are predicted to create enhancer sites. Each of these variations may increase
the expression of GLS. The minor allele of SNP rs1921907 is predicted by the PERFECTOSAPE software to decrease the likelihood of binding to the transcription factor ETS1. ETS1
has been shown to be expressed in brain
(http://www.proteinatlas.org/ENSG00000134954-ETS1/tissue) (Uhlén et al. 2015) and to
interact with the GLS gene (Hollenhorst et al. 2009). Because ETS1 can be either a
repressor or an activator of transcription (Dittmer 2003), it is not possible to predict the
direction of regulation. The statistical association of the SNP rs883844 with AD is likely the
result of an indirect association. The SNP may possibly act as a marker for a nearby
unsequenced variation involved in the disease process, or its association may be due to its
proximity to the other three SNPs in the GLS gene identified in this study as being
associated with AD. Data in Table 6.8 reveal rs883844 is in LD with rs2355570 (D' =
0.995, r2 = 0.561), rs1921907 (D' = 0.990, r2 = 0.777), and rs6758866 (D' = 0.987, r2 =
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0.764). This may explain the significant association with AD in the absence of a predicted
function.
As mentioned earlier, GLS is the isoform of glutaminase mostly found in the brain
and kidneys (Uhlén et al. 2015). In contrast, GLS2 is mostly localized to the liver
(http://www.proteinatlas.org/ENSG00000135423-GLS2/tissue) (Uhlén et al. 2015). GLS
breaks down glutamine to ammonia and glutamate. Glutamate, an excitatory
neurotransmitter, is important for synaptic transmission and memory formation (Esposito
et al. 2013), but increased levels can lead to excitotoxic neuronal cell death in the brain. If
the observed variants in the GLS gene or nearby unsequenced SNPs in LD affect
glutaminase levels and enzyme activity, they would affect the regeneration of the glutamate
used to remove neurotoxic ammonia. Changing these glutamate levels could impact
cognitive function in AD (Myhrer 1998). Several studies agree that GLS levels in AD brain
are decreased (Akiyama et al. 1989; McGeer et al. 1989; Burbaeva et al. 2014). Two of the
three SNPs associated with AD and predicted to have a function may create an enhancer
site, but enhanced expression of GLS in AD is inconsistent with the published literature. It
is possible that the predicted enhancer sites created are in linkage disequilibrium with
nearby unsequenced SNPs that are more important for transcriptional regulation, or ETS1
usually acts as a relatively strong activator in this system. Experimental studies of
autopsied AD patient brains have found an increase in glutamate levels (Xu et al. 2016).
However, another study found decreased glutamate in the temporal cortex of AD brain
(Gueli and Taibi 2013). Both increases and decreases in brain glutamate are associated
with cognitive decline (Myhrer 1998). It is possible that changes in glutamate levels in AD
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brain are region-specific and occur because of disrupted glutamate and ammonia
homeostasis.

Major Depressive Disorder
Several SNPs in the CPS1 gene were linked to MDD in this study (Table 6.3). CPS1 is
critically important in ammonia metabolism as evidenced by the devastating effects of
hyperammonemia in CPS1-deficient individuals (Suzuki et al. 1986; Finckh et al. 1998).
Therefore, the variations identified in this study could potentially have major effects on
blood ammonia levels if the variations are linked to changes in CPS1 activity. As previously
mentioned, CPS1 is mainly found in the liver
(http://www.proteinatlas.org/ENSG00000021826-CPS1/tissue) (Uhlén et al. 2015), and it
catalyzes the incorporation of ammonia into carbamoyl phosphate in the urea cycle. The
clinical observations described above suggest changes in CPS1 activity may have an impact
on blood ammonia levels, and changes in blood ammonia levels may also impact glutamate
levels in the brain, affecting cognition (Suárez et al. 2002). Several studies suggest changes
in glutamate levels in several areas of the brain could be linked to mood disorders through
disruption of the levels of glutamate and glutamine (Sanacora et al. 2012).
Bioinformatics analyses suggest two SNPs in HWE analyzed in this study may have a
functional role in MDD (Table 6.9). The minor allele of the SNP rs9789405 is predicted by
the Human Splice Finder program to create an enhancer site. The same SNP variant is
predicted by PERFECTOS-APE to decrease the likelihood of binding by the transcription
factor E2F4. E2F4 is mainly a transcriptional repressor (Crosby and Almasan 2004) and
has been experimentally demonstrated to interact with the CPS1 gene (Litovchick et al.
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2007). The minor allele of the SNP rs2287602 is predicted by Human Splice Finder to
create an enhancer site and by PERFECTOS-APE to decrease the likelihood of association
with the transcription factor FOXP3. This transcription factor mainly plays a role in
regulatory T-cell function (Vent-Schmidt et al. 2014), but it has recently been found to play
a role in promoting mitochondrial oxidative metabolism (Angelin et al. 2017) and can even
localize to mitochondria in hepatocytes (Rojas et al. 2016). FOXP3 is known to either
increase or decrease gene expression depending upon the other transcription factors with
which it associates (Szylberg et al. 2016). The Human Protein Atlas reports mRNA for both
E2F4 (http://www.proteinatlas.org/ENSG00000205250-E2F4/tissue) and FOXP3
(http://www.proteinatlas.org/ENSG00000049768-FOXP3/tissue) in human liver (Uhlén
et al. 2015). Based on the predicted functions of these variants, we predict there may be
altered expression of CPS1 in the liver of some MDD subjects. Altered CPS1 expression may
change the levels of ammonia in the blood, therefore changing the glutamate levels in the
brains of individuals with MDD. A SNP in CPS1 significantly associated with MDD that was
not assigned a function by our bioinformatics analysis, rs6749597, is in linkage
disequilibrium with the predicted functional SNPs (rs6749597:rs9789405, D' = 1, r2 =
0.941; rs6749597:rs2287602, D' = 1, r2 = 0.937). All variations in CPS1 that passed the
quality control tests are in the same haplotype block (Figure 6.1).

Type 2 Diabetes
SNPs in the GLS and CPS1 genes were associated with T2D (Table 6.4). The SNP in
the CPS1 gene (rs2302909) is not in HWE, so it will not be further considered. The liver is
the major hub of ammonia metabolism and gluconeogenesis, so it is not surprising that
201

ammonia metabolism genes are linked to type 2 diabetes. Excess glutamate in the liver can
be deaminated, fed into the citric acid cycle, and then used for gluconeogenesis,
contributing to the high blood glucose levels observed in T2D. Although T2D is
traditionally associated with insulin resistance in liver and peripheral tissues, one of the
hallmarks of the later stages of T2D is the inability of β-cells in the pancreas to secrete
enough insulin to activate insulin signaling pathways in insulin-resistant tissues (Cantley
and Ashcroft 2015). The incretin pathway is involved in insulin secretion in the pancreas
(Yokoi et al. 2016). Several experimental drugs for the treatment of T2D have been
designed to increase the effectiveness of the incretin pathway (Drucker et al. 2010).
Glutamate has been found to increase insulin excretion by amplifying the incretin pathway
in beta cells (Gheni et al. 2014). Therefore, changes in glutamate levels in the pancreas
may affect the response to glucose signaling in T2D. As discussed above, CPS1, GLUL, and
GLS may all affect the levels of glutamate available for signaling. GLS is expressed in
pancreatic tissue (http://www.proteinatlas.org/ENSG00000115419-GLS/tissue) (Uhlén et
al. 2015), so changes in expression of these genes could affect pancreatic function. These
changes may play a role in the disease processes of T2D.
One SNP in HWE in the GLS gene is predicted to have a functional role that may be
associated with T2D (Table 6.9). The SNP rs1517354 was predicted by Human Splice
Finder to create an enhancer site (Table 6.9), possibly leading to an increase in GLS gene
expression in T2D. This variation may lead to an increase in the rate at which glutamine is
catabolized to glutamate and ammonia. When released from neurons, increased glutamate
levels in the synaptic cleft can lead to excitotoxicity (Zhou and Danbolt 2014). A recent
study suggests some of the pathology of T2D may be due to increased activity of pancreatic
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receptors for glutamate (Huang et al. 2017). Glutamate excitotoxicity in the brain is mainly
mediated by the NMDA receptor (NMDAR) (Lau and Tymianski 2010). A functional role
for NMDARs has also been found in pancreatic beta cells (Inagaki et al. 1995; Marquard et
al. 2015). The NMDAR agonist, glutamate, was found to be increased in the plasma of
diabetic patients and in a rat model of diabetes (Huang et al. 2017). In vitro studies have
shown that blocking NMDAR activation reduces glucose-mediated damage to pancreatic
beta cells and improves beta cell function (Huang et al. 2017). These results suggest that
changes in the expression of genes involved in glutamate metabolism may play a role in
type 2 diabetes by affecting the function of pancreatic beta cells.

Changes in Expression of Ammonia Metabolism Genes: An Explanation for Some Common
Pathologies in AD, MDD, and T2D?
Cortical thinning is a feature of AD (Du et al. 2007), MDD (Tu et al. 2012), and T2D
(Yoon et al. 2017 Apr 27). The temporal cortex appears to be specifically affected. Cortical
thinning may be caused by cell death due to glutamate excitotoxicity. As previously
discussed, the epidemiology of these diseases seems to be linked. For example, a study
found that individuals with AD are at increased risk for T2D (Janson et al. 2004). A more
recent study concluded that comorbidity of MDD and T2D increased the risk of dementia
(Katon et al. 2012).
Memantine, an NMDAR antagonist, is a drug used to reduce glutamate excitotoxicity
for the treatment of AD. Memantine was also found to have protective effects on pancreatic
beta cells and to reduce blood glucose levels in a mouse model of diabetes (Huang et al.
2017), and it improved some measures of cognitive functioning in a mouse model of type 2
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diabetes (Iwanami et al. 2014). Double-blind studies suggest memantine may also be an
effective treatment for MDD (Amidfar et al. 2017). The efficacy of this drug for the
treatment of several different diseases suggests clinically significant commonalities in the
disease mechanisms. Because glutamate signaling is so tightly tied to ammonia
metabolism, changes in the expression of ammonia metabolism genes may be at least
partially responsible for the observed cortical thinning and disease phenotypes in all three
of these disorders.

Testable Hypotheses Generated and Study Limitations
This study generates several testable hypotheses: 1) Individuals with the minor
allele variants of rs6758866, rs2355570, and rs1517354 have altered GLS gene expression
and glutaminase enzyme activity. 2) Individuals with abnormal GLS gene expression are at
greater risk for AD or T2D. 3) Individuals with the minor allele variants rs9789405 and
rs2287602 have altered expression of the CPS1 gene and altered CPS1 enzyme activity. 4)
Individuals with altered CPS1 gene expression are at higher risk for major depressive
disorder. 5) Individuals with abnormal blood ammonia levels are at higher risk for major
depressive disorder, and reducing blood ammonia may alleviate some of the symptoms of
MDD. 6) Changes in glutamate levels in the brain due to changes in the expression of GLS,

GLUL, or CPS1 are common to AD, MDD, and T2D, and these changes contribute to the
common tissue pathology observed in these diseases. 7) Drugs that regulate glutamate
signaling may alleviate some symptoms of AD, MDD, and T2D.
While this study’s results generate many hypotheses consistent with the published
literature, the study also has several limitations. We report a genetic association from just
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one data set; to decrease the risk of a type 1 error, other data sets with similar and different
study designs should also be examined for comparable associations. Only rs1517354, the
C-C haplotype from rs1517354 and rs883844, and the C-A haplotype from rs12468557 and
rs2302909 with T2D (Tables 6.4 and 6.7) showed significant associations after a
Bonferroni correction (p < 0.00111). Thus, our current findings might be subject to type I
error, and the results need to be supported by additional large samples in a future study.
Second, it was not possible to predict the direction of change in gene expression of the
SNPs rs2287602 and rs1921907 because they were predicted to interact with
transcription factors that can be either activators or repressors. Third, GWAS have largely
not indicated ammonia metabolism gene associations with AD, T2D, or MDD. This may be
because the associations are weak or because of incomplete genomic coverage in GWAS
datasets. Lastly, the bioinformatics results of this study need to be supported by
experimentation to verify these predictions. Even with these limitations, the findings of
this study are potentially clinically relevant and warrant further investigation due to their
high explanatory power and their consistency with experimental results.

Conclusions
This study used data from a family-based study design to find a novel
epidemiological association of select ammonia metabolism genes with Alzheimer’s disease,
major depressive disorder, and type 2 diabetes. Bioinformatics analyses suggest a
functional role for many of the identified SNPs. These functional roles generally fit with
previously published experimental results. The associations found in this study should be
confirmed by other genetic epidemiological studies to increase confidence in our
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conclusions. One data set which may replicate the current results is from the Columbia
University Study of Caribbean Hispanics with Familial and Sporadic Late Onset Alzheimer's
Disease, dbGaP Study Accession: phs000496.v1.p1. The next step would be to
experimentally verify the effects of these SNPs on gene expression and protein levels. This
study is a step toward understanding the genetic and metabolic underpinnings of complex
diseases with heritable components.
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CHAPTER 7
CONCLUSIONS

Hypotheses Supported
The studies reported in this dissertation investigated similarities in factors involved
in the pathogenesis of several neurological diseases. Two main hypotheses are supported
by this research:
(A) Amyloidogenic proteins have similarities in their residue interaction network
structures that will provide insight into the formation of amyloid plaques.
(B) Altered ammonia metabolism and changes in the amount of dietary protein
under certain conditions affect neurological function and play causative roles
in several neurological diseases.

Specific Aim 1: Conclusions and Future Directions

To determine if amyloidogenic proteins have commonalities in their residue
interaction networks and to determine how these network structures may affect amyloidbeta plaque formation when combined with 3D structural data. This aim addresses
hypothesis (A).
Results from the use of lysozyme as a model for amyloidogenesis demonstrated that
combining 3D structural data and RIN data can be a powerful approach in the study of
amyloid formation. Novel residues were identified that are likely to be involved in its
primary nucleation (residues 21, 62, 104, 122, and 112-117). Next, similar techniques were
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applied to compare a group of amyloidogenic proteins to random network controls or real
protein controls. Network characteristics specific to amyloidogenic proteins were
identified. These characteristics may provide insight into the primary nucleation of a
variety of amyloidogenic proteins. Abeta42 was analyzed in more detail, and two residues
(residues 24 and 31) were identified which may be involved in preventing primary
nucleation.
The results reported in this manuscript are in silico and are therefore preliminary.
Experimental studies are needed to verify the findings. The group of amyloid proteins
studied was small, so data from the analysis of more structures obtained using a variety of
solvent conditions would increase confidence in the findings. Mutating the amino acid
residues that we identified to be of interest for both lysozyme and Abeta42 could provide
support for the conclusions drawn.

Specific Aim 2: Conclusions and Future Directions

To create a mathematical model to determine if the amount of dietary protein and
degree of liver function interact to affect blood ammonia levels and to determine if the
predicted changes could affect neuron health. This aim addresses hypothesis (B) and
investigates the potential role of ammonia metabolism in neural function using an
organismal and tissue level approach.
There is a large body of evidence that suggests Abeta contributes to oxidative
damage in AD. One of the most susceptible proteins to oxidative damage in the brain is
GLUL, an enzyme that functions in the removal of ammonia from the brain and other
peripheral tissues. Because of the primary role of glutamate metabolism in neural function
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and the toxicity of ammonia to the central nervous system, I next investigated the effects of
changing the activities of enzymes involved in liver ammonia metabolism on blood and
brain ammonia levels. The relationship between dietary protein intake and blood ammonia
is surprisingly understudied in humans. The in silico model of whole-organism ammonia
metabolism supports a complex interplay between the amount of dietary protein, the blood
ammonia concentration, and the activities of ammonia metabolism enzymes. Protein
restriction for the treatment of hepatic encephalopathy may be appropriate for some
patients to limit blood and brain ammonia levels. In addition, heterozygosity for CPS1, a
prevalent condition, may cause chronic, low-level hyperammonemia. Because of the high
relative toxicity of ammonia on neural cells, the hyperammonemia may lead to cognitive
impairment and other neurological dysfunction.
Considering the potential link between protein level in the diet and blood ammonia
level, clinical studies elucidating the relationship between the two should be performed.
Many of the animal studies examining the relationship used exaggerated protein diets, so
studies using diets that are comparable in protein level to those consumed by humans are
needed. The decreased viability of differentiated neuroblastoma cells exposed to
pathological ammonium chloride levels warrants further investigation into the role of
ammonia in the pathogenesis of neurological diseases.

Specific Aim 3: Conclusions and Future Directions

To determine if there is an association between single nucleotide polymorphisms
(SNPs) in the GLS, CPS1, and GLUL genes and AD, MDD, and T2D, and to predict the effects
of any associated SNPs in the disease processes. This aim addresses hypothesis (B) where I
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suggest that altered ammonia metabolism stimulates neuropathology on a molecular and
cellular level.
Data from investigating Specific Aim 2 resulted in further evidence supporting a role
for pathological changes in the activities of enzymes involved in ammonia metabolism
causing changes in blood ammonia levels and demonstrated that these altered ammonia
levels may be toxic to neurons. Considering these results and the existing literature on the
involvement of changes in glutamate and ammonia metabolism in AD, I investigated the
possibility that mutations in ammonia metabolism genes were linked to AD, MDD, or T2D.
SNPs in the GLS gene were found to be linked to AD and T2D, and SNPs in the GLUL and

CPS1 genes were found to be linked to MDD. Bioinformatic analysis revealed that some of
these SNPs are predicted to affect the binding of certain transcription factors to the
promoters of the genes, possibly affecting the levels of expression of the ammonia
metabolism genes in these diseases. Since these diseases are each associated with cortical
thinning, since treatment with the NMDA receptor antagonist memantine is beneficial, and
since they often display comorbidity, dysfunctional ammonia metabolism may partially
explain some of the common pathologies of these diseases.
To further test the hypotheses generated from the data obtained from investigating
Specific Aim 3, the data from a separate set of subjects could be analyzed to test for similar
associations. The predicted changes in the affinity of transcription factors for DNA
sequences containing the predicted functional SNPs would lead to further insight as well.
Because of the reported associations with ammonia metabolism genes, the beneficial
effects of memantine and other drugs that interfere with glutamate signaling should be
further evaluated for the treatment of AD, MDD, and T2D. Altered ammonia and glutamate
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metabolism appears to be an important factor in the development of several neurological
diseases.

Summary of Conclusions
The studies performed further elucidate several common features of neurological
diseases. First, I used RINs to detect similar features of amyloidogenic proteins that have
not previously been reported. Because Abeta and ammonia both cause oxidative damage in
the AD brain, and GLUL, an ammonia metabolism enzyme, is especially susceptible to
oxidative damage, I explored the possible role of altered ammonia metabolism and altered
dietary protein intake in the regulation of systemic ammonia levels using a computational
model of hepatic encephalopathy and CPS1 deficiency. As hypothesized, I found blood
ammonia levels likely depend heavily on the interaction of protein diet with the activities
of GLUL, GLS, and CPS1. Because high ammonia levels are toxic to neurons and ammonia
metabolism genes are involved in critical glutamate signaling, I investigated the possibility
that SNPs in ammonia and glutamate metabolism genes are linked to AD, MDD, and T2D.
Each of these diseases had an association with GLUL, GLS, or CPS1, and some of the intronic
SNPs are predicted to regulate gene expression. These associations may partially explain
the common neural pathology observed in these diseases. This dissertation demonstrates
that taking a broad view of neurological diseases and their causes can provide novel
insights into their pathogeneses.
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Personal Perspective
My undergraduate research included elucidating the interaction of Abeta with
resveratrol and the interaction of insulin with phenol red. This work with amyloidogenic
proteins in monomeric form sparked an interest in AD and related amyloidoses that I
carried with me into my Ph.D. studies. During my graduate coursework, I realized that
complex network analysis could provide a unique perspective on protein structural studies
because it is a relatively new approach. I was able to find no studies that had applied
complex network analysis to amyloidogenic proteins. Since there is little 3D structural and
sequence similarity among amyloidogenic proteins in their soluble form, I hypothesized
that there may be similarities in network connections. The results of my studies have
encouraged me to continue using the approach in future research.
There is a need for more protein structural studies using network analysis. To
advance the field, protein structures with well-known functions should be re-examined
from a network perspective to find correlations with network metrics (Chapter 2). In
addition to correlations, drug design approaches that consider residue interaction
networks could be effective. For example, the results reported in Chapter 3 suggests that
drugs that stabilizes the network structure of Abeta42 in a more nonpolar environment
could prevent unfolding and subsequent oligomer and fibril formation. This could occur
through stabilizing the predicted interaction between Val24 and Ile31. However, if
stabilizing the network is the goal, perhaps other residues in the vicinity could also be a
target. A network perspective could provide a wider range of drug targets not previously
considered. The allosteric inhibition and activation of enzymes provides an example of this
principle. The binding of an inhibitor or activator to residues away from the active site can
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change both the 3D and network structures of a protein and therefore change the activity
of the enzyme. Similarly, network analysis may help researchers discover previously
unidentified drug targets that exert profound effects on enzyme activity even though they
are not near the active site.
The series of studies on ammonia and glutamate metabolism in this dissertation was
inspired by my grandfather, Wayne Birchfield. His stroke and subsequent medical care
helped me understand the strong connection that exists between ammonia and glutamate
metabolism and brain function. During a literature search on the cognitive effects of
hyperammonemia, I found research supporting a role for ammonia in other neurological
diseases, particularly AD. I came to appreciate the roles that ammonia and glutamate
metabolism appear to play in a variety of neurological diseases (Chapters 4, 5, and 6).
When initiating my research, I discovered that the focus of AD research is currently
on the Abeta peptide. While Abeta exerts negative effects on the brain in AD, the lack of
understanding of the nature of its role in both AD and normal physiology is striking. Even
the structure of Abeta and which forms in the brain are most prevalent are contested after
25 years of intense study (Wildburger et al. 2017), a testament to the complexity of AD
pathogenesis.
The paucity of current treatment options should encourage researchers to examine
other factors of AD pathology besides Abeta oligomerization and fibrillization (Herrup
2015). I reviewed the literature on changes in amino acid metabolism in AD (Chapter 5)
and found much evidence supporting pathological changes. Furthermore, identifying these
changes provides opportunities for therapeutic intervention. Researchers need to untangle
which changes contribute to disease and which changes are protective adaptations to
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disease processes. Treatments for AD patients may one day include dietary supplements to
help alleviate some symptoms that may occur due to changes in metabolism in AD. While
AD will not be cured by dietary interventions alone, they may alleviate some symptoms or
delay progression of the disease.
After finishing my Ph.D. studies at East Tennessee State University, I will begin as an
Assistant Professor of Biology at Mars Hill University. There I will continue research into
neurological diseases and other interests. I would like to continue exploring the role of
ammonia in neurological functions using C. elegans as a model organism. Does ammonia
affect the ability of C. elegans to learn? (Yes, there are assays for C. elegans memory
(Nuttley et al. 2002; Ardiel and Rankin 2010; Li et al. 2013)!) If so, what factors are
involved? Because magnetic fields are effective as a treatment for some neurological
diseases (Chou et al. 2015; Rutherford et al. 2015), I would also like to use C. elegans and S.

cerevisiae as models for the effects of static magnetic fields on mitochondrial function
(which declines in neural aging). I plan to further investigate residue interaction networks
in CPS1, antimicrobial proteins, and protein toxins. I will also continue ongoing projects
investigating tryptophan metabolism in AD, glutathione metabolism in AD, and pneumonia
infection in AD patients. My Ph.D. research has helped me understand the power of the
scientific method and an interdisciplinary approach. I will emphasize these points in my
future endeavors in both research and higher education.
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